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Stroke is associated with a significant disease burden across the world (1). Ischaemic stroke 
accounts for over 80% of the total number of strokes and specifically refers to central nervous 
system infarction accompanied by overt symptoms (2). Cell therapies (CTs) represent a composite 
of different cell types being investigated in different phases of stroke, with use of different dose 
and delivery regimens (2). Preliminary evidence for meaningful clinical translation is now 
available with CTs in stroke, as early studies have demonstrated safety and a trend towards 
functional improvement over a longer time window of application (2).  
Research Aims 
This research aimed to analyse study design, regulatory policy, ethical and economic 
considerations, as well as to describe their impact on the quality of execution of early-phase clinical 
CTs studies in stroke 
Methods  
The thesis is a compendium of subprojects that evaluated these considerations for efficient 
implementation of early phase CTs studies, using a mixed methodology approach. 
Results 
Study design considerations: a systematic review of early phase clinical studies with CTs in 
ischaemic stroke indicated a trend towards improvement across varied domains of functional 
impairment and reasonable safety and feasibility, in patients with stroke receiving CTs (2). A high 
level of heterogeneity was observed, in terms of differences in cell types used and route, dose and 
time of administration, use of randomised control design and selection of trial endpoints. Most 
viii 
studies reported temporal changes in global endpoints such as those measured by the National 
Institutes of Health Stroke Scale (NIHSS), Barthel Index (BI) or Modified Rankin scale (mRS).  
Regulatory considerations: a narrative review examined different national regulatory provisions 
and described standardization of research terminology and access to expertise in manufacturing as 
the key determinants critical to the execution of early phase studies with CTs in stroke.  
Ethical considerations: a qualitative study was undertaken to understand the perspective of stroke 
survivors on the research design of a proposed early phase clinical study with adult human dental 
pulp stem cells in chronic ischaemic stroke. The study found that patients considered outcomes 
such as recovery in social participation and decreased dependence on carers as most meaningful to 
them. Whilst improved motor function was important, the impact on cognition, memory, mood, 
pain and fatigue were bigger determinants of their perception of benefit. The perception of risk 
versus benefit was influenced by the time elapsed since stroke.  
Health economic considerations: a systematic review reported that there is limited evidence for 
economic evaluation at early stage of research in CTs. Only three studies have been published to 
date. All studies undertook a cost utility analysis of CTs versus current standard of care using 
decision analytical modelling and reported that CTs could provide meaningful cost savings in terms 
of direct costs of disease management accrued to the government (healthcare bodies and social 
services).  
Discussion 
Successful clinical translation of CTs in stroke requires efficient development strategies potentially 
comprising the use of adaptive trial designs and the use of domain specific endpoints for efficacy 
evaluation (8, 9). Addressing regulatory requirements and patients’ preferences in research design 
can significantly improve the eventual clinical relevance of data generated within these trials (11, 
ix 
12). Collection of data on cost-effectiveness of their use from the early phase of research is critical, 
as these therapies are likely to be expensive (13).  
Conclusions  
Development of a practical framework comprising key elements of study design and regulatory 
policy, as well as ethical and health economic considerations that is available to different research 
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CHAPTER 1:  INTRODUCTION 
Stroke represents a neurological deficit resulting from an acute focal injury in the central nervous 
system (CNS) due to a vascular cause such as cerebral infarction, intracerebral haemorrhage (ICH), 
or subarachnoid haemorrhage (SAH) (1). Two main types of stroke are recognised based on the 
initial causative mechanism: ischaemic (IS) and haemorrhagic stroke (HS). Ischaemic stroke 
accounts for over 80% of the total number of strokes and specifically refers to central nervous 
system infarction accompanied by overt symptoms (2). 
1.1 Definition of Stroke  
While the terminology of ‘stroke’ was introduced in 1689, it was in 1976 that the World Health 
Organisation (WHO) defined stroke as “rapidly developing clinical signs of focal (or global) 
disturbance of cerebral function, with symptoms lasting 24 hours or longer leading to death, with 
no apparent cause other than of vascular origin”, for universal use (3). This definition included 
ischaemic stroke due to cerebral infarction or due to an arterial or venous blockage, and 
haemorrhagic stroke, resulting from a haemorrhage into CNS tissue. The cut-off time-period of 24 
hours was an arbitrary decision at the time, based on very limited evidence (4).  
Episodes of temporary brain dysfunction with vascular aetiology that typically resolved within 24 
hours were termed ‘transient ischaemic attack’ (TIA) (5). In 2009, the American Heart 
Association/American Stroke Association (AHA/ASA) defined TIA as “transient ischaemic attack 
(TIA): a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal 
ischemia without acute infarction” (5). As brain imaging techniques have improved, it became 
apparent that the persistent brain infarction can occur much sooner and may not correlate accurately 
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with clinical presentation. An update in 2013 suggested the use of imaging data along with clinical 
presentation to differentiate between TIA and stroke (1). Australian clinical practice guidelines 
(2017) for stroke management define TIA as “focal neurological symptoms due to focal ischemia 
that have fully resolved”. These guidelines recommend that if an ischaemic lesion is present on 
brain imaging, then the same is classified as a stroke even if symptoms have fully resolved (6). 
The International Classification of Diseases (ICD) system aims to standardize diagnostic 
classification for most diseases. The current (10th) revision along with its clinical modification 
(ICD-10-CM) published in 2016, defined cerebrovascular disorders as comprising TIA, cerebral 
ischaemic stroke, ICH, or SAH (7). 
The updated definitions of stroke and its different subtypes, supported by guidelines across the  
globe such as those from the American Heart Association/American Stroke Association (2013), 
Australian Stroke Foundation (2017) and European Stroke Organisation (2008), incorporate both 
clinical and tissue criteria that have emerged due to significant improvement in sophistication of 
brain imaging (6, 8, 9). It is now possible to localize regions of brain infarction and haemorrhage 
at high spatial resolution, estimate regions of hypoperfusion that are potentially salvageable and 
identify smaller lesions such as silent infarcts and microhaemorrhages. These advances would 
likely increase the number of stroke diagnoses from roughly 3% to 15% of the population but can 
potentially address relatively underestimated consequences of these events such as cognitive 




1.2 Disease Burden of Stroke 
Changes in lifestyle and demographic patterns over the last few decades have led to an increase in 
the overall numbers of people affected by stroke. The Global Burden of Disease Study (2013) 
reported that stroke is the second highest cause of years of life lost (YLL) globally (10). With 
expanding access to protocolised care in the acute stroke setting, the mortality associated with 
stroke has been declining across the globe, though more so in developed as compared to developing 
countries. The mortality rates from IS and HS combined in developed countries were almost halved 
from 1990 to 2013 (112.9/100,000 and 67.2/100,000), while in developing countries IS and HS 
mortality rates were reduced by only approximately 15% (from 160.9/100,000 in 1990 to 
136.9/100,000 in 2013) (10). However, the absolute number of people affected in the world over 
the same time-period, has increased for both IS: 291.2/100,000 (95% confidence interval (CI): 
278.7 to 303.8) in 1990 to 299.1/100,000 (95% CI: 290.2 to 309.2) in 2013, and HS: 105.6/100,000 
(95% CI: 102.0 to 109.2) in 1990 to 116.6/100,000 (95% CI: 113.1 to 120.5) (10). Krishnamurthi 
et al. (2015) highlighted the fact that between 1990 and 2013, there were significant increases in 
absolute numbers and prevalence rates of both HS and IS for younger adults (20-64 years of age) 
(11). The death rates for all types of strokes among younger adults, declined in both developing 
and developed countries to a variable extent (11). However, there was a 24.4% (95% CI: 16.6 to 
33.8) increase in total disability-adjusted life years (DALYs) for this age group, with a 20% (95% 
CI: 11.7 to 31.1) and 37.3% (95% CI: 23.4 to 52.2) increase in HS and IS numbers, respectively 
(11).  
In 2013, there were almost 25.7 million stroke survivors globally (71% with IS); 6.5 million deaths 
from stroke (51% died from IS); 113 million DALYs due to stroke (58% due to IS) and 10.3 million 
new strokes (67% IS) (10). The proportional contribution of stroke-related DALYs and deaths due 
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to stroke at a global level, compared to all diseases, increased from 1990 (3.54% (95% CI: 3.11 to 
4.00) and 9.66% (95% CI: 8.47 to 10.70), respectively) to 2013 (4.62% (95% CI: 4.01 to 5.30) and 
11.75% (95% CI: 10.45 to 13.31), respectively) (10). Stroke is second only to ischaemic heart 
disease globally as a contributor to DALYs in developing countries, and it is the third largest 
contributor to DALYs in developed countries (10).  
With increasing life expectancy across the globe due to enhanced food security and improved 
control of communicable diseases, stroke is likely to represent an increasing burden for patients, 
families, society and governments (10). The gap between life expectancy and healthy life 
expectancy (HALE) has been widening over the past few decades. This increase has been attributed 
largely to the rise in prevalence of chronic diseases such as stroke, dementia, diabetes, and 
ischaemic heart disease (12). 
1.3 Current Management Landscape: Ischaemic Stroke 
The management of stroke has been steadily evolving to address the whole continuum of stroke 
care. The management strategies that have a supportive evidence base to date are aspirin, 
protocolised management in a stroke unit, decompressive craniectomy (where indicated), early 
blood flow restoration through pharmacological thrombolysis or mechanical thrombectomy, or a 
combination of both strategies and rehabilitation to complement all these treatment strategies (9). 
In 2018, AHA/ASA updated the guidelines for management of acute ischaemic stroke to 
summarise the existing evidence for the various components of stroke management and proposed 
standards for optimal care (8). In September 2017, The National Health and Medical Research 
Council and the Stroke Foundation released an update to Australian Clinical Practice Guidelines 
for stroke management (6). Similarly, there have been ongoing updates to guidelines for the 
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management of stroke in different countries to keep abreast with new research happening in this 
field (9). In order to meet the standards, set by the guidelines, well-defined stroke systems of care 
are required, that enable patient care pathways to coordinate and optimize the entire stroke care 
continuum, from primary prevention to rehabilitation (13). Systems include the designation of 
comprehensive stroke centres, development of regional strategies to guarantee appropriate 
interventions like thrombolysis and stroke unit care, inter-provider collaboration with telemedicine 
and establishment of performance measures for all these components (14). Ganesh et al. (2016) 
reported that the crude 30-day mortality rate decreased from 15.8% in 2003-2004 to 12.7% in 2012-
2013 in Canadian provinces with established stroke systems as compared to remaining at 14.5% in 
provinces without such systems (13). The study provides evidence for population-wide reduction 
in mortality associated with access to stroke systems of care (13). In Australia, the National Stroke 
Foundation developed the Acute Stroke Services Framework (2015) and the Rehabilitation Stroke 
Services Framework (2013) (15, 16). These frameworks guide the planning, monitoring, and 
optimisation of acute and rehabilitation stroke services in the country to support the delivery of 
care in line with the clinical practice guidelines. The following sections discuss the key components 
of these guidelines: 
1.3.1 Pre-Hospital Care: Early Assessment, Diagnosis, Triage  
1.3.1.1 Emergency Medical Services (EMS)  
All guidelines recommend that potential stroke patients be managed with urgency, as treatment is 
time critical (6, 8, 9). Berglund et al. (2012) reported that a shorter time to reach the stroke unit and 
an increase in thrombolysis frequency was achieved for patients by targeted prioritisation of EMS 
dispatch in response to calls with presentations likely to be stroke (17). Ekundayo et al. (2013) 
reported that timely access to EMS was independently associated with (18): 
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• quicker arrival to hospital (onset-to-door time ≤3 hours; adjusted odds ratio [OR] 2.00, 95% 
CI: 1.93 to 2.08) 
• quicker imaging (door-to-imaging time ≤25 minutes; OR 1.89, 95% CI: 1.78 to 2.00) and, 
• faster access to thrombolysis (door-to-needle [DTN] time ≤60 minutes; OR 1.44, 95% CI: 
1.28 to 1.63). 
Studies [O'Brien et al. (2012), McKinney et al. (2013)] have reported that preferential transfer of 
patients directly to a hospital with capacity to provide reperfusion therapies and stroke unit care 
led to decreased time to imaging and specialist assessment (19, 20). Lahiry et al. (2018) reported 
that a pre-hospital acute stroke triage protocol to prioritise transfer to a primary stroke centre in 
regional New South Wales, Australia, significantly increased the likelihood of eligible patients 
receiving thrombolysis (OR 17, 95% CI: 9.42 to 31.2, p < 0.05) which was potentially cost-
effective as well (average cost of $10,921 per DALY avoided per patient) (21).  
The National Stroke Audit report released by the National Stroke Foundation in 2017 reports that 
76% of overall stroke patients arrived at hospital by ambulance. However, only 58% of acute stroke 
services reported established protocols with local ambulance services to enable pre-notification 
and only 69% had protocols in place to implement bypass and transfer to regional stroke centres 
with facilities for thrombolysis. As a result, only 36% of patients with stroke in Australia reached 
hospital within the critical 4.5-hour time window for thrombolysis (22).  
Some research groups have investigated whether providing thrombolysis in a specialized 
ambulance is safe and effective. Ebinger et al. (2014) reported ambulance-based thrombolys is 
resulted in decreased time to treatment without an increase in adverse events (23). Bowry et al.  
(2015) in a similar study corroborated the decrease in time to treatment in their study but indicated 
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that this strategy may result in a larger number of stroke mimic patients receiving thrombolysis in 
error (24). As adoption of mobile stroke units with capacity for performing onsite imaging and 
thrombolysis is increasing across the world, future data will indicate whether the overall impact on 
treatment metrics and long-term outcomes is sufficient to trigger change in management pathways  
(25, 26). 
1.3.1.2 Transient Ischaemic Attack 
Timely diagnosis and immediate referral to a stroke team of all patients with suspected TIA has 
been shown to result in meaningful long-term benefit in terms of significant reduction in recurrent 
stroke (27, 28).  
Since the risk of stroke following TIA is high within the first two days (29), Australian practice 
guidelines strongly recommended that diagnostic work-up and implementation of optimal therapy 
should be completed within 24 hours of symptom onset (6). This includes assessment by a stroke 
specialist, extended monitoring with electrocardiography (ECG) as required and brain imaging 
[computerised tomography(CT) or magnetic resonance imaging (MRI)] (6). Both ASA guidelines 
and Australian guidelines highlight the importance of organised and effective communication 
between general practitioners (GP), EMS personnel, emergency department (ED) staff and the 
specialist stroke team to achieve this. Multiple studies such as Lavallee et al. (2007), Rothwell et 
al. (2007) and Dutta et al. (2015) have reported that establishment of dedicated TIA clinics have 
been associated with a significant fall in the number of 90-day recurrent stroke (27, 30, 31).  
In pre-hospital settings, high-risk indicators such as crescendo TIA, current or suspected atrial 
fibrillation, current use of anticoagulants, carotid stenosis or high ABCD2 score have been used, to 
identify patients for urgent specialist assessment (32). However, Leung et al. (2012) reported in a 
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cross-sectional study in Western Adelaide in South Australia that GPs lacked access to neurologists 
and that knowledge of relevant guidelines and deficient education was identified as a key barrier 
to timely diagnosis and referral to specialist care (33). Ranta et al. (2015) reported that use of 
electronic decision support in a primary care setting may accelerate diagnostic and triage decisions  
and improve outcomes (OR for risk of 90-day stroke, vascular event, and/or death = 0.27, 95% CI: 
0.09 to 0.78, p = .016) (32). The ‘Stroke/TIA integrated decision support tool’ has been available 
to GP practices around New Zealand since 2015. The 2017 Australian guidelines acknowledge that 
access to such a tool in Australia would be of benefit in timely management (6). The Australian 
National Stroke Audit report (2017) observed that 83% of all acute services reported having a 
defined clinical pathway for assessing TIA patients but only 29% reported access to a rapid access 
TIA clinic for patients not admitted to hospital, where average waiting time was reported as 4 days 
(first quartile: 2 days, third quartile: 10 days) (22).  
1.3.2 Hospital Management 
1.3.2.1 Rapid Assessment in the Emergency Department 
As per the National Stroke Audit (2017) report, 46% of patients with stroke in Australia present to 
ED) (22). Therefore, a well-defined protocol for prioritised evaluation of these patients is critical.  
In 2011, the National Institutes of Neurological Disorders and Stroke (NINDS) panel, proposed 
goals for time intervals for key milestones from first contact with a stroke patient in the ED to 
thrombolysis. These goals aimed to optimise the ‘stroke chain of survival’ by establishing time-
sensitive targets for critical milestones in the ED such as identification, specialist evaluation, 




Table.1: NINDS: Stroke Chain of Survival 
Action  Time 
Door to physician ≤10 minutes 
Door to stroke team ≤15 minutes 
Door to imaging initiation ≤25 minutes 
Door to imaging interpretation ≤45 minutes 
Door to needle ≤60 minutes 
Door to stroke unit admission  ≤3 hours 
Reproduced with permission from Jauch et al. (2013) (34) 
The 2017 Australian practice guidelines recommend the implementation of coordinated ED 
systems that can ensure prioritised assessment of every stroke patient, preferably by the stroke team 
or other experienced personnel. These systems require the use of multi-level interventions such as 
the use of validated screening tools and triage categories and targeted protocols for timely 
recombinant tissue plasminogen activator (rt-PA) administration, e.g., ‘Code Stroke’, and urgent 
access to imaging (35, 36). The National Stroke Audit reports that the availability of coordinated 
emergency department systems had risen from 86 to 92% in the period 2015-2017 across Australia  
(22).  
A ‘Target: Stroke’ program was initiated in 2010 in the United States (US) with the initial aim to 
achieve DTN times within 60 minutes in at least 50% of ischaemic stroke patients treated with 
intravenous(IV) rt-PA through incorporation of multi-level coordinated care delivery (37). Xian et 
al. (2017) reported that the Phase II of the program resulted in an increase in the percentage of 
patients with DTN time of ≤60 min from 33.9% (1849/5460) in 2010 to 59.3% (10,020/16,901) in 
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2015. The study reported that the use of standardized stroke care procedures was critical to the 
achievement of DTN times within 60 minutes in ≥ 50% of acute ischaemic stroke patients treated 
with IV alteplase (38).  
1.3.2.2 Stroke Units 
In 2013, the Stroke Unit Trialists' Collaboration published a Cochrane review of 28 trials (5855 
patients) evaluating benefit from organised stroke unit care (39). Substantial reductions were 
observed in: the odds of death recorded at final (median one year) follow-up (OR 0.81, 95% CI: 
0.69 to 0.94, p = 0.005); the odds of death or institutionalised care (OR 0.78, 95% CI: 0.68 to 0.89, 
p= 0.0003), and the odds of death or dependency (OR 0.79, 95% CI: 0.68 to 0.90, p = 0.0007) (39). 
The provision of comprehensive specialized stroke care that incorporates rehabilitation and ensures 
uninterrupted continuum of care for patients with stroke, is perhaps the most important 
recommendation made in guidelines across the world (6, 8).  
The 2017 Australian national guidelines strongly recommend that all people with stroke should be 
managed by a stroke unit with a multidisciplinary team and be admitted directly to a stroke unit 
(preferably within three hours of stroke onset) (6). It is also recommended that hospitals without a 
dedicated stroke unit, have established transfer protocols to guide urgent transfers to the nearest 
stroke unit hospital (6). 
The Australian National Acute Stroke Services Framework issued in 2015 defined the minimum 
criteria for a stroke unit as follows (15): 
1. co-located beds within a geographically defined unit 
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2. a dedicated, inter-professional team with members who have a special interest in stroke 
and/or rehabilitation (The minimum team would consist of medical, nursing and allied 
health.) 
3. the inter-professional team meeting at least once per week to discuss patient care. 
4. regular programs of staff education and training relating to stroke.  
Different models of stroke unit care are reported depending on resource availability (39). These 
are: acute stroke unit (acute unit in a discrete ward for acute short-term care), comprehensive stroke 
unit (integrated acute and rehabilitation management in a discrete ward), stroke rehabilitation unit 
(discrete rehabilitation unit for transition from acute care), and mixed rehabilitation ward 
(rehabilitation provided on a general caseload ward).  
The 2017 National Stroke Audit reported an increase in access to stroke unit care in Australia to 
69% from 58% in 2013 with the number of stroke units increasing to 95 from 87 in 2015 (22). 
However, significant differences persisted in stroke unit access in metropolitan (77%) areas as 
compared to regional (47%) areas (22).  
1.3.2.3 Early Reperfusion Strategies 
Interventions to restore blood supply to the penumbral zone of the brain either by intravascular clot 
lysis with tissue plasminogen activators or endovascular removal of the clot are two significant 
milestones in the management of stroke (8). 
1.3.2.3.1 Thrombolysis  
Significant literature exists to support that timely intravenous thrombolysis in eligible patients is 
the cornerstone of optimal acute management of ischaemic stroke (40, 41). The 2018 AHA/ASA 
12 
 
guidelines recommend timely administration of rt-PA in eligible patients (8). Further to this, it 
suggests that patients eligible for IV alteplase should receive IV alteplase even if endovascular 
therapy is being considered (8). These recommendations are mirrored in Australian guidelines as 
well as other guidelines across the globe (6, 9). 
Wardlaw et al. (2014) have followed the evolution of evidence in this field through the last two 
decades. Their first review on the subject was published in 1992 and their latest update in 2014 
analysed evidence from 27 trials, involving 10,187 participants, testing different thrombolyt ics 
(42). A majority of these trials started treatment up to six hours after stroke and analysed IV 
thrombolytic administration (42). The data suggests that thrombolysis, delivered up to six hours 
after ischaemic stroke, was associated with significant reduction in the proportion of patients who 
were dead or dependent (mRS=3-6) at three to six months after stroke (OR 0.85, 95% CI: 0.78 to 
0.93) (42). However, there was an associated increased risk of symptomatic intracranial 
haemorrhage (OR 3.75, 95% CI: 3.11 to 4.51), early death (OR 1.69, 95% CI: 1.44 to 1.98) and 
death (OR 1.18, 95% CI: 1.06 to 1.30) seen at three to six months after stroke. Intracranial 
haemorrhage was found to be the predominant driver of this excess early death (within 7-10 days) 
occurrence (42). The data indicates that delivery of thrombolysis in eligible patients within three 
hours of stroke was associated with an optimal benefit versus risk scenario, as this timing was more 
effective in reducing death or dependency (OR 0.66, 95% CI: 0.56 to 0.79) without any increase 
in death (OR 0.99, 95% CI: 0.82 to 1.21; 11 trials, 2187 participants) (42). An analysis of the 
impact of time to thrombolysis on outcomes reported that for every 1000 patients given rt-PA 
within three hours, 90 additional patients would be alive and independent (P < 0.0001) with no 
heterogeneity between the relevant trials, as compared with 10 additional patients, if treated 
between three and six hours after stroke (P = 0.58) (42). This provided further confirmation of 
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evidence that earlier treatment increased the proportion of patients with better outcomes than later 
treatment (42). However, results from the third International Stroke Trial (IST-3) trial reported a 
meaningful benefit, even when the treatment window was extended to 6 hours (43). At 6 months, 
a non-significant absolute increase of 14/1000 was reported in the proportion of people alive and 
independent but the shift in Oxford Handicap scores in the rt-PA group was significant compared 
to the control (OR 1·27, 95% CI: 1·10 to 1·47, p=0·001) (43). It is important to note that 53% 
(n=1617) of the study population in the IST-3 trial was greater than 80 years of age (43). Similar 
findings were reported from a subgroup analysis by Wardlaw et al. as part of the Cochrane review 
which indicated that rt-PA administration in the older age subgroup was associated with a 
meaningful benefit (OR 1·35, 99% CI: 0·97 to 1·88) (42). Overall, the Cochrane review by 
Wardlaw et al. concluded that benefit was still seen when the timing window was extended up to 
6 hours (OR 0.84, 95% CI: 0.77 to 0.93, p = 0.0006; 8 trials, 6729 participants) but they highlighted 
significant heterogeneity between the relevant trials, weakening the strength of the available 
evidence (42). Additionally, the review concluded that similar reduction in death or dependency 
(mRS 3 to 6) by the end of follow-up was seen in participants treated up to 6 hours aged ≤ 80 years 
(OR 0.85, 95% CI: 0.76 to 0.95) versus > 80 years (OR 0.80, 95% CI: 0.64 to 0.99) (42).  
Consequently, the 2017 Australian clinical guidelines and the 2018 AHA/ASA guidelines 
recommend that all patients with ischaemic stroke who meet specific eligibility criteria be 
commenced on intravenous alteplase (dose of 0.9 mg/kg, maximum of 90 mg) as early as possible 
(preferably within the first few hours but may be used up to 4.5 hours after onset) (6, 8). 
Coordinated and comprehensive systems of stroke management that incorporate appropriate 
infrastructure, facilities and network support (e.g. telemedicine), are essential to enable timely 
thrombolysis to be feasible for all eligible patients (6).  
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1.3.2.3.2 Endovascular Thrombectomy 
Multiple studies [Goyal et al. (2015), Molina et al. (2015), Campbell et al. (2014), Saver et al.  
(2015), Berkhemer et al. (2015)] reported that mechanical thrombectomy with a stent retriever , 
initiated within 6 hours of symptom onset was associated with successful angiographic reperfusion 
(44-48). This was defined as a modified Thrombolysis in Cerebral Infarction flow score (m TICI) 
of 2b/3 and a favourable disability outcome at 90 days (defined as a favourable shift in mRS 
distribution) in an appropriate stroke population (44-48), who had: 
• pre-stroke mRS score of 0 to 1 
• causative occlusion of the internal carotid artery or middle cerebral artery segment 1 (M1) 
• age (≥18 years)  
• NIHSS score of ≥6 
• Alberta Stroke Program Early CT Score (ASPECTS) of ≥6.  
Saver et al. (2016) published a meta-analysis of individual patient level data from all the 
randomized phase III trials in which stent retrievers or other second-generation devices were used 
(49). A pre-defined subgroup analysis of 390 patients who achieved substantial reperfusion showed 
that each 1-hour delay to reperfusion was associated with a less favourable degree of disability (OR 
0.84, 95% CI: 0.76 to 0.93; absolute relative difference (ARD): -6.7%) and less functional 
independence (OR 0.81, 95% CI: 0.71 to 0.92; ARD: -5.2%, 95% CI: -8.3% to -2.1%), but was not 
associated with significant difference in mortality (OR 1.12, 95% CI: 0.93 to 1.34; ARD 1.5%, 
95% CI: -0.9% to 4.2%) (49). This study reinforced the importance of timely endovascular 
treatment but provided initial evidence to support an extension of the treatment window from 6 to 
7.3 hours after symptom onset. This analysis also reported a treatment effect in the subgroup of 
188 patients who were not treated with IV alteplase (OR 2.43, 95% CI: 1.30 to 4.55) indicating 
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that pre-treatment with IV alteplase was not an essential pre-requisite (49). While the guidelines 
still recommend that all patients should receive rt-PA, it is also recommended that thrombectomy 
should be organised for eligible patients without waiting to observe the clinical response with rt-
PA (8).  
The results of the DAWN trial, published in 2017, support a clinical benefit with mechanical 
thrombectomy performed between 6 and 24 hours from ‘last known well’ timepoint in a select 
patient group with large anterior circulation vessel occlusion who presented with a clinical imaging 
mismatch, i.e. a clinical deficit that was disproportionately severe relative to the infarct volume 
(50). The improvement in functional outcome at 90-days in the thrombectomy group versus the 
standard care group (mRS score 0–2, 49% versus 13%; adjusted difference=33%; 95% CI: 21% to 
44%) was clinically meaningful (50).  
In 2018, the ‘DEFUSE 3’ trial expanded the patient group likely to benefit with thrombectomy 
performed 6 to 16 hours from ‘last known well’ timepoint, to include patients with large anterior 
circulation occlusion likely to have salvageable ischaemic brain tissue, as identified by perfusion 
imaging (perfusion-core mismatch and ischaemic core less than 70 ml) (51). The study showed: a 
favourable shift in the distribution of the mRS at 90 days (OR 2.77; p<0.001); a higher percentage 
of functional independence (45% versus 17%, p<0.001); a lower 90-day mortality rate (14% versus 
26%, p=0.05), but no significant between-group difference in the frequency of symptomatic 
intracranial haemorrhage (7% and 4%, respectively; p=0.75) or of serious adverse events (43% and 
53%, respectively; p=0.18) in the treatment group (51). As a result, the updated AHA/ASA 
guidelines and the Australian clinical practice guidelines support an extension of the time window 
available for thrombectomy in the above patient group up to 24 hours (6, 8). 
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In 2017, the Australian National Stroke audit reported that despite the increase in availability of 
thrombolysis services (72%) and in the number of stroke units from 87 to 95, only 13% of patients 
presenting to hospital were eligible for thrombolysis (15). The mean rates of thrombolysis across 
the globe are reported to be between 5-20% (52). This underscores the fact that despite widespread 
knowledge of the benefit possible with timely thrombolysis, current systems of care all over the 
world lag in terms of real world implementation (52). 
1.3.2.4 Early Assessment for Rehabilitation 
Stroke practice guidelines universally recommend that all stroke patients undergo an early 
functional assessment (ideally within 24-48 hours) conducted by professionals with expertise in 
rehabilitation, who are part of the multidisciplinary team in the stroke unit (6). Determination of 
individual rehabilitation goals should be based on their residual level of ability to: communicate 
and to perform activities of daily living and be functionally mobile. This may be achieved using 
standardized tools such as the ‘Assessment for Rehabilitation Tool’ produced by the Australian 
Stroke Coalition Working Group (2012) (53). It is recommended that the findings of this formal 
assessment should be incorporated into the care transition and discharge planning (5). 
1.3.3 Rehabilitation  
Crichton et al. (2016) published findings from a population-based South London Stroke Register 
of 2625 patients with first-ever stroke, with > 10 years of follow-up data (54). At 15 years, 262 
(21%) had survived, with mild disability in 33.8% of the survivors (95% CI: 26.2% to 42.4%), 
moderate disability in 14.3% (95% CI: 9.2% to 21.4%) and severe disability in 15.0% (95% CI: 
9.9% to 22.3%) of the survivors. At least 1 in 10 of the 15-year survivors had lived with moderate-
to-severe disability since their initial stroke and there was an accumulation of disability with time 
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(54). Similar findings have been observed in other stroke outcomes studies such as Anderson et al.  
(2004) and Hardie et al. (2004) (55, 56). 
1.3.3.1 Definition of Rehabilitation 
Rehabilitation is considered the current standard of care in the chronic phase of stroke and aims to 
augment the natural post-stroke recovery process and prevent further deterioration of function (6). 
The British Society of Rehabilitation Medicine defined rehabilitation as “a process of active change 
by which a person who has become disabled, acquires the knowledge and skills needed for 
optimum physical, psychological and social function” (57). The WHO defined stroke rehabilitation 
to encompass the coordinated delivery of intervention(s) provided by a multi-disciplinary team in 
conjunction with medical professionals, to improve patient symptoms and maximise functional 
independence and participation (social integration) using a holistic biopsychosocial model, as 
defined by the International Classification of Functioning, Disability and Health (ICF) (58). 
1.3.3.2 Models of delivery 
Australian clinical guidelines for stroke management (2017) recommend that stroke survivors are 
treated within a rehabilitation framework that ensures continued monitoring for improvement as 
well as identification and timely management of any deterioration, in consultation with stroke 
specialists (6). Rehabilitation is delivered across a variety of care settings such as acute or 
specialised rehabilitation wards within the hospital, in community outpatient settings and in the 
home. The National Stroke Rehabilitation Audit Report (2016) reported that 73% of hospital 
patients were managed in general rehabilitation wards and only 28% of overall stroke cases audited 
received targeted management in a dedicated stroke rehabilitation unit (6%) or neuro-rehabilitat ion 
unit (8%) or a combined acute/rehabilitation unit (14%) (59). 
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1.3.3.2.1 Inpatient Rehabilitation: Early Mobilisation 
Stroke unit care has incorporated a commitment to early mobilisation as an essential element. 
Despite limited evidence in past years, it has been well accepted that prolonged immobilisat ion 
negatively affects multiple (musculoskeletal, cardiovascular, respiratory and immune) systems, 
that immobility-related complications start early after stroke and that preclinical research postulates 
that there may be an early ‘critical’ period of enhanced neural plasticity during which the injured 
brain is most responsive to targeted interventions (60). 
The evidence regarding the type, dose and timing of these early interventions has been building 
steadily. A review and meta-analysis by Lynch et al. (2014) included five randomized controlled 
trials and 38 cohort studies (61). This review indicated a small improvement (non-significant) in 
the odds of improvement in BI with early mobilisation (OR 1·20, 95% CI: 0·77- 3.18, p=0·23; OR 
1·16, 95% CI: 0·61–2·18; p=0·66, with significant heterogeneity I2=66%). In 2015, the findings of 
the AVERT Phase III trial were published (62). This randomized controlled study, conducted in 
2104 patients reported that patients who received a ‘very early mobilisation’ (VER) protocol 
(average of 6.5 out-of-bed sessions per day, starting 18.5 hours post-stroke) experienced a less 
favourable outcome at 3 months (62). Subsequent subgroup analysis indicated that this is more 
likely to be the case in individuals who had a more severe stroke or intracerebral haemorrhage (62). 
While this changed practice to one that discourages very early, intensive mobilisation training, 
Bernhardt et al. later reported a pre-specified dose analysis that evaluated the impact of dose and 
timing of mobilisation on outcomes (63). The analysis indicated that more frequent but shorter 
duration mobilisation sessions might potentially result in better outcomes. Further to this, Reuter 
et al. (2016) reported insights from an analysis of the Baden-Wuerttemberg stroke registry 
regarding the application of VER in acute ischaemic stroke and intracerebral haemorrhage in real 
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world clinical practice (64). They indicated that in current clinical settings, the selection of patients 
receiving VER and its frequency was often driven by the need to optimize resources, and those at 
either extreme of the prognostic spectrum were least likely to receive therapy. This underscores the 
need for further research to identify the specific patient subgroups likely to most benefit from VER, 
to help in effective resource allocation. 
1.3.3.2.2 Early Supported Discharge  
Early supported discharge (ESD) is an attractive model that links inpatient care with community 
services and provision of rehabilitation services within the home environment with the goal to 
establish skills that are appropriate to the patient’s home setting. The Cochrane review by Fearon 
et al. (2012) reported that ESD groups had a significantly shorter hospital stay equivalent to 
approximately seven days (65). Importantly, ESD was associated with decreased risk (65) of: 
• death or institutionalisation (OR 0.78, 95% CI: 0.61 to 1.00, p = 0.05) and  
• death or dependency (OR 0.80, 95% CI: 0.67 to 0.97, p = 0.02 respectively).  
A recent update to this review published in 2017 included 17 clinical trials recruiting 2422 stroke 
patients (66). The OR for the outcome of death or dependency at a median follow up of 6 months 
(range 3-12 months) was 0.80 (95% CI: 0.67 to 0.95, p = 0.01); for death was 1.04 (95% CI: 0.77 
to 1.40, p = 0.81) and death or requiring institutional care was 0.75 (95% CI: 0.59 to 0.96, p = 
0.02), respectively (66). Participants showed improvement in extended activities of daily living 
scores but the standardized mean difference (SMD) (0.14, 95% CI: 0.03 to 0.25, p = 0.01) was 
small and the impact on participants' activities of daily living scores was unclear. Furthermore, the 
evidence for benefits tended to be weaker at one- and five-year follow-up. Importantly, the greatest 
improvement in outcomes were seen in the trials evaluating a co-ordinated ESD team in 
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comparison to results in those services without a co-ordinated team (subgroup interaction at p = 
0.06) (66). In addition, patients with mild to moderate disability at baseline showed greater benefit 
than those with more severe stroke (subgroup interaction at p = 0.04) (66). These studies support 
the recommendations by the Australian Clinical Guidelines for Stroke Management 2017, as well 
as the AHA/ASA Rehabilitation guidelines for stroke (2016). The guidelines reiterate that 
appropriately resourced ESD services with co-ordinated multidisciplinary team input can reduce 
long-term dependency, admission to institutional care and the length of hospital stay, especially in 
patients with mild to moderate disability (6, 8). Notwithstanding this, the Australian National 
Stroke Audit found that only 4% of overall patients discharged from acute care received EDS (22). 
It is critical that goals for recovery are client-centred, clearly communicated and documented and 
are determined in collaboration with the stroke survivor and their family/carer. The beneficial effect 
of establishing clear goals and seeking input of the stroke survivor in articulating these goals has 
been reported in multiple studies (67-69). 
1.3.3.2.3 Rehabilitation in community  
Stroke rehabilitation for people living in the community, is delivered in either a centre, outpatient 
or day hospital setting. A meta-analysis published by Hillier et al. (2010) included 11 randomized 
controlled trials that compared home-based and centre-based rehabilitation and reported that home-
based rehabilitation was associated with a significant increase in BI scores at 3-6 months versus 
centre-based rehabilitation (mean difference (MD) of 4.07 points, 95% CI: 0.81 to 7.44, p=0.99) 
(70). However, the differences were no longer significant at 6 months (70). Rasmussen et al. (2016) 
reported on the findings of a randomized control trial (RCT) that assessed quality of life and 
disability outcomes among patients assigned to home-based or standard care (71). The home-based 
21 
 
rehabilitation group demonstrated significantly improved quality of life measured by EuroQol-5D: 
intervention median = 0.77 (Interquartile Range (IQR) 0.66 to 0.79) versus the control median = 
0.66 (IQR 0.56 to 0.72, p=0.03) and lesser disability (reduced mRS): intervention median=2 (IQR 
2 to 3); control median = 3 (IQR 2 to 4, p=0.04) (71). Coupar et al. (2012) published a Cochrane 
review that analysed the relative benefit from home-based rehabilitation for individuals with upper 
limb impairment following stroke (72). This review included four studies with a total of 166 
participants. Three studies compared the effects of home-based upper limb therapy programs 
versus usual care and one study compared the effects of a home-based upper limb program with a 
similar hospital-based programme (72). No statistically significant difference in the activities of 
daily living (ADL) score, functional movement of the upper limb, extended ADL or upper limb 
motor impairment was found in either comparison (72). The 2017 Australian practice guidelines 
recommend that home-based rehabilitation may be considered as a preferred model for delivering 
rehabilitation in the community (6). However, centre-based care should be available to all patients 
with stroke in the community if home-based rehabilitation is unavailable (6). 
1.3.3.3 Targets of Rehabilitation 
1.3.3.3.1 Sensorimotor Impairment 
Weakness is the most often reported impairment after stroke (73). Strength training and task-
oriented training have been the ‘cornerstone’ strategies to manage weakness. Recently, 
electromechanical and robot-assisted training have been reported to assist passive and active 
movement training and augment motor learning (73). A Cochrane review by Mehrholz et al. (2018) 
analysed data from 45 trials (involving 1619 participants). Electromechanical and robot-assisted 
arm training improved: activities of daily living scores (SMD 0.31, 95% confidence interval (CI) 
0.09 to 0.52, P = 0.0005; I² = 59%; 24 studies, 957 participants, high-quality evidence); arm 
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function (SMD 0.32, 95% CI 0.18 to 0.46, P < 0.0001, I² = 36%, 41 studies, 1452 participants, 
high-quality evidence); and arm muscle strength (SMD 0.46, 95% CI 0.16 to 0.77, P = 0.003, I² = 
76%, 23 studies, 826 participants, high-quality evidence) (73). In 2014, Nascimento et al. published 
a review and meta-analyses that showed that the use of cyclical electrical stimulation had a 
moderate positive effect on muscle strength, along with a small-to-moderate improvement in 
activity (74). Importantly, the effect was seen across different levels of initial weakness and in both 
subacute and chronic phase stroke (74). Mehrholz et al. (2017) recently evaluated evidence 
regarding the effect of electromechanical-assisted gait training in combination with physiotherapy 
on walking (75). Data analysis from 36 RCTs (1472 participants) in this review provided moderate-
quality evidence supporting the use of electromechanical-assisted gait training in combination with 
physiotherapy (75). The intervention increased the likelihood of regaining independence in 
walking (OR 1.94, 95% CI: 1.39 to 2.71, p < 0.001; I² = 8%) but did not indicate any significant 
benefit in terms of walking velocity or walking capacity (75). It was also noted that the benefit with 
this strategy was only seen in the acute phase and not in the chronic phase. However, the authors 
expressed caution about the clinical interpretation of these findings due to significant variability in 
study design, study population and types of devices used. Post-hoc analysis suggests that 
differences between the types of devices may have a significant impact on walking velocity but not 
on the overall ability to walk (75). Therefore, the current Australian practice guidelines support the 
use of electromechanical training in patients with upper/lower limb weakness who have less than 
antigravity strength (6). 
Somatosensory impairments, especially in touch sensation and proprioception are detected in 
approximately 40% of stroke patients (76) and these can negatively impact on motor recovery and 
compromise a patient’s ability to lead a safe independent life and regain their levels of participation 
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prior to stroke (76, 77). The National Stroke Rehabilitation Audit indicated that 78% of Australian 
hospitals had local protocols for assessment of sensory deficits (59). Most research in the context 
of sensory impairment has focussed on the upper limb using either a sensory retraining approach 
or sensory stimulation approach. Though multiple interventions have been described in the 
literature such as tactile stimulation, mental imagery, mirror therapy, thermal therapy and 
pneumatic compression therapy, the overall impact of these interventions on recovery of sensation 
and ADLs has been small and inconclusive (76, 77,78). Lynch et al. (2007) investigated sensory 
retraining for the foot and lower limb in a small RCT and reported no benefits (79). 
1.3.3.3.2 Visual Impairment 
Visual impairment most commonly presents as visual field loss and is seen in approximately 30–
60% of stroke survivors (59, 80). Patients may have diplopia, difficulties with ocular convergence, 
impaired saccadic movement, over-sensitivity to light, nystagmus or dry eyes. These often interfere 
with activities such as reading, writing, moving around and driving (80). Interventions for visual 
impairments have mainly targeted deficits in eye movements, visual fields and visual-spatial or 
perceptual deficits by employing either restitutive or compensatory strategies (such as Fresnel 
prism glasses, computer-based visual retraining programs or visual scanning, multimodal audio-
visual exploration training and virtual reality training) (80). Even though seven systematic reviews 
have been published in this field, conclusive evidence is still lacking due to the poor methodology 




1.3.3.3.3 Physical Activity  
1.3.3.3.3.1 Amount of Rehabilitation 
Systematic reviews (82, 83) and meta-regression analysis (84) have established that structured 
rehabilitation to maximise therapy time within individual tolerance limits, is associated with 
consistent, moderate benefit in improving walking ability, arm function and quality of life . 
Schneider et al. (2016) pooled data from 14 studies (954 participants) that focussed on upper limb 
activity, walking ability or a combination. Increased therapy time was associated with improvement 
in activity though there was significant heterogeneity between studies (upper limb and lower limb 
combined, SMD=0.39, 95% CI: 0.07 to 0.71, I2=66%) (82). English et al. (2016) published a meta-
analysis and reported that the provision of therapy for seven days /week instead of the usual five 
days/week in an inpatient setting reduced the average length of stay in the rehabilitation unit but 
resulted in no significant difference in walking speed or functional independence and health-related 
quality of life measures at discharge (83). Winstein et al. (2016) reported the results from a large 
RCT (the I CARE trial) with no additional benefit found from doubling the amount of arm motor 
therapy (~ 28 hours/week) (84). Thus, the literature is still inconclusive regarding what may be the 
optimal quantum of therapy as well as the best strategy to deliver that consistently over the long-
term. The 2017 Australian guidelines suggest that a minimum of three hours a day of scheduled 
therapy that ensures at least two hours of active task practice may be reasonable, but the feasibility 
of attaining this consistently is dependent on multiple factors such as level of disability, patient 
engagement and modality of delivery (6).  
1.3.3.3.3.2 Cardiorespiratory Fitness 
Compromised cardiorespiratory fitness is very common amongst stroke survivors as reported by 
multiple studies that documented peak oxygen consumption (VO₂ peak) values of stroke patients 
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to be 26-87% of values seen in age- and gender-matched normative values (85). Activities essential 
for independent living require peak VO2 of 15-18 mL O2/kg/min and limited cardiorespiratory 
reserve represents a significant functional and quality-of-life challenge (86). Saunders et al. (2016) 
published a Cochrane review including 58 trials (797 participants) that evaluated cardiorespiratory 
interventions, resistance interventions and mixed training interventions (86). Cardiorespiratory and 
mixed training interventions resulted in moderate improvement in: global indices of disabilit y 
(combined disability scales) and physical fitness (peak VO2), as well as a small improvement in 
mobility (maximum walking speed, preferred gait speed and walking capacity) and balance 
measures (86). Recent research indicates that generic exercise after stroke can result in clinically 
meaningful health benefits across other disability domains in addition to activity level (87). At the 
impairment level, exercise potentially improves bone health, fatigue, and executive functioning, 
memory and post-stroke depression. At the participation level, exercise training has been associated 
with increased likelihood of social participation, return to work and improved quality of life (87). 
All practice guidelines recommend early assessment of cardiorespiratory fitness and inclusion of 
individually tailored exercise interventions in the rehabilitation plan for all stroke survivors (6, 8).  
1.3.3.3.4 Balance, Posture and Mobility  
Balance dysfunction following stroke is common and sitting balance has been used as a prognostic 
indicator for motor recovery (Feigin et al. 1996) (88). Sitting balance is an important predictor of 
recovery. Sitting equilibrium after a stroke has been found to have moderate to strong correlation 
with: BI score at 1 week (Loewen & Anderson, 1990) (89); walking ability at 6 months (Feigin et 
al. 1996) (88); and 6 -week gait ability (Sandin & Smith, 1990) (90). Sitting training interventions 
such as lateral weight transfer training, trunk exercises, body vibration and the practice of reaching 
beyond arm's length while sitting, were studied in various studies with different design elements. 
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Veerbeek et al. (2014) examined evidence from six RCTs (150 participants) using these 
interventions (91). Only studies with repetitive training interventions for reaching beyond arms-
length (3 trials, 50 participants) were associated with improvement in reach distance and ground 
reaction force. Bank et al. (2016) provided more recent data from 11 low to moderate quality RCTs 
published up to 2013, with cohort size between 9-65 participants (92). Meta-analysis of pooled 
data reported a non-significant improvement in Trunk control test (TCT) and significant 
improvement in Trunk impairment scale (TIS) (92). This is important in the context of the 
recommendations from the American Physical Therapy Association that suggest that TIS may be 
the preferred outcome measure for sitting balance due to its responsiveness and reliability across 
different patient settings (93). Additional randomised trials assessing novel interventions such as 
training on a tilted platform, weight-shift training, and combined transcutaneous electrical nerve 
stimulation (TENS) and task-related trunk training were published recently and provide initial data 
on their effectiveness (94, 95, 96). The ability to transfer from sitting to standing position is critical 
to independent functioning after a stroke. Rehabilitation approaches have focused on repetitive task 
practice, strength training and more commonly, a combination of both (91). These are delivered as 
part of general interventions such as task-specific walking training and circuit class therapy, ideally 
initiated early after stroke. Multiple reviews have reported on the evidence for improved sit-to-
stand ability following repetitive task practice and general interventions respectively (91, 97, 98). 
Use of consistent biofeedback, e.g., the number of repetitions/session/day, and time to complete a 
specific number of sit-to-stands, may augment training effectiveness as reported by Stanton et al.  
(2011) (99). French et al. (2007) published a review of seven RCTs and reported moderate benefits 
on the ability to stand from sitting (SMD 0.35, 95% CI: 0.13 to 0.56) following repetitive task-
specific training (97). Veerbeek et al. (2014) reported non-significant improvement in body weight 
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distribution, sit-to-stand, and balance (91). Pollock et al. (2014) pooled data from 13 trials (603 
participants) that used different interventions such as repetitive sit-to-stand training and exercise 
programs that included sit-to-stand training, sitting training and augmented feedback (98). The 
authors reported that only four studies were of high quality. Only one study (48 participants) 
reported on the ability to sit-to-stand independently as an outcome, reporting significant increase 
in the odds of independent standing following training (OR 4.86, 95% CI: 1.43 to 16.50) (98). More 
commonly, studies reported on change in measures such as time taken to stand (7 trials) or lateral 
symmetry (5 trials), wherein significant improvements were seen (98). 
Standing balance plays a key role in the ability to walk and perform various activities of daily living 
and in decreasing the risk of falls after stroke (100). Stroke survivors present with limitations in 
postural sway, weight transference, and maintaining their balance in standing posture (100). 
Evidence from systematic reviews supports improvement of standing balance following exercise 
training that specifically includes either functional task practice in standing and weight-shifting or 
walking training that includes a balance challenge, e.g., overground walking or walking on obstacle 
courses (91, 100, 101). Miklitsch et al. (2013) demonstrated that balance training on a dynamic 
surface as compared to a stable surface did not result in a significant difference as measured by 
Timed Up and Go (TUG) performance (between-group difference of 2.89 sec; p = 0.100) (102). 
Corbetta et al. (2015) published a meta-analysis of studies evaluating virtual reality training 
interventions (103) and reported that small improvements in standing balance (Berg Balance Scale 
increase of 2.1 points, 95% CI: 1.8 to 2.5) and mobility (TUG improvement of 2.3 seconds, 95% 
CI: 1.2 to 3.4) (103). Cheok et al. (2015) examined the use of virtual reality provided through use 
of a Wii balance board in addition to standard care, and reported significant improvement in 
mobility (TUG) (SMD 0.81 (95% CI: 0.29 to 1.33, p=0.002, I2=0%) but not in balance (104). 
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Impaired walking impacts up to 75% of the overall stroke population in Australia and this can 
interfere with independent mobility (22). Systematic reviews by different groups such as Mehrholz 
et al. (2017), van de Port et al. (2012), Veerbeek et al. (2014), English et al. (2017) and Laver et al.  
(2017), analysed and reported data on various interventions that targeted walking impairment (75, 
91, 101, 105, 106). These included: task-specific overground training (19 RCTs; 1008 
participants); rhythmic gait cueing (6 RCTs; 231 participants); joint position feedback (11 RCTs; 
254 participants); electrostimulation by (a) neuromuscular stimulation (NMS) (18 RCTs with 
551participants), (b) electromyography-triggered neuromuscular stimulation (EMG-NMS) (2 
RCTs, 68 participants) and (c) transcutaneous electrical nerve stimulation (TENS) (5 RCTs,  349 
participants); virtual reality training (6 RCTs, 150 participants); mental imagery (6 RCTs, 231 
participants) and use of an orthosis (4 RCTs, 137 participants) (75, 91, 101, 105, 106). These 
interventions are delivered using different modalities such as circuit class training, treadmill 
training (31 RCTs, 1768 participants), electromechanically assisted training with/without 
functional electrostimulation (19 RCTs, 915 participants), and community-based ambulation 
training (3 RCTs, 94 participants) (75, 91, 101, 105, 106). Repeated motor practice has been 
postulated to be the physiological basis of motor learning (107). Repetitive task training (RTT) 
underpins the majority of modalities listed above to deliver interventions aimed to improve walking 
deficits (107). French et al. (2016) published a comprehensive review of the impact of RTT on 
different walking measures: walking distance (change from baseline: MD 34.80, 95% CI: 18.19 to 
51.41; nine studies, 610 participants); walking speed (SMD 0.39, 95% CI: 0.02 to 0.79; 12 studies, 
685 participants); functional ambulation (SMD 0.29, 95% CI: 0.10 to 0.48; 5 studies, 419 
participants) (108). Australian practice guidelines and ASA guidelines strongly recommend 
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tailored repetitive practice of walking delivered via circuit class therapy or treadmill training (6, 
8). 
1.3.3.3.5 Upper limb activity 
In acute stroke patients in Australia, 69% present with upper limb impairment (22). The upper limb 
(UL) function is subdivided into proximal or ‘arm’ (i.e. shoulder/elbow) and distal or ‘hand’ 
function (i.e. wrist, hand and fingers) (6). 
French et al. (2016) reported that there is low quality evidence for benefit in arm function (SMD 
0.25, 95% CI: 0.01 to 0.49; 11 studies, 749 participants) and non-significant benefit in hand 
function (SMD 0.25, 95% CI: 0.00 to 0.51; 8 studies, 619 participants) for RTT delivered via 
different interventions (108). 
Pollock et al. published a Cochrane review in 2014 that analysed 40 reviews investigating different  
interventions for improving upper limb function (503 studies with 18,078 participants) (109). This 
review reported that moderate-quality evidence exists for effectiveness of constraint-induced 
movement therapy (CIMT), mental practice, mirror therapy, interventions for sensory impairment, 
virtual reality and a relatively high dose of repetitive task practice. They also reported that unilateral 
arm training may be more effective than bilateral arm training (109).  
Corbetta et al. (2015) published a Cochrane review of 42 trials (1453 participants) and reported 
that CIMT improved arm function, dexterity (hand function) and arm motor impairment (110). 
However, this was not associated with a significant effect on the overall ability to perform activities 
of daily living in the short- or long-term. Kwakkel et al. (2015) compared the impact of CIMT (1 
hour/day initiated within 2 weeks of stroke) with usual care, in patients with some residual finger 
extension, and reported improvement in the CIMT group as compared to the control (111).  
30 
 
Mehrholz et al. (2015) reported that mechanically assisted arm training modestly improves arm 
function and activities of daily living, though the strength of the evidence is moderate to low due 
to variability in the types of devices used and the number of repetitions (112).  
Laver et al. (2017) reported a small but significant benefit with virtual reality and interactive video 
gaming for arm function and activities of daily living when used as an adjunct to usual care in 
participants with mild to moderate arm impairment. However, this benefit was limited to the early 
(first 6 months) post-stroke period (106).  
Australian and ASA guidelines recommend that all individuals with stroke should receive task-
specific training and ADL training, tailored to individual capabilities and that this training should 
be increased in difficulty on a periodic basis depending on gain in function (6, 8). 
1.3.3.3.6 Communication 
1.3.3.3.6.1 Assessment  
The 2017 National Stroke Audit of acute stroke services reported that 57% of stroke patients 
presented with communication and speech problems (22). Previous studies such as Bowen et al.  
(2012) and Hoffmann et al. (2013) have reported that about one-third of people have persisting 
communication deficit after stroke (113, 114). Practice guidelines recommend that stroke patients 
be assessed by a speech pathologist within 48 hours of admission to determine the type and severity 
of the communication impairment (6, 8). 
1.3.3.3.6.2 Disorders of speech – Aphasia, Dysarthria and Apraxia 
Aphasia is defined as an acquired impairment of the language system following brain damage and 
is seen commonly after a stroke involving the left hemisphere (114). The National Stroke Audit 
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(2017) reported that around a third of stroke patients had aphasia on admission (22). Brady et al.  
(2016) published a Cochrane review that analysed data on speech and language therapy (SLT) from 
57 small RCTs (3002 participants) (115). SLT significantly improved functional communication 
reading, writing, and expressive language (SMD 0.28, 95% CI: 0.06 to 0.49, p = 0.01), as compared 
to no SLT (115). This review also studied the emerging data from comparative studies of different 
therapy regimens (intensity, dosage and duration), delivery models (group, one-to-one, volunteer 
and computer facilitated) and theoretical approaches (constraint-induced therapy and semantic 
therapy) (115). There is currently no indication that delivery models per se have significant impact 
in terms of difference in efficacy (115). There is emerging data to suggest that higher intensity 
interventions were associated with bigger improvements in functional language skills but this came 
at the cost of higher drop-out rates and were likely not maintained long-term (115). The current 
practice guidelines support the provision of SLT as early as tolerated (6, 8). 
Dysarthria is a collective term for a group of speech output disorder problems that result from 
impaired movements of the speech musculature including lips, tongue, palate, larynx and the 
respiratory muscles (113). Approximately 20% of stroke patients present with dysarthria and it 
often leads to restricted efficiency of communication and social participation (116). Mackenzie et 
al. (2014) reported that non-speech oro-motor exercises did not provide additional benefit to 
behavioural speech practice (117). Mitchell et al. published a Cochrane review in 2017 to analyse 
interventions for management of dysarthria (118). These interventions targeted: 
• Impairment: non-speech and oro-motor exercises or external stimulation (via transcranial 
magnetic stimulation or acupuncture) of the muscles  
• Activity: use of augmentative communication devices (non-technical materials such as an 
alphabet chart or text-to-talk computer devices)  
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• Participation: conversational training and behavioural therapy. 
The review analysed data from four small studies in stroke, published up to 2016 and provided 
preliminary evidence for potential benefit from individually tailored interventions including 
behavioural techniques and use of augmentative and alternative communication devices (118).  
Apraxia of speech represents a disorder of motor planning or programming resulting in difficulty 
in volitionally producing the correct sounds of speech (119). A systematic review by Ballard et al.  
(2015) indicated that the current level of evidence is low, as it is predominantly composed of case 
series or uncontrolled case studies (119). Both articulatory–kinematic and rate/rhythm-based 
interventions may facilitate clearer production of speech sounds, but this was not associated with 
improvement in overall communication (119).  
Right hemisphere stroke can be associated with dysfunctional exchange of communicative intent 
through nonverbal and verbal means (120), often at a conversational level. It is characterised by 
prosody (flat melody of speech or difficulties interpreting emotion/intent contained in another 
person’s speech), expressive and receptive discourse (difficulties understanding intent in language)  
and pragmatics (disrupted functional use of language in context) (120). Research literature is 
currently limited (120). Practice guidelines based on consensus, suggest the use of cognitive-
linguistic treatments to improve use of emotional tone (121) and semantic-based treatment to 
improve metaphorical comprehension (122). 
1.3.3.3.7 Cognition and Perception 
The National Stroke Rehabilitation Services Audit Report in 2016 stated that approximately 60% 




Cognitive impairments are comprised of deficits in different domains: attention, memory, 
orientation, language, executive functions, neglect, apraxia and agnosia. Cognitive deficits have 
been associated with doubling the risk of dependent living at 3 months (123) and tripling the risk 
of death (123). Practice guidelines across the globe recognise the significance of this risk and 
recommend screening for cognitive and perceptual deficits by trained personnel, for all stroke 
survivors prior to discharge from hospital (6, 8). 
1.3.3.3.7.2 Disorders: Executive Function, Attention, Concentration, Memory 
and Perception 
Approximately 75% of stroke survivors suffer from some degree of executive dysfunction (124, 
125). The presence of dysfunction negatively affects the ability to regain independence in ADL, 
especially in patients who have concomitant limb weakness, and it can decrease the likelihood of 
success of many targeted rehabilitation interventions dependant on goal-oriented behaviour (124). 
Cognitive rehabilitation strategies (125, 126) to address executive dysfunction can be:  
• Restorative interventions: self-awareness training, intensive neurorehabilitation, standard 
neurorehabilitation combined with cognitive remediation, problem-solving/goa l 
management/strategy training, autobiographical memory cueing, working memory training 
and verbal feedback  
• Compensative interventions: intensive neurorehabilitation, standard neurorehabilitat ion, 
video-feedback, verbalisation, chunking and pacing, and directive feedback 
• Adaptive interventions: interventions targeted to improve independence with ADL. 




Attention is defined as selectively concentrating on a discrete aspect of information. Attention 
impairments may be specific (e.g. selective, sustained, divided) or generalised. Attention deficits 
during the acute phase have been reported to range between 46% and 92% (127). Approximately 
20-50% of stroke survivors continue to suffer from attention deficit up to 5 years post-stroke (128). 
A Cochrane review by Loetscher et al. (2013) analysed data from 6 RCTs (223 participants) and 
found that cognitive rehabilitation improved measures of divided attention (SMD 0.67, 95% CI: 
0.35 to 0.98, p < 0.0001) in the short-term but didn’t improve global measures of attention or 
functional outcome; nor did it provide persisting benefits (129).  
Memory impairment after stroke has been estimated to affect between 23% and 55% of stroke 
patients at three months and between 11% and 31% at one year after stroke (130) and may affect 
different aspects such as language-based memory, visual-spatial memory, differentiating learning, 
recall, recognition and forced-choice memory. Nair et al. (2016) published a Cochrane review that 
analysed data from 13 trials (514 participants) (131). The review analysed various types of memory 
retraining techniques such as computer-assisted programs and training with memory aids (diaries 
or calendars), delivered in community (7 studies), inpatient (4 studies), and mixed community and 
inpatient settings (2 studies) (131). 
The review reported improvement in immediate subjective memory measures (SMD 0.36, 95% CI: 
0.08 to 0.64) (131). However, these benefits did not persist in the long-term. The review found no 
evidence of significant impact on level of independence in ADLs, mood, or in quality of life (131). 
Perceptual impairment after stroke can present as: visual or object agnosia (the inability to process 
sensory information or recognize objects, faces, voices, or places); prosopagnosia (the inability to 
recognize faces); and perceptual disorders involving visuospatial or tactile sensation, location, 
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motion, colour or auditory processing (6). Though literature regarding their prevalence is currently 
scant, according to the National Stroke Rehabilitation Services Audit Report in 2016, some type of 
perceptual deficit is seen in about 25% of stroke patients (59). Rehabilitation strategies usually 
include functional training, sensory stimulation, strategy training and task repetition to target the 
specific perceptual deficit in the individual. However, there is very little evidence, at present, to 
support the use of these interventions (6). 
1.3.3.3.7.3  Limb Apraxia 
Limb apraxia is defined as impairment in planning and sequencing of movement, not caused by 
weakness, incoordination, or sensory loss. Lindsten-McQueen et al. (2014) estimated that the 
prevalence of limb apraxia in people with left hemisphere stroke ranges from 28% to 51% (132). 
This systematic review analysed data from eight studies: four RCTs and four pre-post designs. 
These studies employed different treatment approaches: errorless learning with training of details 
(one trial), gesture training (two trials), and strategy training (five trials) (132). The review provides 
preliminary indication of potential benefit with these treatment strategies but highlights an urgent 
need for validation through larger, adequately-powered studies (132).  
1.3.3.3.7.4  Neglect 
Spatial neglect is described as the failure to attend to sensory or visual stimuli on the affected side  
(133). The National Stroke Audit Report in 2016 stated that approximately 30% of stroke survivors 
in Australia demonstrated spatial neglect (59).  
Rehabilitation interventions such as visual scanning with sensory stimulation, eye patching, simple 
cues, mental imagery and combinations of these trainings, have been used to manage neglect.  
Bowen et al. (2013) reviewed data from 23 RCTs with 628 participants (133). These studies 
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examined strategies such as computerised scanning training, pen and paper tasks, visual scanning 
training, eye patching and mental practice. The review concluded that there was limited evidence 
to support benefit with these interventions. Recent studies that examined use of a combination of 
these therapies (134, 135) and use of mirror therapy (136), reported meaningful benefit . Thus, 
current evidence for use of these interventions is inconclusive. 
1.3.3.3.8 Activities of Daily Living (ADL) 
ADLs are defined as routine self-care tasks that are part of everyday life and are usually divided 
into two types: basic and extended. Basic ADLs are tasks related to self-care and essential mobilit y 
and extended ADLs or instrumental activities of daily living (IADLs) are tasks that may not be 
necessary for fundamental functioning but are important for an individual to live independently 
(137). Around 87% of stroke survivors in Australia were considered to have difficulties with ADL 
(59). The majority of stroke survivors receive some intervention and ADL training in hospitals, 
including task-specific practice (91%) and training in the use of appropriate aids and equipment 
(62%) (59). 
A Cochrane review that examined evidence for the use of occupational therapy for adults with 
problems in activities of daily living after stroke was published in 2017 to update data from recent 
studies (138). In this update, the authors (Legg et al.) reported on data from nine studies (994 
participants). Targeted occupational therapy interventions improved overall ADL performance 
scores (SMD 0.17, 95% CI: 0.03 to 0.31, p = 0.02) and reduced the risk of poor outcome (death, 
deterioration or dependency in personal activities of daily living) (OR 0.71, 95% CI: 0.52 to 0.96, 
p = 0.03) (138). The review indicated a higher likelihood for individuals on occupational therapy 
to be more independent in IADLs (OR 0.22, 95% CI: 0.07 to 0.37, p = 0.005) (138). However, this 
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did not translate into any meaningful impact on mortality (OR 1.02, 95% CI: 0.65 to 1.61, p = 
0.93), combined odds of death and institutionalisation (OR 0.89, 95% CI: 0.60 to 1.32, p = 0.55), 
or death and dependency (OR 0.89, 95% CI: 0.64 to 1.23, p = 0.47) (138). Furthermore, there was 
no benefit of these interventions on mood or distress scores (OR 0.08, 95% CI: -0.09 to 0.26, p = 
0.35) (138). Overall, the quality of evidence was low due to the risk of patient selection bias, 
performance and detection bias, and limited availability of data for key outcomes of interest (138). 
Australian stroke clinical practice guidelines strongly recommend that all stroke survivors undergo 
a comprehensive assessment of their ADLs/IADLs prior to discharge into the community. A 
continuum of care should be ensured while in the community through relevant task-specific 
practice and training in the use of appropriate aids and ongoing assessment and modification of 
intervention by trained clinicians (6). 
Research in the field of rehabilitation has predominantly consisted of small trials with less rigorous 
design, due perhaps to the challenges that persist with the implementation of large scale, rigorous 
trials. Clinical practice has evolved in the field of rehabilitation, based predominantly on systematic  
reviews, which in turn are inherently limited in terms of strength of evidence by the lack of rigour 
in the studies included. The overall volume of stroke rehabilitation publications in the last four 
decades has grown considerably with approximately 35% of all the RCTs published in just the last 
five years (139).  
Some of the challenges that need to be addressed urgently are the understanding of the 
underpinning biology of post-stroke recovery, the complex interactions between different domains 
of disability and the lack of feasibility of having single outcome measures that can adequately 
reflect changes across impairment, activity and participation attributes (139). 
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1.4 Current Gaps in Research: Ischaemic Stroke 
The approaches to stroke research have predominantly been along the following pathological 
principles (139, 140, 141, 142): 
• re-establish blood flow to the ischaemic region (reperfusion strategies) 
• modulate varied molecular pathways involved in ongoing neuronal injury after the initial 
ischaemic insult (neuroprotection) and,  
• augment endogenous neural recovery, either by acquisition of the new skills needed for 
optimum physical, psychological and social function with a given level of disabilit y 
(rehabilitation) or by restitution of neural networks (CTs). 
Of the above approaches, reperfusion is an established part of acute clinical management. However, 






The interruption of blood supply to the brain triggers a neuronal ischaemic cascade and leads to 
energy failure, and ultimately neuronal damage. Basic research has established that neurons are 
most susceptible to the acute onset of ischaemic damage (142). Further to this, ischaemic insult 
leads very quickly to damage of endothelial cells and pericytes, which compromise the integrity of 
the blood brain barrier (142). This leads to local release of Ca+2, enzymes and cytokines (i.e., IL-1 
and TNF-α), activation of resident immune cells (i.e., microglia) and recruitment of peripheral 
inflammatory cells (143). Large multiprotein complexes called inflammasomes, e.g. NOD-like 
receptor proteins, are early central players that efficiently amplify the initial immune response to 
cell injury and lead to ongoing recruitment of peripheral macrophages as well as an increase in 
reactive microglia and astrocytes in the peri-infarct zone (144). These different cell types in 
cerebral tissue are intricately co-located and directly or indirectly influence each other (144). The 
inflammatory cascade represents an interplay of different molecular pathways involved in: 
neuroinflammation, excitotoxicity, calcium channels’ over-activation and reactive oxygen species 
(ROS) production (145, 146). This cascade continues to be relevant in the sub-acute and chronic 
phase of stroke and plays an important role in both neural injury as well as repair (147). 
Numerous chemical and biological candidates targeting different molecular and cellular aspects of 
this cascade have been investigated to date (148). Unfortunately, the potential seen with these 
therapies in the preclinical stage of research was not realised, as clinical trials of both 
pharmacological and non-pharmacological neuroprotective treatments reported negative results 
(148). Examples are the NEST-3 and FAST-MAG phase III trials. The NEST-3 trial (Neurothera 
Effectiveness and Safety Trial 3) examining the use of transcranial lasers in acute stroke reported 
futility in its interim analysis in 2014 (149). The FAST-MAG trial (Field Administration of Stroke 
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Therapy–Magnesium) of pre-hospital magnesium infusion reported no difference in post-stroke 
outcomes between the intervention and placebo groups (no significant shift in the distribution of 
90-day mRS, p=0.28 and no difference in the mean 90-day mRS scores, 2.7 in each group, p=1.00) 
(150). Further to this, the investigators recently reported that there was no association of clinical 
outcomes with achieved magnesium levels, which provides further evidence that magnesium may 
not be neuroprotective in acute stroke (150). A Cochrane review by Zhang et al. (2012) analysed 
data from 34 RCTs (7731 patients) that investigated the use of calcium antagonists (nimodipine in 
26 trials, flunarizine in three trials) (151). There was no benefit observed on the primary outcome 
of death or dependency at the end of follow-up (relative risk (RR) 1.05, 95% CI: 0.98 to 1.13), or 
on death at the end of follow-up (RR 1.07, 95% CI: 0.98 to 1.17) (151). In addition, subgroup 
analysis of different doses of nimodipine indicated that the higher doses were associated with 
poorer outcome (151). 
There has been a recent resurgence of interest in neuroprotection with clinical studies ongoing with 
agents that target immunomodulation (Natalizumab), free radical scavenging (Edaravone) and 
excitotoxicity (PSD-95 inhibitor Tat-NR2B9c or NA-1). A phase II study of safety and efficacy of 
Natalizumab in patients with acute ischaemic stroke (ACTION) reported no difference in infarct 
volume growth from baseline up to day 5 with natalizumab compared with placebo (relative growth 
ratio 1·09, 90% CI: 0·91 to 1·30, p=0·78) (152). However, the Natalizumab group demonstrated 
an improvement versus the placebo group. This improvement was defined as mRS scores of 0 or 1 
at day 30 and at day 90 (OR 2·88, 90% CI: 1·20 to 6·93, p=0·024 and OR 1·48, 90% CI: 0·74 to 
2·98, p=0·18 respectively) and BI score ≥95 at day 90 (OR 1·91, 90% CI: 1·07 to 3·41, p=0·033) 
(152). Isahaya et al. (2012) reported that Edaravone suppressed serum matrix metalloproteinase -9 
(MMP-9) level in a prospective cohort of patients with acute ischaemic stroke (153). The ENACT 
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(Evaluating Neuroprotection in Aneurysm Coiling Therapy) phase II clinical trial with Tat-
NR2B9c reported in 2012 that the Tat-NR2B9c (treatment) group sustained fewer ischaemic 
infarcts than the placebo group, as gauged by diffusion-weighted MRI (adjusted incidence rate 
ratio 0·53, 95% CI: 0·38 to 0·74) (154). Tat-NR2B9c is being investigated in an ongoing multi-
country Phase III ‘A Field Randomization of NA-1 Therapy in Early Responders’ (FRONTIER) 
clinical trial in ischaemic stroke administered within three hours by paramedics in the field (155). 
Since the key premise underpinning neuroprotection in acute ischaemic stroke is to enable 
administration of the agent as rapidly as possible following stroke onset in order to minimize infarct 
volume whilst awaiting reperfusion therapy, the limited time window of opportunity is likely to 
limit the overall impact of these agents, even if they are successful (156). 
1.4.2 Rehabilitation 
Research in preclinical stroke models and human stroke survivors confirms that a period of 
spontaneous recovery occurs early post-stroke with little or no active treatment (156). However, 
the duration and trajectory of this recovery varies across neural systems and across individua ls  
(157, 158). While there is evidence to suggest that the degree and rate of recovery can be predicted 
post-stroke in several domains using proportional recovery algorithms, the biological mechanisms 
determining these are still to be understood clearly (159). The first Stroke Recovery and 
Rehabilitation Roundtable (SRRR) convened in 2016 and published their consensus on key 
concepts in recovery research in 2017 (138). ‘Recovery’ is a biological construct that comprises 
two components: (1) the improvement in each functional outcome across time, and/or (2) the 
mechanisms responsible for this improvement (160). The mechanistic processes underlying 
recovery are believed to be compensation or behavioural restitution (139).  
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The process of ‘compensation’ is defined as the ability to accomplish a task through using a new 
approach rather than using their normal pre-stroke behavioural repertoire (160). This does not 
require neural repair but may require learning new ways of using intact neural or muscular 
pathways or the use of assistive devices to compensate for the function lost due to stroke. 
Rehabilitation strategies predominantly activate compensation mechanisms to effect recovery of 
function after stroke (139).  
 
Figure 1. Critical time points post-stroke that link to the currently known biology of recovery 
 
Reproduced with permission from Bernhardt et al. (2017) (139) 
Behavioural restitution (true recovery) on the other hand, describes the full or partial restoration of 
the repertoire of behaviours that were available to the individual before stroke-induced injury (160). 
This process would require neural repair and restitution of injured neuronal networks. Cell therapy 




1.4.3 Cell Therapies (CTs) 
1.4.3.1 Definition of Stem Cells  
Stem cells are distinct populations of cells in an organism that have the capacity to self-renew by 
dividing and to develop into more mature, specialized cells (163). Stem cells can be unipotent, 
multipotent, pluripotent or totipotent, depending on their potential to mature into different number s 
of cell types (163).  
1.4.3.2 Stem Cell Research in Stroke 
Research into stem cells has come a long way since the first in vitro cultures of stem cells in 1907, 
as reported by Maienschein in 2011 (164). Research in regenerative medicine over the past decades 
has demonstrated that endogenous stem cells and exogenous cell therapies can mediate different 
molecular pathways at different time points in the ischaemic cascade following stroke (165).  
The acute phase of the ischaemic cascade begins directly after the occluding event (146). The lack 
of blood flow to the ischaemic area triggers local oxidative stress and excitotoxicity, which 
damages neural tissue and results in vasogenic oedema and the disruption of ionic and Na+1 and 
Ca+2 accumulation in cells at the ischaemic core, which leads to cell death (146, 166, 167). The 
massive release of glutamate and the Na+1/Ca+2/K+1 imbalance result in cortical spreading 
depolarization characterized by widespread depolarization of neurons and astrocytes that has been 
demonstrated in electrophysiological and imaging studies (168). The cells in the ischaemic 
penumbra begin expressing signals associated with neuronal injury that upregulate local 
neuroinflammation (169) . Neuroinflammation is the pathologic hallmark of the subacute phase, 
which typically lasts for the first few days following the stroke onset, with the release of cytokines, 
chemokines, cellular adhesion molecules (CAMs) and matrix metalloproteases (MMPs) from 
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injured neuronal and non-neuronal cells, such as microglia and astrocytes (170, 171). Secretion of 
cytokines, chemokines, and CAMs, causes recruitment of peripheral neutrophils and macrophages 
through the injured blood brain barrier, resulting in ongoing damage to the neurovascular unit 
(171).  
The ischaemic cascade continues into the chronic phase, wherein activated microglia, astrocytes 
and endothelial cells become dominant players (165). The activated microglia exert a dualistic role 
in neurological recovery through their relative polarization into different phenotypes at different 
stages of injury (171). The reactive microglia and astrocytes release trophic factors such as 
VEGF/Flk1 and Ang-1/Tie2, BDNF, nerve growth factor, VEGF, IGF-1, hepatocyte growth factor 
and GDNF (171). These factors promote angiogenesis, stabilize vasculature, enhance cell survival, 
proliferation and differentiation, trigger neuroblast proliferation, promote neurogenesis and trigger 
migration of endogenous neural stem cells from the subventricular zone (171).  
There is extensive preclinical evidence from in vitro and in vivo models that different cell types 
being developed as (stem) cell therapies have the potential to induce endogenous brain repair 
processes, including neurogenesis, angiogenesis and synaptogenesis and provide trophic support 
to endogenous neural stem cells (165, 171, 172, 173). The administration of cell therapies in 
subacute stroke models has demonstrated suppression of pathways that modulate oxidative stress, 
reduction of mitochondrial activation and inhibition of apoptosis (165, 172). 
Some degree of brain recovery is nearly always achieved as part of ‘spontaneous recovery’ seen in 
all stroke survivors (173). Cell therapies augment this endogenous recovery by potentially 
regenerating and repairing neural pathways (173, 174). Cell therapies potentially present a 
treatment paradigm that may uniquely combat both subacute and chronic inflammatory processes 
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and drive brain regenerative mechanisms such as vasculogenesis, neurogenesis, angiogenesis and 
synaptogenesis to restore cerebral infrastructure and achieve neural repair (172-174). 
Stem cells may potentially address the immense gap that currently exists in the management of 
stroke outside of the acute phase of early brain cell damage (174). Thus, stem cells represent a 
credible opportunity to promote active recovery across functional domains that hitherto remains an 
aspirational goal in the management of stroke (175).  
1.5 Conclusion 
Stroke has long represented a difficult therapeutic challenge. This challenge has translated into a 
significant public health burden in recent times as the number of people suffering from stroke and 
living with disabilities that limit their independence and gainful participation in society has been 
on a constant rise in both the developing and developed world (10). These unmet needs require that 
stroke research explores strategies to ‘recover’ function to levels that are as near as possible to pre-
stroke levels of function. The need to better define recovery after stroke is an underpinning 
physiological concept that is crucial for any future progress in exploring strategies to recover 
neurological function lost consequent to stroke in an individual (156). As translational stroke 
research continues to evolve from secondary prevention and neuroprotection, and now attempts 
neural regeneration and repair, it becomes extremely critical that we examine elements of early 
phase clinical research in this area that are likely to become critical determinants of successful 




CHAPTER 2: LITERATURE REVIEW 
2.1 Burden of Ischaemic Stroke 
The burden of neurological disorders has increased significantly over the last two decades and this 
group is now the worldwide leading cause of disability (10·2% of global DALYs) and the second-
leading cause of mortality (16·8% of global deaths) (177). Stroke contributed to the largest 
proportion of total DALYs (47·3%) and deaths (67·3%) among all neurological disorders (177). 
This is likely to continue in the future due to ongoing demographic changes, including ageing of 
the population in developed countries and health transitions observed in developing countries, most 
notably the rise of ‘lifestyle diseases’ associated with increased risk for occurrence of stroke (177). 
Approximately 10 million new cases of stroke occur every year around the world (177). Although 
age-standardised rates of stroke mortality have decreased worldwide in the past two decades, the 
absolute numbers of people who have a stroke every year and who live with the consequences of 
stroke, and die from their stroke are increasing (10). In Australia, approximately 56,000 new cases 
of stroke are likely to occur every year (178). 
Worldwide, stroke results in 6.5 million deaths annually of which 51% die from ischaemic stroke 
(IS) and 113 million DALYs (58% due to IS) are lost (10). In the context of Australia, this translates 
into 12,507 deaths annually (178). Moreover, the proportional contribution of stroke-related 
DALYs and deaths due to stroke compared to all diseases increased from 1990 (3.54% and 9.66% 
respectively) to 2013 (4.62% and 11.75% respectively) (10).  
According to the Global Burden of Disease Study 2013, ischaemic stroke is the second highest 
cause of years of life lost (YLL) worldwide (11). In Australia, ischaemic stroke is responsible for 
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the third highest number of YLL, after ischaemic heart disease and cancer (179), and the quality 
adjusted life years lost per case is reported to be approximately 5.09 for IS and 6.17 for ICH (180). 
The long-term disability experienced by stroke survivors worldwide represents an enormous global 
healthcare challenge. The cost of providing ongoing healthcare to people with stroke accounted for 
approximately 3–5% of all healthcare expenditure in the United Kingdom in 2017, with the total 
mean costs of healthcare attributable to stroke being £46,039 GBP per patient at five years after 
stroke (181). Gloede et al. (2014) reported lifetime costs per patient of approximately $103,566 
AUD ($68,769 USD) and total lifetime costs of all first-ever cases of ischaemic stroke in Australia  
of $2 billion AUD, based on resource utilisation in patients followed up at 10 years following their 
incident stroke (182).  
The approach to the management of stroke has been centred primarily on restoration of blood 
supply to the infarcted region of the brain and preventing re-occlusion (8). While IV thrombolys is 
and, more recently, endovascular thrombectomy have been transformative in the management of 
stroke and consequently for patient outcomes, the fact remains that progress in achieving a better 
health future after stroke during the last and present century has remained confined to only one  
(acute) aspect of the disease (183). It is well-recognised that while stroke may be acute in onset, it 
is very much a chronic disease with multiple molecular mechanisms that maintain ongoing injury 
and activate repair, simultaneously (184). Recent advances in basic research technologies has 
expanded our understanding of these mechanisms in the infarct brain microenvironment (145, 185). 
Translation of this knowledge into viable clinical options is arguably the next frontier and one that 
needs to be crossed with a sense of urgency to enable us to manage the significant stroke burden 




2.2 Current Research in Ischaemic Stroke  
Ischaemic stroke results in an acute, typically non-progressive blockade of blood supply to a region 
of the brain (1). However, the long-term implications of stroke are a consequence of dysfunction 
of neuronal networks that impair functional ability in stroke survivors (1, 187). 
2.2.1 Mechanisms of Injury in Stroke  
2.2.1.1  Ischemia-Reperfusion Injury 
Primary damage to the neurovascular brain tissue caused by ischaemic stroke is characterised by 
neuronal death due to oxygen and glucose deprivation (188, 189). Cellular depletion of adenosine 
triphosphate (ATP) results in lactic acidosis, ion transport dysregulation, and extracellular 
glutamate accumulation (188). These metabolic changes lead to endothelial swelling and early 
disruption of the blood brain barrier (BBB) and neuronal death (190). These changes result in the 
loss of function mediated by the affected regions. Restoration of blood flow is critical to the 
survival of the area around the infarct core characterised by hypo-perfusion (penumbra) (189). 
However, this is associated with reperfusion injury in damaged cells, which causes free radical 
production, the activation of astrocytes and white blood cells which release cytokines and free 
radicals, and the production of synchronized neuronal activity (191). The initial, reversible damage 
to the BBB that occurs within hours after reperfusion is associated with the disruption of tight 
junction proteins from oxidative stress induced after reperfusion and the local accumulation of 
MMPs (192, 193). Oxidative damage to cellular molecules, upregulation of inflammatory 
mediators and MMPs, and modulation of tight junction proteins maintains ongoing damage to the 
BBB (193). Subsequent irreversible damage occurs 24–72 hours after reperfusion, mediated by 




2.2.1.2  Neuroinflammation 
The initial event is followed by secondary damage mediated by ischemia and reperfusion resulting 
in a neuroinflammatory cascade that persists for days to weeks after stroke (143). Numerous 
mechanisms have been reported to be involved in this cascade, on a molecular and cellular level 
(143). These include: glutamatergic excitotoxicity, loss of intracellular calcium homeostasis, 
energy failure, oxidative stress, neuroinflammation, and axonal degeneration of synaptic inputs 
(anterograde degeneration) and projection neurons (retrograde degeneration) (156).  
In the subacute phase, upregulated inflammation triggers release of cytokines, chemokines, CAMs, 
and MMPs and reactive oxygen species from injured neurons, microglia and astrocytes at the site 
of ischemia (156). This results in recruitment of resident immune cells such as microglia and 
peripheral immune cells such as neutrophils, macrophages and T cells (78, 171). This, in turn, 
sustains neuroinflammation and contributes to the breakdown of normal cerebral microstructure 
(BBB and synaptic networks). Activated microglia, astrocytes and endothelial cells may induce the 
release of molecules that block axonal sprouting, such as chondroitin sulphate proteoglycans (195, 
196) or Ephrin-A5 (197). The resident immune cells clear the dead cells and are involved in the 
formation of a glial scar with aberrant extracellular matrix (ECM) and blood supply, as well as 
persistence of reactive astrocytes and resident activated microglia/macrophages (198, 199). 
Substantial remodelling of neurovascular architecture continues, which may result in compromised 
integrity of key functional tracts (200). 
Temporal resolution of neuroinflammation in the brain is understood to be an active process, driven 
by active suppression of inflammatory mediators. There is evidence that an increase in signalling 
molecules like IL-10, TGF-β and arginase suppresses inflammation and exerts neuroprotective 
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effects on the surviving cells (199). Activated microglia release cytokines that facilitate axonal 
sprouting and dendritic morphogenesis, such as bone morphogenetic protein 7 (201); and several 
molecules belonging to the transforming growth factor (TGFβ) family such as GDF10 (200); and 
the Activin system (202, 203). GDF10 signals through the Smad 2/3 transcription factor to activate 
PI3 Kinase gene systems that mediate axonal sprouting (204).  
Therefore, neuroinflammation plays an active role in both secondary brain injury and neurorepair 
after stroke and animal models of stroke indicate an active cross-talk between inflammation and 
neurogenesis (203, 205). 
2.2.2 Mechanisms of Recovery in Stroke 
2.2.2.1  Neuroplasticity 
Neuroplasticity is the capacity of neuronal networks in the brain to respond to biological and/or 
environmental signals by changing their function and structure (206). This capacity varies during 
the lifespan from being prolific during embryonic development to limited in adulthood (206). 
Neuroplasticity comprises modulation of neurogenesis and ongoing remodelling of synapses and 
neural cells at a structural and functional level (206). 
2.2.2.1.1 Neurogenesis 
There is growing evidence supporting the presence of a distinct population of neural stem cells that 
contribute to ongoing neurogenesis in humans (207). These cells are located in distinct regions of 
the brain: the subventricular zone (SVZ), located adjacent to the lateral ventricle, and the 
subgranular layer of the dentate gyrus in the hippocampus, and possibly other regions of the 
hypothalamus such as the lining of the third ventricle and suprachiasmatic nucleus (208). Ongoing 
research into the functional relevance of these cell populations has clearly established the fact that 
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the brain is a plastic organ capable of regeneration and repair (209). Spalding et al. (2013) measured 
the concentration of nuclear bomb test-derived 14C in genomic DNA, to retrospectively birth date 
cells in the hippocampal region in human brain (210). The study demonstrated that substantial 
neurogenesis in the human hippocampus continued throughout life and postulated that this was 
crucial to learning and cognitive plasticity (210). Post-mortem brain studies demonstrate SVZ cell 
proliferation and neuroblast formation after stroke even in aged humans (211, 212).  
Stroke triggers an increase in neurogenesis (213). These neurogenic niches are highly sensitive to 
oxygen deprivation; studies in vertebrate models have indicated hypoxia and inflammation are 
associated with both potentiation and suppression of neurogenic activity within these areas (214, 
215). The complex interplay between neuroinflammation, neurogenesis and their impact on 
functional recovery after stroke is still being explored (216). Studies have reported that T cells, 
astrocytes and microglia interact to drive the proliferation of SGL and SVZ progenitor cells and 
direct the migration and differentiation of these cells in vitro and in vivo (216). On the other hand, 
TNF-α secretion by activated microglia leads to progenitor cell suppression (217). Resident 
microglia may potentially have a key modulatory role in determining the balance between these 
contradictory processes (218). Studies have shown that whereas acute activation of microglia 
results in suppression of neurogenic signals, chronically activated microglia are predominantly pro-
neurogenic (218). Microglia release Insulin-like Growth Factor (IGF) in the hippocampal region 
and increase the proliferation, migration and maturation of NSCs (213). In addition to the increase 
in neurogenesis in the immediate period following stroke, there is evidence of a transient increase 
in angiogenesis that potentially enables neuroblasts to migrate along these newly formed blood 
vessels and home in to the infarcted area, assisted by chemical and cellular neuroinflammator y 
signals (213).  
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2.2.2.1.2 Reorganisation of Neural Networks and Synaptoplasticity  
A key biological process in neuroplasticity is axonal sprouting and the formation of new 
connections in regions of brain damaged or partially deafferented from the stroke (219). The extent 
of initial stroke injury influences the topography of axonal sprouting (219). In small to medium 
sized experimental strokes, axonal sprouting occurs in peri-infarct cortical areas whereas in large 
infarcts, axonal sprouting from the contralateral cortex to the deafferented side of the cervical 
spinal cord is the predominant pattern (219, 220). Peri-infarct sprouting results in new, significantly 
different connections between motor cortex, premotor and somatosensory cortex (219). 
Contralateral corticospinal axonal sprouting observed in the rat, mouse and non-human-primate 
stroke models results in remapping of motor representations of the ipsilateral limb (221). Morecraft 
et al. (2015) indicated a role for somatosensory input in contralateral axonal sprouting (222). 
Infarction of the parietal somatosensory cortex, in addition to the motor cortex, was associated with 
suppression of contralateral sprouting (222). These anatomical mapping studies suggest that axonal 
sprouting starts early after stroke (within weeks) and remains active at several months after stroke 
(219). Post-stroke axonal sprouting demonstrates three distinct patterns determined by their 
temporal relationship to stroke onset and mediated by the interaction between glial growth inhibitor 
signalling and behavioural cues (219). Early after stroke, reactive sprouting occurs in the 
perilesional cortex as part of scar formation and tissue reorganization. The resultant endogenous 
brain remodelling after stroke may be associated with spontaneous recovery (219). Reparative 
axonal sprouting involves longer distance axonal sprouting activated in a specific environment 
characterised by blockade of NgR1 or EphrinA5, or upregulation of brain growth factor GDF10 
(197, 204). This sprouting is limited to sensorimotor areas of the ipsilateral hemisphere or the 
contralateral spinal cord and remains directionally confined within the same functional domain. 
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The third pattern of unbounded axonal sprouting was observed in models where behavioural 
activity is increased at the same time as a blockade of the glial growth inhibitors. These patterns 
suggest a critical temporal relationship between: time since stroke onset: the dominant 
molecular/cellular signal in the microenvironment (blockade of glial growth inhibitors and 
stimulation of neurogenic pathways); and the behavioural cues to the injured brain functional 
pathway such as through rehabilitation (219). There is also evidence of synchronized low frequency 
neural activity seen in the hyper-acute stage of stroke (223). This activity leads to activation of 
downstream molecular pathways that trigger neuronal growth and stimulate co-activation of 
synapses in a specific region of neurons, resulting in the establishment and stabilisation of new 
neuronal connections (223). 
Prabhakaran et al. proposed that it was possible to predict recovery in most patients with upper 
limb motor impairment (224). They reported that clinical predictors (acute upper extremity Fugl-
Meyer Motor (UE-FM) score, subcortical lesion volume, age, time to reassessment, and y-
intercept) could explain 89% of the variance seen in recovery within the first six months after 
exclusion of outliers with severe initial impairment. Thus, with the exception of the outlier 
subpopulation (characterised by low initial UE-FM score), recovery in patients was well 
approximated by a proportional relationship with the initial impairment (24–48 hours after stroke 
onset (recovery ≅ 0.70 × initial impairment) (224). Studies looking at motor function of the upper 
and lower extremities, speech and visuospatial neglect replicated this ‘70% proportional recovery 
rule’ (225-227). Thus, mechanisms driving spontaneous recovery after stroke generalize across 
neurological impairments and perhaps represent the extent of existing neural tract integrity and 
capacity for reorganisation of neural networks (158). The premise that existing neural tract integrity 
may be an important predictor for recovery was supported by studies that measured intactness of 
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the relevant neuronal networks using transcranial magnetic stimulation and diffusion tensor 
imaging, e.g. corticomotor pathways for upper limb motor function and frontoparietal attention 
networks for visuospatial neglect (228, 229). Clinical and imaging biomarkers that can establish 
this link between structural integrity and functional recovery may enable stratification concerning 
timing, quantum and nature of rehabilitation interventions and efficient selection of a study 
population for rehabilitation trials (158). 
2.2.3 Functional Recovery: Clinical Concepts and Terminology 
Recovery of functional ability after stroke is an aggregate of spontaneous recovery in injured areas 
and compensatory learning in uninjured parts of the brain (139). Spontaneous recovery 
encapsulates regeneration of new neurons to replace the injured ones and structural recovery, i.e. 
re-establishment of the complex arborisation of neurons and synaptic connections along with 
interlinkages between different neural networks as well as the restoration of neuro-vascular synergy 
(197, 230). Behavioural restitution describes the full or partial restoration of the repertoire of 
behaviours that were available to the individual before stroke-induced injury (160). This process 
requires restitution of disrupted neuronal networks, influenced by the local microenvironment and 
factors such as genetic reserve and pre-existing comorbidities such as hypertension, metabolic 
syndrome, hyperlipidaemia and diabetes (231). Cell therapies have demonstrated their potential to 
facilitate a microenvironment that increases endogenous NSC replication and promote neurogenic 
molecular and genetic pathways, thereby contributing to the restitution of disrupted neural 
networks after stroke (165, 232). Initial clinical evidence from Phase I trials have indicated 
potential functional benefits, although the underpinning biology is still incompletely understood 
(175, 233). ‘Compensation’ has been defined as the ability to accomplish a task through using a 
new approach rather than using their normal pre-stroke behavioural repertoire (160). This does not 
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require neural repair but may require learning new ways of using intact neural or muscular 
pathways or the use of assistive devices to compensate for the function lost due to stroke. 
Rehabilitation strategies predominantly activate compensation mechanisms to effect recovery of  
function after stroke (139). However, they may also augment spontaneous recovery, especially 
when applied early in the disease course (234). 
2.3 Current Evidence for Potential Use of Cell therapies in Ischaemic Stroke 
The CTs currently under research are using cells derived from both neural and non-neural tissue 
sources that have been used in various ways (172):  
• undifferentiated stem or progenitor cells, such as adult progenitor cells (mesenchymal 
stromal cells, multipotent adult progenitor cells and haematopoietic stem/progenitor cells) 
• very early neural precursor cells differentiated from embryonic stem cells (ESCs) following 
in vitro expansion and post-mitotic differentiation or production of homogenous 
immortalised cell lines by reversible oncogene transfection; and  
• induced pluripotent stem cells (iPSCs) following retrograde manipulation by transfection of 
relevant transcription factors (Yamanaka factors) (235). 
Depending on the level of differentiation, stem cells may demonstrate unlimited or limited capacity 
to differentiate into different cell types (236). Pluripotent stem cells, namely ESCs or iPSCs, have 
a wide proliferation potential, which may in turn increase their tumourigenic potential. In 
comparison, multipotent adult stem cells, such as neural stem cells (NSCs), haematopoietic stem 
cells (HSCs), extraembryonic stem cells and mesenchymal stem cells (MSCs) derived from bone 
marrow, dental pulp, adipose tissue, skin, menstrual blood and foetal membrane (amnion and 
chorion layers), have a limited differentiation potential with no reported incidence of tumour 
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formation to date. All these cell types have demonstrated capability for terminal neural 
differentiation, using varied differentiation techniques (172). 
There is evidence to suggest that the location of origin and the nature of processing may play an 
important role in determining the relative propensity of stem cells to differentiate into different 
functional cell types (237, 238). In the context of stroke, different stem cell types have been 
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MSCs are the most extensively researched extraembryonic cell type to date. These cells can be 
harvested from any tissue, including bone marrow, placenta, teeth, amnion and adipose tissue and 
can be easily induced to produce neural phenotypes (248). The International Society for Cellular 
Therapy (ICT) defined the minimum criteria for MSCs in 2006 (289):  
• adherence to tissue culture plastic 
• multipotency as demonstrated by in vitro differentiation into osteoblasts, adipocytes and 
chondroblasts 
• expression of surface markers CD73, CD90 and CD105; and negative for CD34, CD45, 
CD14 or CD11b, C79a or CD19 and HLA-DR.  
This was an important milestone towards standardising the characterisation of different types of 
stem cells, but there is growing recognition of a need to update and expand these to keep pace with 
developments in the field.  
Neural stem cells (NSCs) are the other major group of CTs with promising potential for clinical 
application (290). NSCs can be extracted directly from neural tissue, such as the neuroectoderm in 
developing foetuses and the subventricular or subgerminal zone in adults (291). NSCs can also be 
produced by neuroinduction of ESCs, by blocking transforming growth factor-beta/bone 
morphogenetic protein (TGF-β/BMP) signalling pathways (292). Recent protocols, about the 
production of NSCs from iPSCs via a neural differentiation protocol involving blockade of dual-
inhibiting SMAD signalling pathways (292) and from adult somatic cells by using the 
reprograming factors such as Oct4, Sox2, Klf4, and c-Myc, are increasingly becoming the preferred 
techniques to produce stable and homogenous NSC populations (293).  
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A need to develop criteria for standardization of characterization of different cell types is widely 
discussed, as they are progressing to clinical translation (294). Samsonraj et al. (2017) in their 
review have reported on key parameters that are important for comprehensive and standardized 
characterization of MSCs but are equally relevant to characterization of other adult stem cells such 
as NSCs, from different sources (295). These parameters relate to: assessment of cell growth 
potential; survival; quiescence and/or senescence (i.e., viability and growth; ‘colony‐forming units‐
fibroblastic’ (CFU‐F) efficiency; telomere length); cell identity (i.e., multilineage differentiation 
and surface marker expression); and the ability of stem cells to communicate with their 
microenvironment (i.e., immunomodulation and trophic factors quantification) (295). Knowledge 
of immunomodulatory action is important for anticipating graft rejection and the need for 
concomitant immunosuppression (295). The development of release criteria that validate the 
quality of stem cells for use in clinical trials against GMP (Good Manufacturing Practice) 
standards, would need to take these parameters into consideration (296). 
2.4 Potential Opportunity with Cell therapies in Stroke 
The discovery of endogenous niches of neural stem cells in the adult mammalian brain tissue in 
the 1990s revolutionised existing knowledge about the regenerative capacity of the brain and 
heralded an era of research into neuroplasticity and neural repair (297). Since then, regenerative 
medicine research has yielded growing evidence that therapeutic application of exogenous CTs can 
promote recovery from loss of neural function resulting from a diverse range of neurological 
disorders (298). 
CTs may provide a therapeutic option with a potentially longer window of clinical application than 
is currently available with acute stage therapeutic options (298). They represent a novel treatment 
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paradigm that can potentially address both subacute and chronic neuroinflammatory and 
neurodegenerative processes while simultaneously promoting neurogenesis, angiogenesis and 
synaptogenesis in neuronal tissues (298, 299). Age is a well-established biomarker that influences 
the incidence, functional recovery and mortality with stroke in humans (300). Therefore, validated 
models for stroke in aged rats are very clinically relevant (301). Studies with human NSCs injected 
into aged rat brains showed them to successfully integrate into brain parenchyma and this was 
associated with improved performance on hippocampus-based memory tasks (302). 
Studies that followed the fate of human/primate/mouse derived ESC and iPSC-derived neuronal 
subtypes and glial cells in rat stroke models, reported that these cell types differentiated into 
mature, integrated neurons with axonal extensions to distant sites and organised synaptic activity 
as well as into specific glial subpopulations such as astrocytes, and oligodendrocytes (303-306). 
Animal studies have demonstrated that the transplanted stem cells stimulated neurogenesis in the 
ipsilateral SVZ and subgranular zone of the dentate gyrus (307, 308) .  
From a pathophysiological standpoint, it is established that stroke results in a pan-necrosis of all 
cellular elements of neuro-vascular architecture (309, 310). While specific neural cell replacement 
is unlikely to play a major role in the difference in outcomes seen with CT use in stroke, recent 
evidence points to a potential role for CT to reconstruct neuronal circuitry (303, 311). Secondary 
cell loss continues to occur in the areas functionally related to the lesion site, for weeks after stroke  
(172, 312). Implantation of human induced pluripotent stem cells (iPSCs) into acute stroke models 
demonstrated preservation of subcortical structures like substantia nigra, perhaps via release of pro-
neurogenic growth factors (305, 313). The stem cells also release paracrine factors that support 
sprouting angiogenesis surrounding the infarct core, as evidenced by the increased density of newly 
formed blood vessels in the brains of animals treated with bone marrow derived MSC and NSCs 
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(290). Intracerebral injection of human MSCs were associated with modification of the cerebral 
microvasculature and improved cerebral blood flow (314). 
Research on the relative importance of these mechanistic pathways in ischaemic stroke induced 
injury in humans is still inconclusive but preclinical studies have reported both functional and 
structural benefit of the use of CTs in ischaemic stroke. Leong et al. in 2013 reported an overall 
improvement of 40.6% (95% CI: 37.1 to 44.0, p<0.001) in neurobehavioral outcome in rodent 
stroke studies (315). Furthermore, the functional outcomes did not demonstrate time dependency. 
A meta-analysis by Vahidy et al. (2016) concluded that the use of bone marrow mononuclear cells 
in animal stroke models resulted in a reduction in lesion volume (SMD −3.3, 95% CI: −4.3 to −2.3), 
improved function measured by the cylinder test (SMD −2.4, 95% CI: −3.1 to −1.6) and a trend for 
benefit in adhesive removal test and neurological deficit score (232). 
iPSCs and iPSCs-derived mature cell types are likely to be the predominant focus of clinical 
translation as they bypass the ethical issues associated with blastocyst-derived CTs, may be easier 
to generate as a homogenous cell population and may have fewer immune issues if extracted and 
reprogrammed from a patient’s own tissue (316).  
Stroke, unlike other neurodegenerative diseases, results in non-selective loss of all cellular 
elements in the infarct lesion. Hence, replacement by a specifically matched stem cell derived 
population is neither feasible nor appropriate (309, 317). Preclinical stroke research has indicated 
that potential biological effects of CT, that are not reliant on cell replacement, are likely to be the 
main mechanism underlying the benefit with CT (290). Systemic cell delivery, most commonly via 
the intravenous route and investigated predominantly in acute or early subacute phases, is likely to 
modulate the initial neural injury and neuroinflammation and reinforce early reparative tissue 
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responses (290). On the other hand, the intracerebral delivery, predominantly into undamaged 
tissue close to the site of injury, in late subacute or chronic stages, is likely to rely on the pleotropic 
effects of these implanted cells as the dominant mechanism of action (174). Many studies have 
indicated that the functional improvement in stroke models was observed within the first 1–2 weeks 
following transplantation, i.e., before any functional neurons could have developed from the 
grafted cells (290). Interestingly, numerous studies have reported that the behavioural improvement 
early after transplantation of iPSC-derived NESCs was observed irrespective of the degree of graft 
survival and generation of neurons at later time points (313, 318). 
2.5 Challenges in Execution of Early Phase Clinical Studies with CTs in Ischaemic Stroke 
CTs are currently at the stage of clinical translation across the world. However, numerous 
challenges exist that can significantly impede progress in this field (319). The interpretation of 
current knowledge in stem cell research is difficult due to challenges in efficiently designing 
clinical studies (319). The International Society for Stem Cell Research (ISSCR) task force released 
‘Guidelines for Stem Cell Research and Clinical Translation’ in 2016, as an update to the ‘ISSCR 
Guidelines for the Conduct of Human Embryonic Stem Cell Research’ (ISSCR, 2006) and the 
‘Guidelines on the Clinical Translation of Stem Cells’ (ISSCR, 2008), that had covered different 
aspects of the clinical translation of CTs (294).  
These challenges include: the present state of knowledge regarding the heterogeneity inherent in 
disease presentation; the unique propositions posed by use of CTs; practical considerations with 
the administration of stem cells as a therapeutic product; and ethical questions related to the 
sourcing and use of CTs. Furthermore, ensuring equitable but scientifically justifiable access for 
patients if this development process proves successful is an important challenge. Increasing 
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numbers of phase I clinical studies are reporting reasonable safety and potential for efficacy for 
CTs.  
Therefore, it is timely to examine the above challenges. This research can potentially lead to a 
framework that enlists critical considerations in further clinical research with CTs and help enable 
efficient, consistent and relevant research output that is needed to address the ‘valley of death’ or 
failed clinical translation efforts for a number of promising preclinical candidates (320). 
2.5.1 Study Design Considerations  in CTs Research 
Clinical translation of therapeutic candidates is a long process (321). It usually starts from first-use 
testing, called first in human or phase I studies, in appropriate human subjects, conventionally 
healthy volunteers. However, in the context of CTs, this is more likely to be individuals suffering 
from the target disease (322). The focus of these studies is to confirm the safety profile seen in the 
preclinical stage and establish useful and safe doses in humans. If successful, the development 
moves to phase II, where the main objective is to generate proof of concept (postulated benefit) 
and confirm safety in a larger disease population. Phase III is a key milestone that aims to prove 
whether the candidate provides a meaningful incremental benefit versus existing therapies, 
maintains a favourable risk-benefit profile and helps to identify an appropriate patient population 
likely to benefit. If the phase II/III data are supportive, the therapeutic candidates enter clinical 
practice via regulatory approval. Thereafter, phase IV studies continue to expand the understanding 
of the therapy in real world clinical practice and identify any safety signals that may arise with such 
a use (321).  
Kondziolka et al. (2000) reported on the use of stem cells in patients with stroke in the first phase 
I study (323). In the last two decades, numerous phase I studies in stroke have been reported from 
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different parts of the world (324). These studies have been varied in terms of the stroke population, 
CT type, timing and route of delivery and clinical outcomes evaluated (325). Despite two decades 
since the Kondziolka paper, it is only in the last two years that transition to phase II with a focus 
on generating data on effectiveness has reported preliminary success (285, 288). This is in part due 
to the unique biological and therapeutic perspective that stem cells present and the inherent 
heterogeneity of a disease like stroke. The challenge for researchers in this field has been to define 
research methodology that best addresses these issues and enables a scientifically robust but 
efficient development strategy for CTs in stroke (319). 
Researchers from academia and industry convened to discuss the challenges CTs present to stroke 
research. The discussions resulted in the ‘Stroke Treatment Academic Industry Roundtable ’ 
(STAIR) preclinical recommendations and ‘CT as an Emerging Paradigm in Ischaemic stroke’ 
(STEPS) recommendations on consensus-based standards for pre-clinical and clinical development 
of CTs in ischaemic stroke (326-328). These recommendations have been undergoing revisions as 
newer data has emerged regarding mechanistic pathways underlying stroke injury and 
neuroplasticity and in mechanisms of action with different cell types. These include the importance 
of defining mechanisms of action in appropriate animal models prior to proceeding to human 
studies, investigating the impact of co-morbidities in pre-clinical models and selecting the optimum 
route and timing of delivery. In addition, STEPS identified rehabilitation and neuroimaging as 
areas for further research to determine their impact on future clinical trial design (328). RIGOR 
guidelines in 2013, built upon STAIRS and STEPS, recommended considering available 
preclinical evidence along with data for different routes and timing of administration studied in 
animal models whilst defining the various aspects of a clinical trial design (326).  
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Bioluminescence imaging (BLI) and immunohistochemistry techniques in numerous animal 
studies with different CTs have established that the transplanted cells rarely survive beyond 7–30 
days post-implantation although the percentage of viable cells reported has varied depending on 
cell types and assessment techniques used (329, 330). Recent studies have reported success with 
using different techniques for enhancing survival of transplanted cells such as genetic modification 
with pro-survival genes, e.g., Bcl-2, hypoxic preconditioning and pharmacological preconditioning 
(Diazoxide/Minocycline/SDF-1/interferons) (165, 331). However, despite the short life of 
engrafted cells, they initiate molecular pathways that facilitate endogenous neurogenesis by 
upregulation of growth factor genes, promotion of angiogenesis, mobilisation of endogenous neural 
stem cells and modulation of neuroinflammation (165). There is robust evidence to support the fact 
that the potential biological effect of CTs may not depend on the efficiency of cell replacement 
(290, 332). It may be more critically determined by the cell type (lineage, proliferation potential 
and spatial conformity) and by the route and timing of cell delivery (290).  
Therefore, while structural, immunological and biological characterisation of different cell types 
remains critical to optimize cell delivery and targeted biological effect, selective transplantation of 
specific cell phenotypes may not be as important to research success. In contrast, aspects of study 
design such as the choice of study outcomes, timing and routes of CT administration, and temporal 
relationship to rehabilitation, may have a more significant impact on the likelihood of these studies 
demonstrating effective ways to use CTs (309).   
2.5.1.1 Selection of Outcomes Measures: Impact on Study Design Efficiency  
Individuals suffering from stroke experience a unique combination of long-term disability due to 
the heterogeneous nature of stroke as a disease (54). Disability following stroke may present as 
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neurological dysfunctions (e.g. motor, sensory and visual) and limitations in performance of 
activities of daily living (ADL) and neuropsychological deficits (e.g. attention, memory or 
language). Furthermore, an under-represented aspect of stroke is the co-morbid occurrence of 
neuropsychiatric disturbances such as depression (54).  
2.5.1.1.1 Framework for Disability Outcomes 
The World Health Organization’s International Classification of Functioning, Disability and Health 
(WHO-ICF) released in 2001 provides a biopsychosocial holistic model to standardize the 
assessment of functioning of individuals and populations, and provide consistency across clinical 
disciplines, in the understanding and use of the term disability (58). Disability was defined as “the 
negative aspects of the interaction between an individual (with a health condition) and that 
individual’s contextual factors (environmental and personal factors)” and comprised three principal 
domains: impairment (structural and functional), activity limitation and participation restriction 
(58). Quality of life is the personalised evaluation of this disability or lack of functioning in the 




Figure 2. Functioning, Disability and Quality of Life  
Adapted from Stucki G. Am J Phys Med Rehabilitation 2005; 84:733–740 (333) 
 
To facilitate the use of this framework in clinical settings, the WHO developed the ICF Core Sets 
to contextualise disability to specific health conditions (334). These sets comprise aspects of 
impairment/limitation/restriction that are encountered, most frequently in typical patients suffering 
from that disease and describe a measurable outcome in clinical research or practice settings. ICF 
Core Sets (comprehensive and brief sets) for stroke enlist the most impactful aspects of functioning 
affected in patients after stroke (334). The brief ICF Core set for stroke includes 18 categories 
across the ICF components of functioning and contextual factors, based on consensus amongst a 
71 
 
multidisciplinary expert panel to create a list that was relevant but feasible for use in clinical 
settings (Table 3).  
Table 3: Brief ICF Core Set for stroke  
ICF component ICF category 
Body functions Consciousness functions  
Orientation functions  
Muscle power functions 
Mental functions of language  
Attention functions  
Memory functions 
Body structure Structure of brain  
Structure of upper extremity 




Washing oneself  
Dressing  
Communicating- speaking and receiving 
messages 
Environmental factors Immediate family  
Health professionals  
Health services, systems and policies 
Reproduced with permission from Geyh et al. (334) 
This core set has been validated in studies that followed up the health status of ischaemic stroke 
survivors to test the feasibility of its use in clinical settings (335, 336). These studies reported that 
the most significant determinants of overall health status related to memory functions, muscle 
72 
 
power functions and attention functions (337). The issues with walking, speaking and receiving 
spoken messages (understanding) were consistently reported to be the dominant factors responsible 
for limitations of activity and participation (337).  
2.5.1.1.2 Outcome Measures in Stroke Research 
Numerous outcome measures have been used in clinical research to determine the extent of 
disability after stroke. These scales have been validated for use during different timeframes post-
stroke to monitor the clinical impact of pharmacological and rehabilitative interventions in 
ischaemic stroke (338). This wide range of measures presents a challenge in standardization of 
outcome measures to be used in clinical studies, as recommended by guidelines such as STAIR, 
RIGOR and STEPS (328). 
The choice of assessments employed to measure the success of CTs is critical as more clinical 
studies are being planned (338). The appropriateness of the outcome measures to the study 
population is vital. This can ensure optimal evidence generation that can translate into effective 
clinical strategies.  
‘Hard’ clinical endpoints such as stroke mortality or recurrence have historically been important 
determinants of success of interventional trials in stroke. However, with mortality rates steadily 
declining, increasing number of studies are choosing the magnitude of change in clinically relevant 
disability outcomes as the primary endpoint for measuring effectiveness of therapy (339). This 
growing trend is recognised by regulatory authorities, who now recommend a measure of 
functional recovery as primary or co-primary endpoints for ischaemic stroke intervention trials 
(340). Different assessment tools have been used in studies investigating the impact of various 
ischaemic stroke interventions (341). However, there is no single outcome measure that describes 
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or predicts all dimensions of disability. A review of 491 randomized controlled trials of ischaemic 
stroke rehabilitation reported significant heterogeneity in outcome assessment (342).  
Table 4: ICF disability domain measured in Stroke Outcome Measure  Scales   
Body structure/function 
(impairments) 
Activity (limitation) Participation (restriction) 
Glasgow Coma Scale Barthel Index London Handicap scale 
Mini-Mental State Examination Nottingham ADL Scale Medical Outcomes Study 
Short Form-36 
Geriatric Depression Scale Glasgow Outcome Scale Nottingham Health Profile 
Hospital Anxiety and Depression 
Scale 
Katz ADL Scale 
 
National Institute of Health Stroke 
Scale (NIHSS) 
International Stroke Trial 
simple questions 
Stroke adapted sickness 
impact profile 
Fugl Meyer Assessment Modified Rankin Scale Stroke Impact Scale 
Orgogozo Stroke Scale Oxford Handicap Scale Stroke specific quality of life 
Canadian Neurological Scale Hamrin Activities Index Frenchay Activities Index 
Scandinavian Stroke Scale Adams Disability Method 
 
Toronto Stroke Scale 10-meter walk test 
 
(Modified) Mathew Scale Timed get-up-and-go test 
 
European Stroke Scale 
  
Frenchay Aphasia Screening Test 
  
Stroke Specific Scale 
  
Modified Ashworth Test   
Reproduced with permission from McArthur et al. (2014) (338) 
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An understanding of the clinimetric properties of a scale is vital to appropriate selection of an 
assessment tool that would be most suited to the demands of the study population and stroke 
characteristics being studied (343). Use of an inappropriate tool can adversely affect the study 
quality and may invalidate results. Adequate validity and responsiveness to detect clinically 
meaningful change within the time-frame of the trial have been reported to be essential though 
often unacknowledged key pre-requisites to ensure quality and efficiency of a trial (343).  
The most widely accepted outcome measures scales such as the modified Rankin Scale (mRS), 
Barthel Index (BI), National Institute of Health Stroke Scale (NIHSS), Stroke Impact Scale (SIS) 
and Functional Independence Measure (FIM) capture important dimensions of ischaemic stroke-
related disability but these scales have important limitations that are relevant to ischaemic stroke 
(343, 344). The principal measures scales are characterised/examined below for their strengths and 
weaknesses. 
2.5.1.1.2.1 Modified Rankin Scale  
The mRS describes ‘global disability’ and measures aspects across WHO-ICF domains of activity 
and societal participation (345). As a stroke outcome measure, it has key strengths that make it the 
preferred and most commonly used endpoint in stroke research as well as for regulatory assessment 
(342). The mRS is an ordinal hierarchical scale with grades from 0 (no symptoms) to 5 (severe 
disability) with an extra score of 6 to signify death, added in research settings. In contemporary 
ischaemic stroke studies, the mRS is often used both as a measure of baseline ability for patient 
selection and as an outcome measure of interest (345). The mRS has many potential strengths in 
that it demonstrates strong correlation with measures of ischaemic stroke pathology (for example, 
infarct volumes) and it has the  ability to describe an almost full range of ischaemic stroke outcomes 
even though it is not designed to assess an individual’s psychosocial condition (338). The mRS 
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data collected at 90 days has been reported to be a robust indicator of long-term functional 
prognosis. This long-term predictive validity of the mRS supports its preferred use in RCTs (338). 
However, it may be less responsive to change due to a short range of available scores, which makes 
it poorly suited for measuring change over short time-periods, often seen in early phase trials (343). 
A systematic review of published reliability studies looking at different methods of administering 
the mRS assessment, found wide estimates of inter-observer variability (range for k = 0.25 to 0.72) 
despite overall good agreement on pooled analysis (k = 0.61) (345, 346,347). Using various real-
world datasets, power and sample sizes estimates have been generated from simulated trials 
modeled with varying levels of mRS reliability (348). These simulations suggest that 
improvements in mRS reliability (e.g., from k = 0.25 to 0.50 or 0.70) can result in modest 
reductions in sample size required and consequent cost savings (348). Training of research teams 
on use of the scale, use of a structured format for mRS assessments and establishing a process of 
centralized evaluation, have been different ways that have been shown to be useful in improving 
inter rater reliability for mRS (348). Another key limitation of the scale is that it is heavily weighted 
towards physical functioning with no focus on important outcomes areas such as cognition, 
communication, language disorders, fatigue, pain or mood disorders (338). 
2.5.1.1.2.2 National Institute of Health Stroke Scale 
The NIHSS is a widely used scale that comprises 15 items used to assess severity of impairment 
of different neural systems (338). Items are graded on a 3- or 4-point ordinal scale on which 0 
represents no impairment and add up to provide a total score (range= 0 to 42) with higher scores 
reflecting greater severity. Being relatively easy to execute in the acute stroke environment makes 
it a preferred outcome measure in both clinical practice and in research settings in acute ischaemic 
stroke trials (343). The tool is very useful for early stroke severity assessment and baseline scores 
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have strong predictive validity for outcome at 7 days and 3 months and has excellent inter-rater 
reliability in research settings (349). While a very useful tool to guide clinical management 
decisions in the short term, NIHSS has accepted limitations. The literature is divided regarding the 
robustness of the scale’s validity beyond the acute stage of ischaemic stroke, especially in the 
context of chronic functional recovery and ‘real world’ functional impact (343, 350). A ceiling 
effect is widely acknowledged in its administration, with lots of elements being untestable in high 
severity cases (338). The scale items favour left hemisphere events and posterior cerebral 
circulation events are poorly represented in the overall score (351, 352). Overall, the value of 
NIHSS as a long-term functional recovery index may be sub-optimal (338, 350).  
2.5.1.1.2.3 Barthel Index 
The Barthel Index, initially developed to be an index of dependence to evaluate nursing 
requirements, is perhaps the most widely used outcome measure of activities of daily living (338). 
Though not specific to stroke, its appeal lies in the ease of application, robust reliability (low inter -
observer variability) and widespread use (338). Hsieh et al. (2007) reported that that a mean BI 
change score of 1.85 corresponded to patient ratings of minimal clinically important difference 
(MCID), an estimate key to determining the adequate power of a study (353). However, BI 
demonstrates important limitations such as its relative insensitivity and lack of comprehensiveness 
(absence of stroke-specific domains such as communication/cognition) (354). This is reflected in 
the large reported ceiling and floor effects observed with BI, making it sub-optimal for use in 
patients at either end of the disability spectrum (338, 345). 
2.5.1.1.2.4 Quality of Life Scales 
Euro-Qol assesses the impact on quality of life and has been validated in stroke populations (355). 
However, only 61% of ischaemic stroke survivors in a study are able to complete the scale without 
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external assistance (355). The ischaemic stroke-specific QOL scale, validated in ischaemic stroke 
populations, incorporates twelve domains. It defines values for ‘minimal detectable change’ and 
‘clinically important difference’ but similarly suffers from non-completion bias (356). 
2.5.1.1.2.5 Stroke Impact Scale  
Duncan et al. (2001) developed the Stroke Impact Scale (SIS) as a patient-reported outcome 
measure to assess multiple domains of stroke recovery without administering multiple tests (357). 
Though relatively new, its application may lower workload for the patient and increase utility for 
researchers (358). It is a stroke-specific, comprehensive, health status measure that incorporates 
domains from across the full WHO-ICF continuum (359). The limitations currently arise from the 
fact that limited normative data is available to date. In addition, the scale reports sub-optimally on 
the memory, communication, emotion and social participation domains (359). 
2.5.1.1.2.6 Functional Independence Measure  
Functional Independence Measure (FIM) is a measure that defines the burden of caring for an 
individual with stroke by assessing physical and cognitive disability (354). It is a less lengthy 
patient-reported measure with the ability to yield more detailed individualised information, which 
makes it an attractive tool in the clinical setting (354). Studies reported that a change in FIM score 
of 22 (total FIM), 17 (motor FIM) and 3 (cognitive FIM) could represent the MCID in a stroke 
population (354). These estimations are extremely useful to enhance the interpretability of changes 
seen in therapeutic intervention studies. However, FIM has its limitations in that the reliability of 
the scale is significantly impacted by rater training, which may result in high inter-rater variabilit y 
(354). It is an ordinal scale with step changes for the component items and sensitive to the statistical 
analysis methodology used. Though it does not have a ceiling effect, the responsiveness to change 
may not be significantly better than the BI (354). 
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2.5.1.2 Statistical Methodology 
Inappropriate choice of statistical methodology may have been a possible factor contributing to the 
disappointing results seen in many past stroke trials (338). The choice of analysis depends on the 
outcome measure of interest, as a number of these are ordinal in nature (360). Different approaches 
used so far comprise dichotomized analysis, selection of a composite global statistic that 
simultaneously analyses multiple outcome measures, responder analysis, and shift analysis.  
2.5.1.2.1 Dichotomized Analysis  
Dichotomized analysis uses logistic regression to dichotomize an outcome as a success or failure  
defined by a chosen cut-off point, e.g., mRS 0-2 versus 3-6 (345). This analysis is easy to perform 
and interpret in terms of clinical meaningfulness, e.g. via calculation of numbers needed to treat 
for a certain outcome (345). However, it results in the loss of clinically relevant information, as a 
step change in scales such as mRS or NIHSS represents a significant change in terms of different 
aspects of disability. In addition, transition across different health states holds variable relevance 
to individual patients and an arbitrary choice of a single transition may not be useful in assessment 
of benefit. Furthermore, the selection of cut-off point for this dichotomization in past studies has 
been inconsistent, making cross-study comparisons infeasible (348). 
2.5.1.2.2 Responder Analysis  
Responder analysis is a variant of dichotomized analysis that allows definition of success to vary 
according to baseline prognostic variables that are chosen a priori as compared to a fixed one in 




2.5.1.2.3 Shift Analysis  
Most recent trials have used shift analysis: an ordinal approach utilizing proportional odds logistic 
regression and the Cochran Mantel Haenszel methods to analyze change in outcome distributions 
over the full range of selected outcomes (362). This analysis examines benefits and harm 
experienced across all disease state transitions. Unlike the responder analysis, it does not make any 
prior assumptions of relationship between likely change in health state and baseline characteristics 
of study participants (345). The main disadvantage with shift analysis lies in its computational 
complexity. Although modern statistical software may provide a solution, the appropriate 
application in context of a specific clinical trial design requires the research team to have access to 
enhanced statistical expertise (363). It may also be a challenge to perform this analysis across the 
full range of scales with a high number of health state levels, e.g., NIHSS, although it has been 
used successfully with scales that use fewer levels, e.g. mRS (348). It has been reported that trials 
using ordinal logistic regression required smaller sample sizes (typically 28% smaller) than the 
dichotomous approach (348). This aspect can contribute significantly to numerous aspects of 
research: the cost of the trial, recruitment success, operational efficiency and robustness of data.  
2.5.1.2.4 Composite Global Endpoints 
Another commonly used approach is the use of composite endpoints that combine different scales 
(345). The NINDS trial reported the clinical effect of rtPA as a change in a composite score 
comprising NIHSS, BI, mRS, and Glasgow Outcome Scale (364). Makin et al. (2017) reported that 
use of a composite outcome comprising vascular, dependency and cognitive endpoints was 
associated with improved power in a trial in acute minor stroke and acute ischaemic stroke (365). 
However, these composite endpoints may be difficult to interpret and incompletely reflective of 
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the specific changes in the component outcome measures and prone to exacerbation of error if the 
component measures are correlated (345).  
2.5.1.3 Trial Design 
The inherent heterogeneity in neurological functions impacted by stroke has represented a 
challenge to recruit a homogenous patient population in the large numbers needed to ensure 
sufficient power (366). This is compounded further by the fact the rate and degree of spontaneous 
recovery expected differs between individuals based on the initial severity, initial neuronal reserve 
(influenced by factors such as co-morbid medical conditions and genetic factors) and timing and 
appropriateness of other established stroke interventions (226, 366). It is therefore plausible to 
consider that the overall stroke population is a composite of smaller subgroups defined by the 
shared characteristics such as the dominant functional system impaired or predicted trajectory of 
recovery. STEPS III recommended that development of stem cell therapies would benefit from the 
use of domain-specific end points in research, i.e., analysis of change in relevant domains of 
functioning would likely result in more clinically relevant data (328). However, the use of domain 
specific endpoints can provide useful information only if the populations being compared are 
sufficiently homogenous with regards to the domain of interest (367).  
One of the strategies suggested to achieve the above objectives is to adopt a cluster randomized 
study design in preference to a conventional individual randomized study design (348). However, 
the use of cluster randomization may result in loss of rigour if appropriate analytical methods for  
power calculation and sample size calculations are not used. This is due to the fact that individua ls 
in the same cluster tend to be correlated in terms of their characteristics and this reduces the 
effective sample size (348). Therefore, cluster trials’ size is inflated by a factor called the ‘design 
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effect’, which depends on the average cluster size and the degree of correlation within clusters 
(intracluster correlation coefficient or ICC) (348). ICCs are calculated as the inter-cluster variance 
divided by the sum of the intracluster and inter-cluster variance. ICCs provide an estimate of the 
proportion of variance that can be attributed to the cluster level (348). Knowledge and use of 
accurate estimates of ICCs for specific outcome measures is key to scientifically appropriate 
sample size calculations in cluster-randomised trials. ICCs for common outcome measures selected 
in stroke studies such as NIHSS, mRS and BI have been reported in previous studies (368). These 
estimates of relevant ICCs could be helpful in the planning of stem cell studies. The need for 
calculation of ICCs for other domain specific endpoints is acknowledged as an important unmet 
need (348).  
2.5.1.4 Concomitant Rehabilitation with CT Delivery 
Research supports the assessment, mobilisation and initiation of targeted rehabilitation early after 
stroke (after the first 24 hours) and as a standard of care in the chronic phase (139). There is an 
acknowledged need to understand the impact of rehabilitation as a variable in CT studies (328).  
As the understanding of mechanistic pathways involved in both these treatment strategies has 
evolved, there is now biological evidence to support their concurrent use (369). The premise is that 
stem cells enhance brain plasticity and create a facilitative brain environment that responds more 
effectively to rehabilitative techniques to rebuild the dysfunctional neuronal networks leading to 
the recovery of function (370). In turn, targeted activity maintains the neuro-reparative pathways 
initiated in a post-stroke environment that are augmented by the presence of implanted stem cells 
(370). Imura et al. (2013) reported that NSC/NPCs transplantation in mice followed by treadmill 
exercise training was associated with significant functional motor and electrophysiologica l 
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improvement, increased differentiation of transplanted cells into neurons and astrocytes at the brain 
injury site as compared to mice that underwent transplantation alone. Furthermore, the expression 
of brain-derived neurotrophic factor and growth-associated protein 43 mRNAs were significantly 
upregulated early in the mice that underwent transplantation and the treadmill exercise compared 
to those in other experimental groups (371).  
However, the provision of rehabilitation along with CTs introduces two challenges to designing 
stem cell studies. Firstly, current delivery of rehabilitation is inconsistent and while research in this 
field has expanded, there is an insufficient evidence base to standardize therapy for specific patient 
groups. Secondly, the combined delivery of stem cells and rehabilitation introduces complexity in 
the study design in terms of defining patient numbers that ensure sufficient power of the study 
analysis (348).  
2.5.1.5 Summary 
The numbers of early phase clinical trials using stem cell therapy for ischaemic stroke are on the 
rise. It is, therefore, imperative that we investigate the impact of study design components such as 
trial methodology, choice of outcomes measures used, the timing and route of delivery of stem 
cells and the impact of rehabilitation as a confounder in these studies. This will enable more 
appropriate and more efficient study designs for future clinical studies using cell therapies. 
2.5.2 Regulatory Policy Considerations in CTs Research 
Existing regulatory and policy frameworks for the review of therapeutic products across the world 
were based on examination of evidence generated through conventional development pathways, 
i.e. for small molecule pharmaceutical drugs (339). However, there are key differences relevant to 
the context of the development of cell therapies, which are amongst the most sophisticated 
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biological therapies developed to date. Most regulatory agencies are in the process of developing 
regulatory guidance to keep pace with the clinical translation of CT (340).  
2.5.2.1 Harmonisation of Legislative Terminology 
In 2015, the Federal Drug Authority (FDA) in United States of America issued guidance on the 
‘Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy 
Products’ (322). The guidance reflects the acknowledgement on the part of the FDA that the design 
of early phase clinical trials of CT may often differ from the trial designs applied to conventional 
pharmaceutical products, due to either the distinctive features of these products or their clinical 
application. These differences include structural, functional and biological characteristics of the 
cell product, and manufacturing considerations that may be unique to these products, all of which 
can influence key elements of clinical trial designs. In terms of cell characteristics, the dynamic 
nature of living cells and their ability to respond to the microenvironment over time by changing 
their molecular and functional expression makes it challenging to attribute any signals regarding 
effectiveness or safety to a specific cell morphology. In addition, these cells retain an ability to 
migrate, which requires that methods to track bio-distribution profiles be included in trial designs 
to increase the likelihood of detecting ectopic effects. Inherent complexities of manufacturing CTs 
would likely affect the feasibility of product quantity (volume and concentration) available for 
clinical dosing as well as the timing of administration.  
The FDA also recognised that conventional pharmacokinetic study designs are often not feasible 
in the context of cell products and that factors such as species specificity and immunogenicity make 
extrapolation from animal studies using conventional allometric scaling less reliable (372). 
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The above advice was recommended to be examined in conjunction with other guidance 
documents, particularly the ‘Regulatory Considerations for Human Cells, Tissues, and Cellular and 
Tissue Based Products: Minimal Manipulation and Homologous Use which was released by the 
FDA in November 2017 after multiple iterative changes to keep pace with the growing research in 
this area (373). It enables developers to distinguish between therapies that would require a 
substantial oversight as they are considered drug products under section 351 of the PHS Act in the 
US or that may be exempt per section 361 of the PHS Act. It defines the terminologies such as 
‘homologous use’ and ‘minimal manipulation’ more elaborately to enable widespread 
understanding amongst the research and development community. In 2017, the FDA released a 
comprehensive policy framework for the development and oversight of regenerative medicine 
products, including novel CTs. The framework comprises four guidance documents (374): 
• Same Surgical Procedure Exception under 21 CFR 1271.15: clarifies when the CTs 
are exempted from established regulations (375);  
• Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue Based 
Products: Minimal Manipulation and Homologous Use: clarifies the existing 
terminology and defines actions against unsafe products (350); 
• Evaluation of Devices Used with Regenerative Medicine Advanced Therapies 
(RMAT) (352); 
• Expedited Programs for Regenerative Medicine Therapies for Serious Conditions 
(376). 
The FDA will consider a drug eligible for regenerative medicine advanced therapy (RMAT) 
designation (377) if:  
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1. It is a cell therapy, therapeutic tissue engineering product, human cell and tissue product, 
or any combination product using such therapies or products, except for those regulated 
solely under Section 361 of the Public Health Service Act and part 1271 of Title 21, Code 
of Federal Regulations;  
2. It is intended to treat, modify, reverse or cure a serious or life-threatening disease or 
condition; and  
3. Preliminary clinical evidence indicates that the drug has the potential to address unmet 
medical needs for such diseases or conditions. 
The adoption of this framework is likely to foster harmonisation with other regulatory bodies across 
the world and provide impetus to the faster translation of CTs in diseases with present unmet needs.  
The regulatory framework for the evaluation of CTs in the European Union (EU), defined in 2008, 
is the ‘Regulation on Advanced Therapies (Regulation No 1394/2007)’ (378). This framework was 
expanded to provide further clarity by the release of the ‘Reflection paper on classification of 
advanced therapy medicinal products’ in 2015 (379). Regulatory bodies across the world have 
followed suit by establishing initial frameworks for research, development and clinical application 
of these innovative therapies in their respective countries. In Australia, the Therapeutic Goods 
Administration (TGA) regulates cell products, including blood products, vaccines and 
haematopoietic stem cells used in allogeneic transplantation (380). Autologous use of CT, defined 
as a single course of treatment with self-donated cells under the supervision of a medical 
practitioner who has the management of care responsibility, are not deemed to be therapeutic goods 
and are therefore exempted from TGA regulation. The autologous use of CT is currently regulated 
under clinical practice norms by the Medical Board of Australia and the Australian Health 
Practitioner Regulation Agency (AHPRA) in accordance with the Health Practitioner Regulation 
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National Law. In 2015, the TGA released a discussion paper providing its perspective on possible 
options for regulation of CTs which ranged from a continuation of the current pathway to a 
complete oversight by TGA as implemented in the context of other biological drugs (381). 
Following continued consultation, the TGA announced key changes to the existing legislation: the 
Biologicals Regulatory Framework, which took effect from 1st July 2018 (380). The framework 
provides specific guidance to define situations regarding the use of autologous CTs that need more 
rigorous oversight mechanisms from those that may not. This change will also bring the Australian 




Table 5. Key changes in Regulatory Pathways for CTs in Australia 




Key Change 1. Regulation of autologous human cell and tissue 
products could be regulated either under the 
Biologicals framework or as blood and blood 
components. 
2. Biologicals classification and terminology 
definitions updated. 
Autologous human cell and tissue 
products definition 
Autologous human cell and tissue (HCT) products are 
those that are removed from, and applied to, the same 
person, i.e. the donor and the recipient are the same.  
• These include some products commonly referred 
to as 'stem cell treatments'. 
• Where an autologous HCT product meets the 
definition of a blood component it may be 
regulated as a blood and blood component rather 
than under the Biologicals framework. 
Advertising to consumers is 
prohibited 
Autologous HCT products cannot be advertised to 
consumers from 1 July 2018, though services (that do 
not mention specific products) will still be permitted 
to be advertised 
Regulatory pathways for supply 
of autologous human cell and 
tissue products 
Risk-based regulation implemented 
Explanation of key terms 1. Autologous HCT products used in hospitals -
excluded from regulation by the TGA, that meet 
all the following criteria: 
• collected from a patient who is under the clinical 
care of a medical or dental practitioner registered 





Table 5. Key changes in Regulatory Pathways for CTs in Australia (continued) 
Components of the New 
Biologicals Regulatory Framework  
Details  
Explanation of key terms 
(continued) 
• manufactured by that medical or dental 
practitioner, or by a person or persons under 
the professional supervision of that medical 
or dental practitioner in a hospital, for that 
patient who must be a patient of that hospital 
• for therapeutic use in that patient by the same 
medical or dental practitioner, or by a person 
or persons under the professional supervision 
of the same medical or dental practitioner 
• not advertised or promoted directly to 
consumers. 
2. Autologous HCT products for use outside 
hospitals regulated with some exemptions 
such as: using 'unapproved' product pathways; 
inclusion on the Australian Register for 
Therapeutic Goods (ARTG); holding evidence 
that the manufacturing facility satisfies good 
manufacturing practice (GMP) requirements, 
if they meet all the following criteria: 
• collected from a patient who is under the 
clinical care of a medical or dental 
practitioner registered under a law of a State 
or an internal Territory. 
• manufactured by that practitioner, or by a 
person or persons under the professional 
supervision of that practitioner, for a single 
indication and in a single procedure on that 
patient by the same practitioner, or by a 
person or persons under the professional 
supervision of the same practitioner. 
• for therapeutic application in a homologous 
use. 
• minimally manipulated. 
3. Autologous HCT products will be fully 
regulated as biologicals or blood components 
if they do not satisfy any of the criteria for 
exclusion/exemption specified above. 
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Table 5. Key changes in Regulatory Pathways for CTs in Australia (continued) 
Components of the New 
Biologicals Regulatory Framework  
Details  
New definitions related to 
classification 
1. Classification of biologicals-updated:  
• Class 2 biological: has been subject to a 
process that is minimal manipulation and is 
for homologous use 
• Class 3 biological: has been subject to a 
process that is more than minimal 
manipulation and/or is not for homologous 
use 
• Class 4 biological: is mentioned in Schedule 
16 as a Class 4 biological that includes 
viable products that contain viable tissue of 
animal and/or human origin that are 
considered to pose a high risk, due to the 
level of manipulation and/or the current lack 
of safety data to appropriately classify them.  
2. Minimal manipulation – new definition to link 
processing and intended use: if the process 
does not result in the alteration of any of the 
biological characteristics, physiological 
functions or structural properties that are 
relevant to the intended use of the cells or 
tissues. 
3. Homologous use – new definition and 
recommendation that distinguishing between 
homologous and non-homologous use also 
applies to autologous use: the repair, 
reconstruction, replacement or 
supplementation of a recipient's cells or tissues 
with cells or tissue that perform the same basic 
function or functions in the recipient as the 
donor. 
Adapted from the revised TGA Biologicals regulatory framework effective 1 st July 2018 (380) 
Regulatory bodies and researchers are aligned in the view that consideration of the level of product 
manipulation and the intended use (autologous or allogeneic) should determine the level of 
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regulatory oversight required. CTs research has been led by academic groups until the very recent 
past. As different candidate cell types are moving along the translational spectrum, the knowledge 
and fulfilment of quality standards for data and cell biology have become critical determinants of 
the successful execution of stem cell studies.  
2.5.2.2 Application of Standards for Good Manufacturing Practice 
As research moves from bench to clinical translation, it is critical to understand that standards for 
manufacturing clinical biological agents are stricter than the standards for research-grade cell lines 
(382). Since the predominant types of CTs in the clinic are likely to be ones that have undergone 
prior differentiation to more committed cell lineage and typically more than ‘minimal 
manipulation’, these are likely to be subject to comprehensive review and full regulation like other 
biological products. In 2016 the ISSCR recommended that in view of the huge variation in cell 
types and tissue sources, individualized processing and manufacturing approaches should be used 
(294). The comprehensiveness of review of these cell processing and manufacturing protocols 
should be proportionate to the risk induced by the level of manipulation of the cells and their 
intended use, as well as the nature and size of the clinical trial. In line with broad GMP principles, 
standard operating procedures to ensure the quality of the reagents and consistency of protocols 
need to be established early in research (294). This is particularly important because the techniques 
for cell characterisation and standardisation of release criteria that are acceptable to regulators are 
still being developed for several cell types (294). In addition, given the innate risk with pluripotent 
stem cells (hESCs as well as iPSCs) for potential tumourigenicity, the release criteria need to ensure 
minimisation of risk from cell-culture-acquired abnormalities, such as karyotypic instabilities, as 
well as relevant global genetic and epigenetic parameters (294). ISSCR guidelines as well as 
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regulatory guidelines across the world have recommended adherence to GMP requirements from 
early stages of research as well as in innovative clinical use situations (294, 374, 380, 383). 
2.5.2.3 Expedited Pathways for Approval and Concern for Unregulated Use 
The regulatory bodies across the world recognize the need to define clear risk-based pathways that 
ensure patient safety in instances where CTs may have preliminary evidence of benefit in disease 
management where currently there is no other option available. The FDA has released draft 
guidelines on expedited pathways available for CTs: Priority Review and Accelerated Approval 
(374). A ‘Priority Review’ designation enables a shorter review cycle by the FDA. ‘Accelerated 
Approval’ allows for expedited review and approval based on data related to scientifically valid 
surrogate endpoints instead of established clinical endpoints. Meanwhile, the passage of ‘right to 
try’ (RTT) in USA, which can potentially be pursued for individual ‘gravely ill’ patients for access 
to cell therapy products ahead of FDA approval has raised concerns that some stem cell clinics are 
already willing to provide inadequately tested cell therapies utilizing this current gap in legislation 
(384). Similarly, the European Medicines Agency (EMA) launched the ‘PRIority MEdicines’ 
(PRIME) scheme in 2016, to enable early proactive regulatory dialogue regarding development 
plans for therapies of ‘major public health interest’ and which represent significant innovation  
(385). The European Commission introduced the ‘hospital exemption clause’ by the Regulation 
(EC) No.1394/2007 for Advanced Therapy Medicinal Products (ATMPs). This clause is applicable 
to those ATMPs that are prepared on a non-routine basis, i.e. individually prescribed, according to 
specific quality standards, for an individual patient (386).  
Autologous delivery of CTs has been considered ‘innovative medical practice’, and this has led to 
multiple ‘stem cell clinics’ offering untested/unapproved CTs in routine practice (387). While 
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agencies like the FDA have worked to strengthen oversight and regulation mechanisms, the ISSCR 
issued a statement highlighting the risk to patient safety that these clinics represent. Increasing 
collaboration between researchers and regulators is likely to lead to more streamlined and effective 
mechanisms to ensure appropriate access while safeguarding patient well-being (294). 
2.5.2.4 Summary 
Early phase CTs research has been led by academic groups. However, the awareness of these 
regulations and ability to address them through appropriate design and operationalisation of these 
studies is critical. It is acknowledged that this is an important skill gap within the research 
community and capacity building in this area is vital to future translational success. It is therefore 
important to review existing pathways to identify similarities and differences across different 
countries and identify key areas that are critical to increasing the efficiency and scientific quality 
of early phase clinical studies with CTs in ischaemic stroke.  
2.5.3 Ethical Considerations in CTs Research 
Stem cell research and its potential application in different disease indications has been a subject 
of ongoing social debate (388). Unique aspects have emerged due the novelty of the science, the 
incomplete understanding of neural regenerative processes, challenges in the context of existing 
theological and philosophical constructs, and the interplay of all of these factors within a changing 
political climate in which this research has been happening for the past four decades (389). One of 
the major ethical debates was the use of embryonic tissue as a source of stem cells for research, 
with concerns that this would amount to ‘killing’ human beings (at the embryonic stage) (390). 
Researchers have since worked on discovering alternative strategies: defining adult stem cell 
populations and re-programming somatic cells to pluripotent stage by techniques such as somatic-
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cell nuclear transfer and induction with transcription factors (391, 392). Recently, novel protocols 
have been generated that enable trans-differentiation of terminally differentiated cells such as 
fibroblasts into neurons or neural precursors while avoiding an intermediate pluripotent cell state 
(393).  
While these developments have influenced the evolution of stem cell research, other key areas have 
practical relevance as research transitions into the clinical phase. In the specific context of 
ischaemic stroke, issues such as the perspectives of patients on recovery following stroke and the 
consequent impact on the appreciation of risk and benefit as well as issues with patient selection 
and consent in clinical studies are likely important determinants of the eventual success and quality 
of these studies (394). 
2.5.3.1 Study Design: Relevance to Stroke Survivors 
The concept that patients have more to offer than mere participation has been gaining ground in 
the last few decades. This underscores the belief that research is more effective if it serves the  real 
needs of the ‘consumers’ of research findings, i.e. patients (395). The value of involving patients 
in research planning and seeking their input regarding study design has been described previously 
(396). This has been reported to help in making the study activities more relatable and resonant 
with patient priorities (397). Patient input has been found to be very insightful in terms of what 
data should be collected and how these research findings need to be communicated back to the 
patient community (398). In the rapidly evolving field of stem cell research, it is paramount that 
patients be given adequate information and opportunities to participate in the conduct of research 




2.5.3.2 Risk – Benefit Analysis and Communication 
Early phase stem cell clinical research in ischaemic stroke is accompanied by uncertainties 
regarding associated risks. These risks include further deterioration in neurological function, 
tumourigenicity, aberrant differentiation and mistargeting of transplanted cells, and potential 
genetic risks associated with germ cell integration (400). The transplantation of stem cells is an 
irreversible phenomenon and subject to delayed effects due to cell proliferation following delivery 
(175). The use of preclinical animal models can provide relatively limited predictive information 
due to issues with species specificity, the limited period of follow up and the fit of the model to 
human disease pathology (390). Delivery of stem cells in research settings, particularly in the 
context of autologous delivery, creates challenges with variability in the quality of individual donor 
cell batches. While standardised manufacturing protocols that address the requirements of good 
tissue practices (GTP) and good manufacturing practices (GMP) have not conventionally been 
required in early stage research, the unique characteristics of stem cells may require these to be 
established at an early phase in the clinical trials. This complicates the risk – benefit assessment 
conducted by oversight bodies and institutional review boards (IRB). These bodies may need to 
determine the adequacy of the type and duration of monitoring incorporated into study designs and 
the communication about this with prospective trial participants (389).  
2.5.3.3 Selection of Trial Participants and Informed Consent 
Since CTs carry a potential for extended or permanent deleterious effects, there can be no 
justification for recruiting healthy volunteers in early phase clinical trials (322). The researchers 
and IRBs have deliberated on the ethical and scientific rationale for selecting ‘seriously ill’ patients 
versus comparatively ‘healthier’ patients in early trials. While selective enrolment of patients with 
more severe disability may seem more justifiable, the risk of ‘therapeutic misconception’ is 
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particularly important in this cohort of participants (401). Lee et al. (2001) reported that participants 
often persisted with high expectations regarding outcomes despite receiving information indicating 
lower estimates of benefit during the informed consent process (402). One study reported that only 
16% of highly educated individuals were able to interpret risk magnitude accurately (403). This, 
in conjunction with misestimation regarding potential benefit, is a challenge for the process to be 
truly ‘informed’ especially as it is difficult to articulate the risk – benefit profile comprehensively 
at an early stage of research (390). It is therefore critical to ensure that participants understand that 
CTs have the potential for life-long effects and informed consent should be viewed as an ongoing 
exercise to preserve participants’ autonomy in dealing with subsequent effects (404).  
The neuro-behavioural impairments common after stroke may compromise a subject’s ability to 
make free and informed choices. This is a consideration for researchers in any stroke study, 
including those investigating CT and raises an issue about inequity of access to therapies with the 
potential to benefit and limit its eventual extrapolation to those patients with stroke who have 
behavioural limitations (404). The ISSCR (2016) recommendations suggest that the capacity to 
consent should be assessed formally along with the feasibility of proxy consent in stem cell 
research (294).  
2.5.3.4 Summary 
It may therefore be useful to understand the expectations of prospective trial participants about the 
risk-benefit information made available to them at the time of participation in early phase clinical 





2.5.4 Health Economic Considerations in CTs Research  
2.5.4.1 Cost of Stroke 
Stroke represents a huge economic burden for patients, healthcare systems and society and this has 
been reported by multiple studies such as Gloede et al. (2014) who reported lifetime costs per 
patient in Australia of approximately $103,566 AUD ($68,769 USD) (182); Gustavsson et al.  
(2011) who reported that the annual costs per person for stroke care as 7,775 € PPP (power purchase 
adjusted Euro) which comprised of 5,141 € PPP (direct medical cost), 2,035 € PPP (direct non-
medical cost) and 599 € PPP (indirect cost) (405). Di Carlo et al. (2009) reported that these costs 
for the United States were $65.5 billion (67% for direct and 33% for indirect costs) (406). Xu et al.  
(2018) analysed the total cost of health and social care for patients with acute stroke in England, 
Wales and Northern Ireland (407). The cost of stroke care in this study was £3.60 billion in the first 
five years after admission (mean per patient cost: £46,039) (407). Importantly, this study reported 
that social care costs accounted for a bigger proportion of total costs than direct health costs after 
the first year following stroke (407). Joo et al. (2014) reviewed data on indirect costs associated 
with stroke across 31 studies (408). The study revealed that indirect costs have been reported using 
diverse methods and definitions, which may account for the wide range (from 3% to 71%) in the 
proportion of the total cost of stroke that is represented by indirect costs (408).  
2.5.4.2 Value Proposition of CTs and Implications for Research 
Healthcare systems across the globe are struggling with the rising costs of providing care and cost 
is recognised as a fundamental dimension of healthcare quality. This follows from a need to define 
healthcare quality in terms of ‘value’: health outcomes achieved per unit of expenditure rather than 
simple cost reduction (407, 409). Innovative therapies like CTs are likely to have high initial costs 
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driven by the complexities in manufacture and delivery of these products, and so cost is a critical 
determinant of access to therapies in real world clinical practice (407). This increases the risk 
involved in research and development (R&D) investment in high technology products such as CTs. 
There is a recent argument for early heath technology assessment in parallel with phase I/II clinical 
research (410). Generating economic evidence at an early stage can accelerate clinical translation 
by enabling strategic R&D decisions, preclinical market assessment, portfolio decisions, clinical 
trial design, and market access and pricing strategy arrangements (411). Hettle et al. (2017) 
reviewed existing health technology assessments in the context of the high level of uncertainty 
regarding data on the effectiveness of CTs at the current stage of research (386). They reported that 
the existing methodology was adequate despite the additional complexities in the context of the 
variability of current data. Explorative decision-analytic models used in different disease 
indications can simulate long-term effects of therapeutic strategies in terms of economic value  
(412). The application of one such health-economic model in Sweden by Svennson et al. (2012) 
showed that CTs offer the potential for cost offsets and cost savings in a long-term perspective by 
reducing the disability after stroke (413). However, the results of such modelling may vary between 
countries due to differences in treatment practices, distribution of disease burden, health access, 
pricing structures and probable impact of emerging data on safety and efficacy on future resource 
utilization.  
2.5.4.3 Summary 
CTs have resulted in improvement in functional recovery following stroke in preclinical and early 
clinical studies. This has the potential to positively influence the quality of life and reduce ongoing 
lifetime costs of care for stroke survivors. As these therapies enter the clinical phase of 
development, generation of economic evidence early in the development phase is likely to be 
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critical to ensure that development costs are in line with the potential benefits to consumers from 
these interventions (414, 415).  
2.5.5 Conclusions 
Stroke management has evolved from its initial focus on the acute event to the chronic, progressive 
condition that warrants ongoing monitoring and intervention after the event. The mortality of stroke 
has been declining over the last few decades, but the morbidity associated with stroke continues to 
represent a significant burden. Approximately 80% of stroke survivors return home with some level 
of residual disability and more than 30% of stroke survivors report persistent restrictions in 
participation at four years after stroke (e.g., difficulty with autonomy, engagement or fulfilling 
societal roles) (54).  
Currently, significant unmet needs persist in many domains such as health-related quality of life, 
maintenance of daily activity and independence, and social reintegration. Therefore, there is a 
critical imperative to explore interventions at all stages of stroke. Research with CTs so far holds 
a unique potential for applicability throughout the stroke continuum. Evaluation of different aspects 
of research and the creation of a practical framework to enable efficient research output are critical.  
This evaluation and consequent findings can add to knowledge available to researchers engaged in 




CHAPTER 3: STUDY DESIGN CONSIDERATIONS 
3.1 Background 
Clinical research with different types of CTs in ischaemic stroke has gathered momentum in the 
last decade. ClinicalTrials.gov, a database provided by the U.S. National Library of Medicine for 
clinical studies across the world, listed 150 clinical studies investigating different types of CTs in 
ischaemic stroke in July 2018. The ‘Stem Cell Therapeutics as an Emerging Paradigm in Stroke’ 
(STEPS) was initially convened in 2007 as a collaborative platform in the USA between academia, 
industry and key government bodies like the NIH and FDA and was updated last in 2014 (299). 
This resulted in a series of guidelines (I/II/III) which provide a high-level consensus approach to 
understanding barriers to: successful translation of preclinical research; increasing data regarding 
the mechanisms of action of CTs; and important elements of clinical trials in the context of the use 




Table 6: STEPS III Recommendations   
STEPS III: Suggestions for Phase II/III Efficacy Trials  
Entry criteria for Participants   Recommendations 
Understanding the properties of the 
cell therapy (CT) of interest  
Exclusion of participants who are at high risk 
of known adverse events concerned with CT 
Understanding the natural history of 
the stroke syndrome 
More information needed regarding 
spontaneous stroke recovery and 
prognostication markers 
Choice of study end points to assess 
hypotheses 
Selection of endpoints aligned to study 
population 
Time window for patient selection Recommendations 
Selecting an optimal time window 
for CT administration 
Align to the intended pathophysiological 
targets known from preclinical studies 
Assessment of efficacy  
The use of domain-specific end 
points, which are sensitive to the 
differences in recovery 
Use of domain specific endpoints along with 
established global endpoints 
Biomarkers of Activity 
Identifying markers that can define 
mechanisms of action and CT 
effects  
Research is needed for their use 
Concomitant Rehabilitation Therapy 
Implications of including 
rehabilitation in study design 
Rehabilitation could be a confounding factor 
in the assessment of efficacy 
Concomitant rehabilitation can have labelling 
implications 
Adapted with permission from Savitz et al. (2014) (328) 
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Numerous studies using different types of CTs, administered at different phases of stroke, were 
published in recent years. These studies have used diverse trial designs, patient populations and 
routes of administration for investigational CTs. There is robust preclinical evidence to support the 
premise that the predominant mechanism of action of all types of CTs is not cell engraftment, but 
the pleotropic effects they exert that augment endogenous neurovascular repair, support brain and 
synaptic reorganization, and reduce secondary tissue injury (232, 315). Early human studies of CTs 
in stroke have demonstrated adequate safety and provided preliminary evidence of a beneficial 
effect in acute, subacute and chronic phases of stroke. The publication in 2016 of two early phase 
clinical studies with SB623 and CTX0E03 (genetically modified stem cell types, isolated from 
adult bone marrow and foetal brain tissue, respectively) was an important milestone (285,288), as 
the first industry-driven clinical studies in the CT research space, hitherto driven by academic 
centre led trials. It is crucial to evaluate findings from these studies to understand the critical 
elements that need to be addressed pragmatically to ensure subsequent trial designs are optimized 
to generate good data on the relative effectiveness of these therapies.  
A perspective on key developments in clinical CT research in stroke was published in The Medical 
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reatment of stroke in the acute phase has come a 
long way with the development of paramedic, 
emergency department and stroke team pathways  
for hyperacute assessment and management with 
intravenous thrombolysis, endovascular clot retrieval and 
hemicrani ect o my. Acute stroke units reduce mortality and 
morbidity by up to 20% or more.1 An estimated 80% of stroke 
patients survive for one year after stroke, with the large 
majority being left with chronic disability.2 In Australia and 
many other countries around the world, stroke is the 
leading cause of adult disability.3 It is estimated that up to 
450 000 Australians have disability after stroke.4,5 
The only intervention currently available to stroke 
survivors is rehabilitation. Increasing evidence suggests 
that rehabilitation complements the natural functional 
recovery process that can often continue for months or 
years after stroke.6 However, there are persisting gaps in 
our understanding of the basic biological pathways that 
drive post-stroke recovery, and these pose challenges in 
applying evidence-based rehabilitation strategies in the real 
world. This becomes especially critical as patients often 
need a combination of rehabilitation strategies that cater for 
their specific disability and complement their potential for 
long-term recovery. These are often required beyond the 
period for which rehabilitation services are currently made 
available due to resource constraints.7 So where does that 
leave us in 2017? 
Regenerative neurology or stem cell therapy may provide an 
answer to this unmet need by potentially restoring 
neurological function in an individualised manner. Many 
stem cell researchers and clinicians hold the view that the 
field of regenerative medicine may have as large an impact 
on humanity as antibiotics.8 
Basics of stem cells 
Stem cells are unique in possessing two qualities — the 
capacity for self-renewal and the potential for multilineage 
differentiation. If a stem cell is pluripotent, it can give rise 
to cells derived from all three germ layers (ectoderm, 
mesoderm and endoderm) that differentiate into different 
tissues during embryonic development. On the other 
hand, a multipotent stem cell tends to generate limited cell 
types, often relevant to the organ from which the stem cell 
was derived — for example, haematopoietic stem cells 
(HSCs) tend to generate blood and immune cell types. 
Embryonic stem cells isolated from the very early embryo are 
pluripotent while adult somatic stem cells derived from 
adult organs, such as mesenchymal stem cells from bone 
marrow, are multipotent, similar to HSCs. 
A significant clinical limitation to the use of embryonic 
stem cells therapeutically is the potential for them to form 
tumours, such as teratomas which have multiple cell types 
from the different embryonic lineages (hair, bone, teeth, 
heart muscle, etc).9 In contrast, to date, multipotent cells 
such as mesenchymal stem cells are considered safer, with 
animal studies reporting no increase in tumorigenicity.10 
In 2006, Yamanaka (2012 Physiology or Medicine Nobel 
Laureate) showed that somatic cells (skin fibroblasts) could 
be engineered genetically by four genes (known as the 
Yamanaka factors) to produce pluripotent cells similar to 
embryonic stem cells.11 This third type of stem cell is 
termed an induced pluripotent stem cell (iPSC). This 
discovery has radically transformed stem cell research and 
proffers the concept of personalised regenerative medicine. 
Early clinical trials have already started deriving iPSCs 
from an individual’s fibroblasts for autologous (self-
)treatment or personalised medicine.12 The findings of 
preclinical studies in stroke models have provided 
encouraging evidence for potential for neuroregeneration 
and useful insights into potential applicability in the 
future.13-15 
Chronic stroke and local injection 
 
Last year was an exciting one for stem cell therapy in stroke 
patients. There were two high impact publications 
documenting early phase clinical studies with two different 
multipotent stem cells, SB623 and CTX0E03. Both are 
genetically modified stem cell types, one isolated from fetal 
brain tissue16 and the other from adult bone marrow.17 Two 
independent research teams from reputable institutions in 
the United Kingdom and United States performed these 
studies with industry funding (ReNeuron and San Bio, 
respectively). 
This research examined two key questions in relation to 
study design: 
• Is it potentially useful to treat stroke survivors in the 
chronic phase when their disability has plateaued, 
sometimes as long as 3 to 4 years after stroke? 
• Is intracerebral implantation of stem cells a feasible 
route of administration? 
Published preclinical and preliminary clinical data indicate 
that the design of the studies was valid, although research 
opinion is often divided as to optimum timing and route of 
administration of cell transplantation.9 
Why was stem cell therapy not administered in the acute 


























of clinically pragmatic answers to this 
question — in the acute phase, patients 
may be too medically unstable to 
undergo neurosurgery. Moreover, 
patients are often still showing rapid 
improvement, so it would be 
problematic to measure any benefit 
above that of optimum acute stroke unit 
care, when disability has not yet 
plateaued.18 
Why was a neurosurgical implantation 
chosen? “Functional neurosurgery” is a 
fast-developing specialty and these 
neurosurgeons routinely implant 
electrodes for deep brain stimulation to 
treat Parkinson disease. Thus they have 
the expertise to inject, via a narrow 
bore cannula, deposits of stem cells 
into multiple sites within the human 
brain. One benefit to the patient of 
intracerebral implantation is that the 
cells remain  
within the brain and can be imaged non-invasively.19 An 
alternative route of administration used in earlier clinical 
studies was intravenous injection.20 Initially, this approach 
was considered safer than intracerebral implantation, but 
it is now appreciated that there is a theoretical risk of 
distant tumorigenicity, in that stem cells injected 
intravenously may deposit widely throughout a number of 
organs within the body (ie, lung, liver, etc.) and may interact 
with presymptomatic tumours.20 
Is it safe? 
Early phase clinical trials characteristically involve small 
numbers of patients to minimise the number at risk if there 
is a serious treatment-related adverse event. In the two 
studies described above,16,17 27 patients were followed for 
12 months after treatment, which is a generally accepted 
timeframe. The studies stated that no adverse event directly 
attributable to the stem cell therapy was found. However, 
the neurosurgical procedure of creating a burr hole and 
entering the brain to administer the cells did result in 
appreciable anticipated adverse events (ie, haematoma, 
headache and other symptoms related to the consequent 
reduction of intracranial pressure). It is noteworthy that 
both studies will continue surveillance of all patients after 
12 months to detect any longer term adverse events. 
We propose an alternate perspective with respect to the 
claims that no stem cell-related adverse events occurred. 
Stem cells implanted into the brain are known from 
preclinical data to differentiate into neural cells and 
probably integrate within the brain.9 In theory, this cellular 
behaviour has the potential to form an epileptogenic focus. 
A small number of patients in each of the two high impact 
studies16,17 were reported to have seizures. With this 
limited clinical dataset it cannot be concluded whether 
their seizures arose from the neurosurgical procedure, as 
suggested in the publications,16,17 or was related to the 
stem cells. We propose that larger phase 2/3 studies should 











understand the association of seizures with intracerebral 
implantation stem cell therapy. 
The clinical data in these two early phase clinical studies 
supports the clinical feasibility and safety of intracerebral 
implantation of stem cells in patients with chronic 
disability after stroke. Both studies used an escalating dose 
of stem cell therapy. Cell doses of up to 10 million SB623 
and 20 million CTX0E03 stem cells may be used for future 
larger phase 2 studies. 
So: does it work? 
This question will not be answered with any degree of 
certainty for a number of years as we await the results 
from large, multicentre, multinational, double-blind, 
randomised controlled clinical trials. While preclinical data 
from animal studies suggest an overall functional 
improvement of 40.6%, the extrapolation of these findings to 
human stroke pathophysiology is limited by: (i) species-
specific differences; and (ii) the fact that controlled induction 
of cerebral ischaemic lesions in animals is not fully 
representative of the heterogeneous lesion load seen with 
human stroke.9 
Early clinical studies enrolled a heterogeneous mix of 
patient groups. Most of these studies were open label and 
single arm and thus not designed to answer the question of 
efficacy. Therefore, at present, it is difficult to postulate any 
differential benefit for specific patient or stroke subgroups.18 
From a mechanistic perspective, there are a number of 
theories from preclinical data on how stem cell therapy may 
decrease post-stroke disability (Box), with neuroplasticity 
considered to be an important factor.21 
An aspect of immense practical relevance is that 
standardised rehabilitation was not provided to participants 
in these studies. There is an ongoing debate about the 
potential confounding effect of rehabilitation on functional 
and structural outcomes. However, rehabilitation is accepted 
as a standard of care to optimise natural recovery, and 
guidelines for stem cell research such as Stem Cell Therapy 
as an Emerging Paradigm for 
 






























Stroke (STEPS)22 recommend its inclusion in trial design. 
Stroke clinicians will know from everyday experience that 
significant improvement in neurological function many 
years after an ischaemic stroke is rarely observed. The two 
studies described above16,17 are very important in the field of 
regenerative neurology in that both found an associated 
improvement in function in the chronic phase of stroke 
among patients with different areas of stroke-induced 
injury. In light of the emerging evidence for long-term 
potential to relearn that can be harnessed by rehabilitation, 
stem cell implantation along with targeted and protracted 
rehabilitation could have a synergistic and biologically 
plausible impact on post-stroke recovery. 
It is of fundamental interest that both studies described 
changes on magnetic resonance imaging (MRI) of the 
human brain after treatment. It was suggested that these 
MRI findings may not be explained by the neurosurgical 
procedure alone.17 These preliminary findings may present 
an opportunity for reverse translational research, from the 
clinic back into the research laboratory, to gain a better 
understanding of how changes in the human brain may 
occur after stem cell therapy. 
At this juncture of stem cell research in stroke, there are 
three important points to be considered: 
• The preclinical and early clinical data which suggest 
that stem cell therapy may be helpful are becoming 
encouragingly robust.23 
• The preponderance of failed translation efforts 
from preclinical to clinical therapeutics in stroke 
highlights that continued exercise of scientific 
rigor is critical. 
• Ongoing stem cell tourism across the world and in 
Australia to reach centres that operate for financial gain 
without regard to research integrity or patient safety 
poses a significant danger to the credibility of this 
field.24 
The current regulatory framework in Australia for 
oversight of cellular therapies has significant gaps in scope 
as well as implementation. It is a matter of urgency that our 
politicians and regulatory authorities collaborate with their 
counterparts in the US, European Union, Japan and other 
regions where innovative approaches are being 
implemented to develop the field while creating adequate 
safeguards to protect patient interests.25,26 
Exciting scientific research is that in which the questions 
raised outweigh the answers. We suggest the quest to fulfil 
the unmet need for treating disability after stroke has taken a 
step forward. 
Competi n g interes ts: No relevan t disclosures. 
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3.2 Research Objectives 
A systematic review of published clinical studies was undertaken to understand the choice of study 
design elements, endpoints, CT characteristics, dose and mode of delivery, and to analyse their 
impact on the quality of evidence generated in early phase clinical studies with CTs in ischaemic 
stroke. 
3.3 Methods  
A systematic review of all published clinical studies in stroke investigating cell therapies was 
conducted.  
The protocol for the review, defined a priori was published in PROSPERO: International 
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Is stem cell transplantation effective in patients with stroke?  
Is stem cell transplantation safe in patients with stroke? 
Searches 
Databases such as PubMed, EMBASE, SCOPUS, Web of Science and the Cochrane Central Register of 
Controlled Trials (CENTRAL) trials registry of the Cochrane Collaboration will be searched. The specific search 
strategies will be created in consultation with a Health Sciences Librarian with expertise in systematic review 
searching. After the PubMed strategy is finalised, it will be adapted to the syntax and subject headings of the other 
databases. The International Clinical Trials Registry Platform Search Portal and ClinicalTrials.gov will be searched 
for ongoing or recently completed trials and PROSPERO will be searched for ongoing or recently completed 
systematic reviews. As relevant studies are identified, reviewers will check for additional relevant cited and citing 
articles. 
Types of study to be included 
We will include studies with all study designs, except case reports and segregate them into two groups for further 
analysis: controlled studies with comparator arm and studies without comparator arms.  
Condition or domain being studied 
Stroke (all types) 
Participants/population 
Inclusion Criteria: 
Trials investigating use of stem cell therapy in adult patients who have experienced a stroke inclusive of all types 
of stroke, in any phase from acute to chronic phase, following stroke 
Exclusion Criteria: 
Trials investigating combination therapies including stem cells 
Intervention(s), exposure(s) 
All types of stem cell therapies inclusive of all study designs, all types of cell source (autograft, allograft or 
xenograft; embryonic, fetal or adult), route of administration (intracerebral/intravenous/intra- arterial/intrathecal) 
and dosage. 
Comparator(s)/control 
Non-exposed control group for analysis of studies with control comparator design 
Context 
Studies reported between 2005- 2016 Studies reported in English 
Primary outcome(s) 
PROSPERO 
International prospective register of systematic reviews 
 




Effectiveness measures will be assessed using validated body structure/impairment (NIHSS/Fugyl- Meyer 
assessment/modified Ashworth scale/European stroke scale); activity (Barthel index) and participation (Stroke 
Impact scale/ modified Rankin scale) measures. 
Timing and effect measures 
These outcomes will be assessed at 6 months. 
Secondary outcome(s) 
Post-procedure safety outcomes such as deaths, infections, stroke recurrence and neoplasms will be analysed.  
Timing and effect measures 
The minimum period of follow up considered will be 6 months. 
Data extraction (selection and coding) 
Selection process: 
All studies identified using the search strategy described above will be screened independently by two review 
authors (AN and FCC) to identify studies that potentially meet the listed inclusion criteria outlined above. The full 
text of all potentially eligible studies will be independently assessed by the two review authors (AN and FCC). Any 
disagreement between them over the eligibility of particular studies will be resolved through discussion with senior 
reviewers (SK and SH). 
Data collection process: 
A standardised data extraction form will be used to extract data from the included studies for assessment of study 
quality and evidence synthesis. The data extraction form will be designed in consultation with statistician in the 
team (SH). Extracted information will include: study setting; study population and participant demographics and 
baseline characteristics; details of the intervention and control conditions; study methods; recruitment and study 
completion rates; outcomes and times of measurement; information for assessment of the risk of bias. Two review 
authors will extract data independently, discrepancies will be identified and resolved through discussion with 
senior reviewers (SK and SH). Missing data will be requested from study authors through email. 
Data items: 
Data will be collected from studies pertaining to year of publication, country where the trial was conducted, study 
design elements such randomization, blinding, treatment allocation and interventions in the control group. 
Characteristics of study participants such as demographics, phase and type of stroke, time between stroke onset 
and enrollment, time between stroke onset and administration of stem cell therapy and delivery of rehabilitation will 
be recorded. The outcomes assessed in different trials for determining safety, efficacy and feasibility will be 
recorded along with the period of follow up used in different studies. 
Risk of bias (quality) assessment 
Two review authors (AN and FCC) will independently assess the risk of bias at the study level for all the studies 
included in the review, considering the characteristics recommended by the International Cochrane Collaboration. 
These include allocation bias, assessment bias and reporting bias. A determination of risk of bias for each study 
and as a body of evidence will be illustrated and considered in final reporting.  
Strategy for data synthesis 
We will provide a narrative synthesis of the findings from the included studies, structured around the type of 
intervention, study design, target population characteristics, type of outcome and intervention content. 
The included studies will be segregated depending on study design into two groups for further analysis: controlled 
studies with comparator arm and studies without comparator arms. 
We anticipate that there will be limited scope for meta-analysis because of the range of different outcomes 
measured across the small number of existing trials, within group. However, where studies have used the same 
type of intervention and comparator, with the same outcome measure, we will pool the results using a random-
effects meta-analysis, with standardised mean differences for continuous outcomes and risk ratios for binary 
outcomes, and calculate 95% confidence intervals and two sided P values for each outcome. 
PROSPERO 
International prospective register of systematic reviews  
 




Heterogeneity between the studies in effect measures will be assessed using both the Chi-squared test and the I-
squared statistic. We will consider an I-squared value greater than 50% indicative of substantial heterogeneity. 
Analysis of subgroups or subsets 
The following subgroups will be considered, subject to feasibility: 
1. Phase of Stroke at stem cell delivery: 
a. Acute and subacute (within three months of ischemic stroke) versus chronic (more than three months after 
ischemic stroke). 
2. Treatment Characteristics: 
a. Source of stem cells: autologous or allogeneic 
b. Route of administration: intracerebral/intravenous/intra-arterial/intrathecal 
Contact details for further information 
Dr Nagpal anjali.nagpal@adelaide.edu.au 
Organisational affiliation of the review 
The University of Adelaide 
Review team members and their organisational affiliations 
Dr ANJALI NAGPAL. The University of Adelaide 
Dr FONG CHAN CHOY. The University of Adelaide Dr Susan Hillier. University of South Australia 
Dr Stuart Howell. The University of Adelaide 
Dr Anne Hamilton- Bruce. The University of Adelaide Dr Simon Koblar. The University of Adelaide 
Anticipated or actual start date 
15 June 2016 
Anticipated completion date 
20 September 2016 
Funding sources/sponsors 
Stroke Research Programme (The University of Adelaide) 
C/O Heart Health Theme - Level 6 
South Australian Health & Medical Research Institute (SAHMRI) GPO Box 11060 
Adelaide 






Stage of review 
Review_Ongoing 
Subject index terms status 
Subject indexing assigned by CRD 
PROSPERO 
International prospective register of systematic reviews  
 







This information has been provided by the named contact for this review . CRD has accepted this information in good faith and 
registered the review  in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any 
associated f iles or external w ebsites. 
Subject index terms 
Genetic Therapy; Humans; Safety; Stem Cell Transplantation; Stroke 
Date of registration in PROSPERO 
 
30 June 2016 
Date of publication of this version 
30 June 2016 
Details of any existing review of the same topic by the same authors 
Stage of review at time of this submission 
Stage Started Completed 
Preliminary searches Yes No 
Piloting of the study selection process Yes No 
Formal screening of search results against eligibility criteria No No 
Data extraction No No 
Risk of bias (quality) assessment No No 
Data analysis No No 
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This review included 26 clinical studies that investigated CTs in stroke and were published in the 
12-year time-period: 2005-2016. The number of studies published increased from nine studies in 
the period: 2005-2010 to 20 studies in the period: 2011-2016. It was interesting to note that a higher 
proportion of studies published since 2011investigated autologous use of CTs (15 out of 20 studies) 
as compared to the earlier studies prior to 2011[autologous (n=4); allogeneic (n=5)]. Mesenchymal 
stem cells were the predominant stem cell type studied in all these trials (n=18). A meta-analysis 
indicated a benefit in the CTs group in terms of functional impairment, activity and participation 
following stroke. Data synthesis across studies provided reassurance of the relative safety of the 
different CTs administered in these trials. Our review evaluated different aspects of the study 
designs used in the included studies.  
The findings of the systematic review and meta-analysis were published in Stem Cell Research & 
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Stroke, classically characterised as a neurological deficit  
attributed to an acute focal injury of the central nervous  
system (CNS) by a vascular cause (infarction or 
haemorrhage), is a major cause of disability and deat h 
worldwide [1]. While stroke represents a single event of  
cell/tissue injury, it sets in motion a complex interplay of  
inflammation and repair involving neural, vascular and 
connective tissues, in and around the affected areas of the 
brain [2, 3]. Molecular and imaging research is genera t in g 
new insights into mechanistic interactions at the cellular level 
[3]. The American Heart Association/ American Stroke 
Association (AHA/ASA) proposed an updated definition for 
stroke in 2013 that incorporates clinical and tissue criteria [4]. 
These criteria reflect the advances in imaging techniques and 
consequent under- standing of disease pathophysiology in 
the past few 
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decades. However, the translation of these advances int o 
meaningful therapeutic options has until recently been met  
with limited success. While interventions for early re- perfusion 
such as thrombolysis and endovascular revascularisation have 
shown significant benefit, they are still subject to a limit ed 
window of opportunity [5, 6]. 
There is now a significant body of evidence from pre- clinica l 
research which postulates that stem cells potentially modulat e 
multiple pathways involved in endogenous neurogenes is ,  
angiogenesis, immune modulation and neural plasticity, in 
addition to or instead of cell replacement [7–9]. These effects  
may potentially be harnessed for effecting structural and 
functional regeneration after stroke with a prolonged window 
of opportunity [10, 11]. An encouraging number of pilot and 
definitive early- phase clinical studies have been published in 
the last decade, signalling a critical milestone in clinica l 
translation of stem cell therapies in stroke [12–39]. However, the 
interpretation of current knowledge in stem cell research seems  
challenging due to heterogeneity in the study de- sign,  
publication bias and the possible confounding effects of  
concomitant interventions such as immunosuppressa nt use 
and rehabilitation. Early meta-analyses have attempted 
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction  
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to investigate efficacy and safety data for particular cell 
types (e.g. mesenchymal cells) [40], stroke type (ischaemic)  
[41] or study design (single-arm studies) [42]. However,  
these analyses have been limited by the small number and 
size of studies considered. Other reviewers have taken 
more of an ‘all-comers’ approach to inclusion of all 
potential regenerative interventions including 
combinations of cell-based and biological therapies [43]. 
This approach, while attractive on a broader 
pathophysiological level, may present over-simplified  
assessment of the complexities involved in the use and 
investigation of living cells as therapeutic products. 
Objectives 
The present review and meta-analysis aims to assess the 
effectiveness and safety of cell therapies, studied as a 
monotherapy (inclusive of any type/source/route of ad- 
ministration) in adult patients with stroke (inclusive of all 
types and phases of stroke) and published in English. 
 
Methods 
Protocol and registration 
The protocol for the review was prepared and regist ered 
on PROSPERO (international prospective register of 





The review evaluated all studies investigating the use of  
stem cells in stroke, other than case reports, reported in 
the English language during the period 2005–2016. The 
included studies were segregated into two subgroups for 
further analysis: controlled studies with a comparat or 
arm and studies without comparator arms. 
Inclusion criteria 
Trials investigating the use of stem cell therapy in adult 
patients who had experienced a stroke, inclusive of all  
types of stroke and in any phase from the acute to chronic 
phase, were included. 
Exclusion criteria 
Trials investigating combination therapies including 
stem cells with other therapies. 
Intervention(s) of interest 
Stem cell-based interventions with any type (autograft ,  
allograft or xenograft; embryonic, fetal or adult) of cell 
source, route of administration (intracerebra l/int ra v e n-
ous/intra-arterial/int ratheca l) and dosage. 
 
Search strategy 
Databases including PubMed, EMBASE, SCOPUS, Web 
of Science and the Cochrane Central Register of Con-
trolled Trials (CENTRAL) registry of the Cochrane Col-
aboration were searched until November 2016. The 
specific search strategies were created in consultat i on 
with a health sciences librarian with expertise in 
systematic re- view searches. After the PubMed strategy 
was finalised, it was adapted to the syntax and subject  
headings of the other databases. The Internationa l 
Clinical Trials Registry Platform Search Portal and 
ClinicalTrials.gov were also searched for trials  
completed recently. AN, FC and FCC checked for 
additional relevant articles. The authors of ar-ticles were 
contacted via email when pertinent informa-tion was  
missing in the published manuscripts and additiona l 
data thus obtained were included in the final analysis  
(Additional file 1). 
Study selection 
All studies identified using the search strategy de-
scribed were screened independently by two review 
authors (AN and FCC). AN and FCC independent l y 
assessed full texts of all eligible studies. Any disagree -
ment regarding the eligibility of a particular study was  
resolved through discussion with senior reviewers (SAK 
and SHi). 
Data collection process and data items 
A standardised data extraction form was used to extract  
data from the included studies for assessment of study 
quality and evidence synthesis. The data extraction form 
was designed in consultation with the methodologist on 
the team (SHo). Extracted information included: study 
setting (year of publication and country); study popula-
tion demographics and baseline characteristics; details of  
the intervention and control conditions, if applicable;  
recruitment and study completion rates; information for 
assessment of the risk of bias; and study design element s  
such as randomisation, blinding, treatment allocation 
and interventions in the control group, outcomes and 
times of measurement. 
Two review authors (AN, FCC) extracted data inde -
pendently and differences identified were resolved  
through discussion with senior reviewers (SAK, SHi,  
AHB). Study authors were contacted via email for 
missing data. 
Characteristics of study participants such as demo -  
graphic characteristics, the phase and type of stroke,  
time between stroke onset and enrolment, time between 
stroke onset and administration of stem cell therapy and 
delivery of rehabilitation were recorded. The outcomes  
assessed in different trials for determining safety,  
efficacy and feasibility were recorded along with the 
period of follow-up used in different studies. 




Risk of bias (quality) assessme nt 
AN, FCC and SHi assessed the risk of bias in individua l 
studies for the two subgroups included in the review,  
considering the characteristics recommended by the 
International Cochrane Collaboration [44]. 
Summary measures 
Primary outcomes 
Primary outcomes of interest were based on the WHO  
ICF framework [45] and included effectiveness measures  
assessed at the 6-month time point using validated scales  
for body structure/impairment measures (e.g. Nationa l 
Institutes of Health Stroke Scale (NIHSS)/Fugyl-M ey e r 
assessment/Modified Ashworth Scale/European Stroke 
Scale), activity measures (e.g. Barthel index (BI)) and 
participation measures (e.g. Stroke Impact  
Scale/Modified Rankin scale (mRS)). 
 
Secondary outcomes 
Post-procedure safety outcomes such as death,  
infections, stroke recurrence and neoplasms were 
considered. The minimum period of follow-up wa s  
established as 6 months. 
Strategy for data synthesi s 
A narrative synthesis of the findings from the included 
studies was carried out structured around the type of  
intervention, the study design, the target population 
characteristics and the effectiveness and safety outcomes  
measured. The included studies were segrega t ed 
depending on study design into two subgroups for 
further analysis: controlled studies with a comparat or 
arm and studies without comparator arms. 
Method for meta-analysis 
The data were analysed by SHo using STATA/SE v14.1  
(StataCorp LP, College Station, TX, USA). 
For the single-arm studies, patient data were used to 
calculate a difference score, which represents the cha nge 
from baseline to day 180. Meta-analyses were performed 
using only the mean and 95% confidence limits of the 
difference scores. Data from the controlled studies were 
explored using treatment effects (treatment vs control 
group) at 6 months. Baseline data for each study were 
inspected to ensure that the randomisation produced 
groups which did not differ in terms of mean scores for 
the three scales under investigation (NIHSS, BI and 
mRS), for which there were adequate data available. For 
both subgroups, a separate meta-analysis was  
performed for each instrument. The meta-analyses were 
performed using a DerSimonian–Laird random effect s  
model to account for potential heterogeneity across  
studies [46]. Pooled estimates were presented as the 




Heterogeneit y was summarised using the I-squared 
statistic. 
A formal evaluation of heterogeneity and publicat ion 
bias was planned in the event of data being available 




The review followed the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA )  
guidelines [47]. 
Twenty-six studies, which fulfilled the defined inclu -
sion and exclusion criteria, were selected for further data 
synthesis (Fig. 1). 
Study characteristics 
The type of stem cell intervention (cell type; source; rout e 
of administration; time between stroke onset and 
administration of stem cell therapy; delivery of rehabili -
tation), study design and target population 
characteristics (phase and type of stroke; time between 
stroke onset and enrolment) are presented in Table 1. 
The majority of studies (n=18) utilised autologous  
adult human bone marrow-deri ve d 
mesenchymal/mono- nuclear cells [13, 16–22, 24-26, 
30–34, 36, 37, 39]. The remaining studies utilised varied 
allogeneic cell sources such as human neural stem cells  
derived from fetal tis-sue (n=3) [15, 29, 38], mesenchyma l 
cells from umbilical cord blood (n=1) [23], neuronal cells  
derived from em- bryonic tissue (n = 2) [12, 14] and 
autologous peripheral blood haematopoietic stem cells  
(n = 1). One study in- vestigated the use of a xenogra f t  
(porcine fetal cells; n = 1) [16]. 
The most common route of delivery of stem cells was  
intravenous (n = 11) followed by intracerebral (n = 9), 
intra-arterial (n = 6) and intrathecal (n = 2). 
Studies without a comparator arm 
Fifteen studies were evaluated in the single-a rm study 
subgroup (Nexperimental = 131). Ninety-six participa n t s  
received stem cell transplant ation within 3 months of 
the incident stroke, of which only one patient had a 
haemorrha gic stroke. Sevent y-nin e patients receiv e d 
stem cell transplant ation more than 3 months post  
stroke, of which 65 participant s had ischaemic stroke 
and two patients had haemorrha gic stroke. 
 
Studies with a comparator arm 
Eleven studies were evaluated in the controlled study 
subgroup (Nexperimental = 330; Ncontrol = 329). Four of these 
studies evaluated the impact of stem cell trans-  
plantation within 3 months of the incident stroke. The 
patients in these studies were more likely those with 






haemorrha gic stroke (Nexperimental = 170; Ncontrol = 136)  
than ischaemic stroke (Nexperimental = 70; Ncontrol = 70). On 
the other hand, seven studies that report e d  
transplantat ion of stem cells more than 3 months pos t  
stroke had more patients with ischaemic stroke 
(Nexperimental = 79; Ncontrol = 116) than haemorrh a g i c 
stroke (Nexperimental = 11; Ncontrol = 7). 
 
Synthesis of results 
Safety 
Studies reported a varied period of safety follow-up to a 
maximum of 60 months following stem cell delivery.  
Safety events of particular interest are presented in Table 
2. The most commonly reported adverse events included 
headache and fever, mostly self-limited and often relat ed 
to the cell delivery procedures, particularly when 
administered via intracerebra l/int ratheca l routes.
Overall, 16 deaths were reported in participants receiv -
ing stem cell therapies. The cause of death was report ed  
to be recurrent stroke (n = 3), infections (n = 3), cardiac 
causes (n = 8) and pulmonary embolism (n = 2). How-  
ever, none of these events was ascertained as related to 
the therapy administered. The longest follow-up data 
published were from Lee et al. [19], who reported an 
adjusted hazard ratio (HR) of 0.344 (95% CI: 0.115–1.031, 
p = 0.057) for the mesenchymal stem cell group vs control 
for survival. 
Twenty-one events of seizures were reported across 10 
studies in patients receiving stem cells. The majority of  
these episodes were described as not related to the in-  
vestigational therapy. These resolved with anti-epilep t ic  
treatment with no subsequent recurrence. Overall, five 
cases of tumours were reported (eccrine poroma (n = 1), 
lung cancer (n = 2), malignant melanoma (n = 2)). None 
of these were attributed to the stem cell therapy as 
 




Table 1 Disposition of study design & intervention  
characteristics 













RCT 6 390 
Non-RCT (case–control design) 4 280 
Non-RCT (historic control) 1 10 
Single-arm open-label design 15 97 
Studies included 26 844 
Country 
 
United States 5 45 
United Kingdom 2 16 
Brazil 3 43 
China 4 366 
India 4 195 
South Korea 2 82 
Japan 2 24 
Spain 1 10 
Taiwan  30 
Cuba 1 5 
Russia 1 10 
Stroke phase 
Hyper-acute/acute/sub -acute 15 597 
Chronic 12 247 
Stroke type 
Ischaemic 20 421 
Ischaemic + haemorrhagic 5 77 
Haemorrhagic 2 346 
Stem cell haracteristics 
Cell type 
Human bone marrow-derived MSC/ 
 MNC  18  698 
Human fetal neural stem/ 
 progenitor cells  3a  67 
 Umbilical mesenchymal stem cells 1 14 
 Porcine fetal cells 1 5 
Human embryonic neuronal 
 Cells 2 19 








Not reported 14 
 
 
MSC mesenchymal stem cells, MNC mononuclear cells, RCT 
randomised controlled trial 
aCo-transplantation of neural stem cells and umbilical cord MSC 
bOne study had two unmatched sequential cohorts investigated 
under different routes of administration 
bA treatment cycle in one study used transplants via 
intracerebral route followed by 4 weeks of intravenous infusion 
dOne study reported administration of stem cell therapy in two 
settings (1st setting before and 2nd after 3 months of stroke) 
 
patients had well-recognised risk factors for tumour (lung  
cancer; melanoma) in their past history prior to receiving stem  
cells. 
Effectiveness 
Studies without a comparator arm 
Meta-analysis evaluated available data from eight single 
armstudies that reported the impact of stem cell therapies at 6 
months post treatment, on recognised validated body 
structure/impairment (NIHSS), activity (BI) and participation  
(mRS) measures (Figs. 2 and 3). NIHSS scores showed a modest 
decrease (SMD= – 4.13 (95% CI– 5.51 to – 2.76; p = 0.000)), although 
I2 = 86.20% indicated significant heterogeneity across the studies.
Peripheral blood 
haematopoie tic stem cells 
Cell source 
 















Autolog ous 18 710 
 
Intra-arterial 6b 57  
Experimental (n =461) Control (n=329)) 
Intracerebral 9c 405 Death 16 27 
Intravenous 11b 332 Tumours 5 0 
Intrathecal 2c 256 Seizures 21 5 







> 3 months 14d 283 Pain 3 0 
   Infections 11 9 
   Fever 19 1 






Autolog ous 18 710 
 





A similar, although numerica lly smaller, trend 
towards improvement was indicated by a decrease in 
mRS (SMD = – 1.63 (95% CI – 2.16 to – 1.10; p = 0.017);  
I2 = 66.60%) and an increase in BI (SMD = 38.41 (95% CI  
27.99–48.83; p = 0.163); I2 = 44.80%). 
Studies with a comparator arm 
Meta-analysis of data from six controlled studies that  
reported the impact of stem cell therapies on NIHSS, BI 
and mRS at 6 months post intervention revealed simila r 
directional trends in the change of all three outcome 
 
Fig.  2 Single-arm studies: National Institutes of Health Stroke Scale (NIHSS)/modified Rankin score (mRS). CI confidence interval, ES effect size 
Fig.  3 Single-arm studies: Barthel index (BI). CI confidence interval, ES effect size 
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parameters. However, the difference in effect size 
between experimental and control groups was very 
small (Figs. 4 and 5). NIHSS scores indicate a decrea se 
(SMD = – 0.75 (95% CI – 1.29 to – 0.22; p = 0.008); I2 =  
74.8%). Similarly, mRS scores indicate a decline (SMD =  
– 0.25 (95% CI – 0.50 to – 0.01; p = 0.726)). BI scores  
demonstrated an improvement (SMD = 0.39 (95% CI  
0.13–0.66; p = 0.113); I2 = 43.80%). 
Assessment of risk of bias 
All studies had at least one or more source of bias (Fig.  
6a, b). 
Allocation 
The sequence generation was adequate in 4/26 included 
studies. The method for sequence generation was not  
specified in three studies. The treatment allocation was  
concealed in only six out of 26 studies. 
 
Blinding 
None of the studies incorporated blinding of  
participants and study personnel. Ten out of 26 studies  
had blinding of outcome assessment. 
Incomplete outcome data 
Most studies reported having complete data for all 
included participants. In three studies, data on outcomes  
at 6 months were missing. 
Selective reporting 
All studies presented per-protocol data. 
 
Other potential sources of bias 
While selective publication of studies with significa nt  
results is regarded as a potential source of bias, there was  
no clear evidence of this in the current review. The 
impact of other sources of bias is equally hard to 
quantify. 
Additional analysis 
Further subgroup or sensitivity analysis was not deemed 




Summary of evidence 
The current review indicates a trend towards improve -  
ment across varied domains of functional impairment in 
patients with stroke given stem cell therapies. The 
quantum of improvement is small from studies that had 















Fig. 4 Controlled studies: National Institutes of Health Stroke Scale (NIHSS)/modified Rankin Score (mRS) Cl confidence interval, SMD standardised 
mean difference 
 





observed in both subgroups (with/without comparator) .  
This may probably be due to the differences in cell types  
used and the route, dose and time of administration and 
other elements of the study design. An exploration of  
these factors as the source of the identified heterogen eit y 
was not found to be feasible owing to the small number  
of patients involved. Therefore it is currently difficult to 
draw any meaningful conclusion about the most appro -  
priate dosage and route of administration or the phase 
of stroke in which these therapies are likely to provide 
most meaningful benefit. Nonetheless, we believe that 
our study provides insights into the overall effect of stem 
cell therapy and provides a starting point for future 
research on this issue. 
It is reassuring that the safety profile of these therap ies  
has been reasonable, with no alarming signals to date, 
especially in relation to tumorogenicity. Most of the 
adverse events were self-limited and resolved spontan-
eously or with appropriate management. The events of  
most note were seizures, headache and events associated 
with procedures used for administering these therapies .  
In addition, all studies reported successful recruit ment  
to target and successful administration of investigationa l 
therapy in study participants. 
It is interesting to note that a greater proportion of  
more recent studies (since 2010) have investigat ed cells  
derived from an autologous cell source (15 out of 20 
studies), whereas earlier studies had a similar number 
of studies with autologous (n = 4) and allo-geneic (n = 
5) sources of cells. 
Implications for clinical practice 
There has been a steady increase in the number of stud- 
ies published over the years (nine studies before 2010 
and 20 studies published in the period 2010–2016). There 
is now an increasing body of evidence that  
administration of stem cell therapies in patients in 
different phases of stroke is feasible and encouragingl y 
safe across different routes of administration. The key 
objective of early-phase clinical studies is to prove the 
concept and investigate preliminary safety of use in 
humans. To that end, our review and meta-analyses  
support the feasibility and safety of varied cell types  
delivered through different routes. 
However, the strength of evidence to support  
effective-ness of these therapies is not robust. This is a 
challenge often seen in the early phase of development  
due to the small size of the studies typical at this stage.  
The direction of change indicates a potential benefit ,  
which is consistent across both groups of studies (wit h 
or without a control comparison) and across outcome 
measures representing changes at the level of body 
function/impairment and those focused on daily 
activity and quality of participation in daily life. To gain 
stringent, clinically meaningful data as to potentia l 
benefit will require further research through well-
designed phase 2/3 studies. 
 
Implications for research 
With early-phase clinical studies investigating stem cell 
therapies reporting encouraging results, the field seems  
set to move into a phase where definitive effectiveness  
 


























Fig. 6 a Aggregate Risk of bias graph b Risk of bias summary 
 
assessment becomes critical. The translational success  
with stem cell therapies in stroke, exciting as it may be,  
has posed questions that need addressing. The present  
review provides assurance for probable safety of cell 
therapies in patients with stroke and potential for 
further research. Our meta-analysis at this early phase of  
research is limited by significant heterogeneity in tria l 
design and therapeutic strategies researched in these 
studies. However, the results of the analysis provide an 
early indication of potential benefit that should be 




explored through further research. This is necessary to 
avoid costly failures as in the past with neuroprotect i v e 
interventions in stroke. Currently there is persist ent  
ambiguity regarding clinical meaningfulness of  
interventions, despite increasing volumes of resea rch 
data. Most importantly, the review reiterates the need to 
conduct adequately powered studies using well -
characterised cell therapy products and investiga t in g 
impact on standardised clinical recovery outcomes. 
Stem Cell Therapies as an Emerging Paradigm in 
Ischemic Stroke (STEPS I/II/III) formulated recommen-
dations on quality standards for pre-clinical and clinica l 
research involving stem cell therapies [48, 49]. While 
these represent a much-needed framework to standard -
ise regenerative research in stroke, most of the published 
studies had started prior to formulation of these guide -  
lines. In fact, the challenges in design, feasibility and 
ethical aspects of these studies provided the impetus for 
the formulation of these recommendations to a 
significant extent. The ability to characterise the cells  
under investigation has been enhanced significa nt ly 
with increased capabilities in immune phenotyping and 
molecular transcriptional profiling of investigational cell 
types. Recent studies have investigated more select ive 
cell types as compared to earlier ones, which used naïve 
cells predominantly. These studies have referred to prior 
evidence of safety and impact on structural, functiona l 
and imaging parameters in rodent models in most in-  
stances. However, it is pertinent to note that the 
extrapolation of those findings may not always be 
straightforward. Numerous factors such as the 
differences in pathophysio-logical mechanisms of stroke 
between rodents and humans, the interplay of co-
morbid conditions in humans and the current dearth of  
evidence for the impact of stem cells in animal models  
simulating such baseline characteristics need further  
investigation. 
Two studies [18, 27] investigated cell disposition using 
cell labels (99mTc and CD34-nano-iron complex) and re-
ported variable homing and persistence of labelled cells  
in the brain. The study by da Fonseca et al. [18] also 
demonstrated distribution to other organs following IA 
administration. Numerous other studies have also re-
ported extra-cerebral distribution of stem cells following 
IV/IA administration, which may have potential impact  
on eventual dosing and safety [18]. While these tracers  
might provide an indication for the initial distribution,  
they are limited in their ability to provide long-term in-
formation relevant to the lifetime of the implanted cells .  
Multimodal fate imaging using bioluminescence and 
fluorescence imaging with functional MRI has generated 
evidence for use for long-term viability and bio-
distribution of stem cells [50]. This can potentially inform 
the period of safety follow-up considered adequate in 
early-phase research. For instance, a safety follow-up of  
6 months is considered adequate for mesenchymal cell 
types, while a period of at least 1 year is recommended for 
most cell types [41, 49]. 
Study design—future considerations 
STEPS III proposed that the inclusion criteria for phase 
2/3 studies should be structured based on properties of  
the cell therapy under investigation, particularly if there 
are any safety signals detected in pre-clinical and phase 
1 studies. While this is evidently sound science, it may  
be important to note here that the predomina nt  
proportion of phase 1 studies have failed to detect any 
obvious cell-dependent adverse events, specifica lly 
linked to a particular cell type. Exclusion of patients wit h 
significant co-morbidities might still therefore be 
required in the interest of safety, although this approach 
would limit extrapolation of eventual results to the 
general stroke population. 
However, an issue of greater clinical releva nce is the 
selection of trial endpoints in phase 2/3 studies. While 
recommendations from expert groups involved in 
stroke research have been highlight ing the need to 
validate and adopt domain-specif ic endpoints, its true 
utility can only emerge if domain-specif ic endpoin t s  
are used to power these studies. There is increa s i n g 
evidence validating the usefulness of domain-spec if i c  
measures in quantifyin g and predicting potent ia l 
trajectory of recovery [51]. However, for these to be 
more consistent ly utilised the following issues ma y 
need to be addressed. 
The objective of phase 3 studies has traditionally been 
to prove effectiveness in as broad a proportion of the tar- 
get population as is feasible considering evidence from 
pre-clinical and early-phase studies. Considering the 
het- erogeneous nature of stroke, it may be more 
meaningful to investigate stem cells in specific areas of  
impairment caused by stroke. This may necessa rily 
restrict patient inclusion to specific disability, but may 
provide more specific domain-centric outcome 
measures. 
However, such study designs may face challenges  
from regulatory authorities who prefer studies to be 
powered to established global endpoints, discoura ging 
the developers from choosing such endpoints. This is  
borne out by the present review, where most studies  
have reported temporal changes in NIHSS/mRS/BI .  
There is therefore an urgent need for researchers ,  
clinicians and regulators to collaborate to review 
evidence on domain-centric out- come measures and 
provide guidance on how these could be incorporated in 
future trial design. 
In addition, it is important to consider the unique 
pharmacodynamics of stem cells in the post-ischaemic 
microenvironment in the brain. The engrafted cells and 
consequent activation of paracrine pathways are poten-
tially unique to the individual area and severity of  
ischaemic injury in a given individual. Even though the 




broad mechanist ic direction of repair and plasticit y 
may be similar across individual patients, the 
interactions be-tween cells and target brain tissue are 
determined uniquely by an individual’s genotypic and  
phenotypic particulars. Thus it is reasonable to postula t e 
that the individual’s natural course of recovery ca n 
impact the quantum of change seen in 
functiona l/st ruct ural outcomes [52]. Emerging data  
from the field of rehabilitation research have put fort h 
an interesting concept of ‘the Maximum Proporti o na l  
Recovery Rule’, which proposes that 70% of maximum 
possible change (i.e. spontaneous recovery) occurs in 
the first few months post stroke. Recent data support  
the applicability of this rule across different doma in-
specific impairments [53]. Potentially useful pre- dict ive 
algorithms that can plot a prognostic trajectory for this  
recovery by combining clinical, neurophys iologi ca l 
and neuroima ging data are being developed [54]. These 
al- gorithms, if validated across domain-specif ic  
populations, may provide a practical tool for stratifyin g 
patients into more homogen eous subgroups. 
Because the effectiveness of rehabilitation and cell  
therapies may be driven by unique patient characterist ics  
differentially, it may be pragmatic to consider delivery of  
stem cells accompanied by targeted rehabilitation as an 
‘intervent ion package’ using a service delivery premise.  
The measures of effectiveness with such restorat ive  
interventions are often continuous variables that require  
definition of the minimal clinically important difference  
(MCID) that is acceptable to prove benefit. The necessa ry 
next question is whether the conventional randomised 
controlled design is the ‘best fit’ for generating data to 
inform clinical practice in this fast evolving field. 
Cluster randomisation with factorial design to in- 
corporate multiple intervent ions (i.e. stem cell trans -
plantation and rehabilitation) may be a pragmatic design 
to consider [55]. Study design can incorporate clusters of  
patients defined by domain-specific impairment  
receiving targeted, standardised rehabilitation in addition 
to stem cells. The effectiveness can then be assessed in 
terms of quantum of change on domain-specif ic  
endpoints. 
An equally important area of research is defining the 
time points in stroke evolution more consistently in line 
with emerging tissue and imaging evidence. The chronic 
phase of stroke represents the area of greatest unmet  
medical need. However, it is interesting to note that while 
there are increasing data from rehabilitation and stem cell 
research in chronic stroke, the clinical deter- mination per 
se of stroke as ‘chronic’ is heterogeneous, making any 
comparison/pooling of data difficult. 
Limitations 
The findings of the present review and meta-analysis  
should be examined in the light of a number of study
limitations. First, high levels of heterogeneity were 
observed across studies, which differed in terms of 
therapeutic characteristics such as route of administra-tion,  
timing after stroke and dose. We acknowledge this  
limitation and therefore have been conservative in our 
pooling and in our analysis techniques. Unfortunately,  
there were too few studies to explore these factors as po-
tential sources of heterogeneit y either through subgroup  
analysis or meta-regression. As a result, we are unable to 
draw any inferences about the optimum dose or route of 
administration. Such investigations may be more feasible 
as further studies appear in the literature. 
Second, most of the studies included had small num-
bers of patients which may have resulted in small study 
effects, particularly in single-arm studies where the sam- 
ples rarely reached double figures [56]. Small sample 
size is expected in early-phase research but this made 
any additional subgroup analysis unfeasible. Third ,  
potentially relevant studies had to be excluded because 
of the lack of published information and non-availabilit y 
of the additional information on request. Lastly,  
language bias remains an issue as we searched only 
English-langua ge databases and journals. 
Conclusions 
This review and meta-analysis provides further evidence 
for the safety and feasibility of cell therapies for stroke.  
There is reasonable evidence to suggest feasibility, safety 
and potential effectiveness of these therapies. In view of 
the heterogeneit y of disease per se and the nascent  
characterisation of therapies, the review poses importa nt  
questions that are critical to translational success.  
Further progress in this field will require execution of 
phase 2/3 clinical trials with study designs that ensur e 
homogeneit y of stroke characteristics, potentially wit h 
domain-specific characterisation of disabilities and 
targeted provision of rehabilitation and with appropria t e 
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This review and meta-analysis supported the overall safety and feasibility and potential 
effectiveness of CTs for stroke. In view of the heterogeneity of the disease per se and uncertainty 
about the optimal type, dose and delivery route of these therapies, the review highlighted the need 
to adopt pragmatic study design strategies. This would enable generation of clinically relevant data 
in homogenous subpopulations and matched controls, based on domain-specific characterization 
of disabilities, standardized co-delivery of rehabilitation and selection of aligned outcome 
endpoints appropriate to answer the fundamental question of effectiveness and progress forward in 
clinical development. Adoption of these aspects can accelerate legitimate research and facilitate 
participation of patients in research. These in turn may provide an effective deterrent to the existing 
risk that vulnerable patients face, of being misinformed about the unsubstantiated efficacy and 





CHAPTER 4: REGULATORY CONSIDERATIONS 
4.1 Background 
The inherent complexity of CTs and the still-evolving understanding of their mechanistic pathways 
of action are challenging to understand especially when used in the context of heterogeneous 
diseases such as stroke (146). While conventional small molecule drugs and, to some extent, 
biologicals have extensive characterization and well-regulated pathways of oversight, CTs have an 
unpredictable developmental pathway because of their dynamic structural and functional profiles  
(417). The fact that there are very few candidate CT products that have progressed beyond the 
initial exploratory clinical studies in human subjects corroborates this lack of predictability (418). 
In recent years, feedback sought from researchers in academia and industry concerning challenges 
in the development of regenerative medicine products has highlighted the lack of awareness and 
understanding of regulatory pathways as a significant deterrent to progress in this field (419). This 
seems to be more prominent amongst academic researchers, which potentially explains the hitherto 
unfulfilled opportunity afforded by numerous successful clinical studies published in this field 
(419). Timely and practical access to expertise in regulatory science is critical for clinician-
scientists, who are still the predominant drivers of translational research with CTs (419).  
4.2 Research Objective 
The key elements critical to the execution of early phase studies in CTs in ischaemic stroke were 





4.3 Methods  
4.3.1 Search Strategy 
The following databases were searched for identifying relevant studies: PubMed/MEDLINE, 
Google Scholar, Scopus, Web of Science, Cumulative Index to Nursing and Allied Health 
Literature (CINAHL), Cochrane and websites of regulatory bodies in various countries and legal 
literature databases such as AustLII and Thomson Reuters Westlaw. The reference list of all 
identified reports and articles were hand-searched for additional studies. The search include d 
papers published until April 2016. A range of keywords and index terms for the search included: 
ischaemic stroke; stem cells; cell therapies; regulatory policy; public policy; and regenerative 
medicine. 
4.3.2 Selection of Literature 
The first round of screening involved the scanning of titles and abstracts of identified studies and 
reports. Following this, full texts of the selected literature were assessed in the context of their 
relevance to CTs research. 
4.3.3 Data Extraction and Analysis  
The primary author completed the extraction process independently. It was reviewed for 
comprehensiveness and appropriateness by the review team. Synthesis of key themes emerging 
from the literature was undertaken and a descriptive analysis presented in the narrative review. 
4.4 Results 
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A B ST R A C T  
The encouraging pace of discovery and development in the field of regenerative medicine holds tremendous  
potential for bringing therapies to the clinic that may offer meaningful benefit to patients, particularly in 
diseases with no or suboptimal therapeutic options. Academic researchers will continue to play a critical role in 
developing concepts and therapies, thus determining whether regenerative medicine will be able to live up to this 
potential that clearly excites clinicians, researchers and patients alike. This review summarises recent  
developments in regulatory frameworks across different countries that aim to ensure adequate oversight of the 
development of regenerative medicine products, which are unique in structural and functional complexity 
when compared to traditional chemical drugs and fully characterised biological drugs. It discusses the 
implications of these developments for researchers aiming to make the challenging transition from laboratory to 
clinical development of these therapies and considers possible pragmatic solutions that could accelerate this 
process that is essential to maintain research credibility and ensure patient safety. 
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Regenerative medicine has come to be a widely accepted term for 
the varied research efforts made in the last few decades to understand 
the basic science underlying regeneration of human tissue, organs and 
cells and translate this growing knowledge into potential therapeutic 
modalities for diseases hitherto not amenable to management or possi -
ble cure [1]. Stem cell therapies hold the potential to provide effectiv e  
disease modification and possible cure for these diseases that have 
posed a tremendous challenge to clinicians and a heavy burden in 
terms of impaired quality and quantity of life for patients [2]. These dis- 
eases are associated with a burgeoning cost of suboptimal care for the 
community and the healthcare system. Successful regenerative medi-
cine has the potential to address all these issues [3]. 
Numerous stem cell therapies are currently in an exciting but critical  
clinical translational phase of development, as borne out by clinical trial 
registries across the world. As of June 2016, there are 4479 studies in-
vestigating use of different cellular therapies in various disease indica-
tions, of which 998 are industry-sponsored studies, as shown by 
listings on the National Institute of Health global clinical trial registry i. 
In stroke, for instance, of the 48 ongoing studies, 18 are sponsored by in-
dustry ii. It is interesting to observe that most ongoing research to date  
has initially been conducted in academic institutions. Industry has 
until recently, adopted a very cautious attitude in terms of involvement 
in development of these therapies [4]. Basic research is yet to provide  
broadly acceptable answers to key questions concerning structural  
and functional characterisation of different cell therapies. The chal-
lenges posed in terms of regulatory uncertainty and potential  
commercialisation models have meant that the key drivers in this field 
have been academic institutions and small to medium enterprises.  
Lack of experience in addressing regulatory requirements and limited fi-
nancial and human resources often challenge such entities. As cell based 
therapeutics move into clinical translation phase, these issues assume 
critical significance as failure to address these efficiently can be a signif-
icant roadblock in procuring funding and approval for meaningful clin-
ical studies critical to ensuring accelerated translation in this field [5]. 
The inherent complexity of stem cell products and the still evolving 
understanding of the basic science underlying their mechanistic path- 
ways of action pose a difficult challenge, especially when applied to 
chronic diseases where there is still an incomplete understanding of dis- 
ease pathophysiology. The characterisation of chemical drugs has been 
relatively well understood, leading to advanced standardisation and 
regulation. However, the structural characterisation and mechanism of 
action for cellular products is poorly understood presently. Additional  
work around the validation and global standardisation of preclinical ef-
ficacy assays is needed, which makes these therapies not amenable to 
standard pharmacokinetic characterisation. This unfortunately makes 
the regulatory pathway difficult and unpredictable. These aspects create 
multiple challenges for scientists involved in the development of such  
therapies as they navigate their way through the complexity of develop-
ment [6]. 
In recent years, feedback sought from researchers in academia and 
industry concerning challenges in the development of regenerative 
medicine products has highlighted the lack of awareness and under- 
standing of regulatory pathways as a significant deterrent to progress 
in this field [7–9]. This seems to be more prominent amongst academic 
researchers, which may potentially lead to the loss of many innovative 
developments in this field [7–9]. In light of the frantic pace of scientific 
advancement in molecular biology and its application in the area of re- 
generative medicine, it becomes even more critical that speedy, accu-
rate and practical access to expertise in regulatory science is made 
available to academic researchers and clinicians, who are still the pre- 
dominant drivers of translational research in the field of regenerative 
medicine. Recognition of this need for mechanisms for interdisciplinary 
collaboration is likely the first step towards accelerating the future pace 
of development of regenerative medicine. 
In this review, we provide a concise description of key developments 
in regulatory pathways in regenerative medicine across the globe, 
aimed particularly at researchers in academic settings. This will enable 
expanded understanding of the key challenges faced in the develop-
ment of regenerative medicine products and provide a summary of ap-
proaches initiated to address them. 
2. Regulator y pathways in different jurisdictions 
 
2.1. United States of America 
 
The Food and Drug Administration (FDA) in the United States has 
been issuing guidance periodically for development of human cells, tis- 
sues, and cellular and tissue-based products (HCT/Ps) for clinical use 
utilising a tiered, risk-based approach [10]. The extent of FDA oversight 
required in the development process is dependent on two key consider-
ations: the level of cell manipulation (minimal/more than minimal) and 
the intended use of cell therapy (homologous/non-homologous) [11]. 
An HCT/P is regulated under section 361 of the Public Health Service Act 
1944, which entails an abbreviated review, if it is minimally manipulated, 
is intended for homologous use only and does not involve the 
combination of the cells or tissues with other materials, which may raise 
new clinical safety concerns. The products that undergo more than 
minimal manipulation and/or are used in a non-homologous manner are 
deemed ‘biological products’ (Fig. 1). These undergo an extensive 
development process with the approval of clinical trials in humans 
requiring compilation of pre-clinical evidence, the submission of an 
Investigational New Drug Application (IND) and the submission of a 
Biologics License Application (BLA) under section 351(i) of the Public 
Health Service Act 1944 and related regulations. 
The FDA issued ‘Considerations for the Design of Early-Phase Clinical 
Trials of Cellular and Gene Therapy Products’ in 2015 [12] providing rec-
ommendations for clinical translation of HCT/Ps that fulfil the criteria for  
being a biological drug product, thereby requiring regulatory oversight 
under section 351 (Table 1). These recommendations pragmatically ac- 
knowledge the fact that the distinctive characteristics and feasibility  
challenges with these products influence the design considerations of 
early-phase clinical trials of HCT/Ps. The recommendations also ac- 
knowledge the limitations in the extrapolation of pre-clinical data to in- 
form early phase study design especially in context of highly humanised 
or species-specific cell based products. In addition, the FDA developed 
recommendations for preclinical assessment of cell therapy products,  
which reflect the authority's openness to move beyond the established 
pre-clinical guidance based on small molecule therapies, supported by 
reasonable and scientifically sound evidence [13]. 
These recommendations lay particular emphasis on the characteris-
tics of cell therapy products such as their ability to express molecules 
and factors that affect and are in turn, affected by the local microenvi-
ronment, and their ability to migrate and differentiate in vivo into 
undesired cell types. In addition, the impact of potential viral vector 
contamination and any adventitious therapy/intervention (e.g. immu-
nosuppression/invasive procedures/combination therapies) needs to 
be evaluated in detail to ensure the safety of potential research partici-
pants in clinical trials. 
The FDA recognises that the challenges with manufacturing these 
products may determine feasible doses and emphasises potential issues 
with the variability within different lots of the products. The guidance 
underscores the importance of establishing and maintaining GMP stan-
dards early in development of the product. 
Whilst the principal intent of early phase trials is the assessment of 
safety and feasibility, as most cell therapy products are likely to be in-
vestigated in disease populations to justify the risk inherent in these  
therapies, the recommendations encourage preliminary assessment of 
efficacy and obtaining ‘proof of concept’ data in humans in early phase 
trials to better inform further development. To that end, activity 
 
 




Fig. 1. Oversight considerations for cell based therapies in United States of America. 
 
assessments in the trial design are required to be detailed and justified in 
the context of the given disease indication and cell therapy product. 
The FDA guidance on Good Tissue Practice (GTP) requirements for 
cell therapies provides safeguards to minimise the risk of communicable 
disease transmission by HCT/Ps and prevent contamination during 
manufacturing [14]. Depending on whether the product is autologous 
or allogeneic, additional requirements such as donor screening may 
also be applicable. 
2.2. European Union (EU) 
In Europe, cell therapies are evaluated under Advanced Therapy Me- 
dicinal Products (ATMP), which include three major types of products 
specifically, gene therapy, somatic cell therapy and tissue engineered 
products, as set out in Regulation (EC) No. 1394/2007 and Commission  
Directive 2009/120/EC amending Directive 2001/83/EC [15,16]. These reg- 
ulations lay down additional scientific and technical requirements re- 
garding the testing of ATMPs for human use. The regulations deem 
that these therapies be considered as drugs if they are intended for  
non-homologous use and have undergone substantial manipulation .  
In this case, the relevant guidelines for development of biological thera- 
pies will be applicable (Fig. 2). The European Medicines Agency (EMA) 
recognises that evaluation of ATMPs requires specific expertise and has 
set up a Committee for Advanced Therapies (CAT) to evaluate the qual- 
ity, safety and efficacy of each ATMP. The CAT acknowledged that stud- 
ies for generating quality and nonclinical safety data for ATMPs are often  
conducted either by small and medium-sized enterprises or in academic 
institutions [17]. The EMA framework proposes a system of evaluation  
and certification wherein the CAT, independent of any marketing autho- 
risation application, can evaluate the data from such studies. It also eval- 
uates the implementation of Good Clinical Practice (GCP) and/or Good 
Laboratory Practice (GLP) in these studies, which may facilitate future
application for clinical trials and marketing authorisation application  
based on the same data. 
The EU regulatory pathway recognises the need to incorporate  
flexibility in evaluation of the manufacturing of these products in  
light of the specific technical characteristics of advanced therapy medic-
inal products [18]. Thus, whilst decreeing that the manufacture of 
advanced therapy medicinal products should be in compliance with  
the general principles of Good Manufacturing Practice (Commissi on  
Directive 2003/94/EC) [19], there are recommendations to develop 
guidelines specific to ATMPs to accurately reflect the specific challenges 
in their manufacturing process. 
 
2.3. Japan 
Japan's new regenerative medicine legislations aimed at accelerating  
the development of regenerative medicine products came into force  
in November 2014 (Fig. 3). The Pharmaceutical, Medical Devices and 
Other Therapeutics (PMD) Act 2014 will regulate the commercial devel-
opment of regenerative therapeutics [20]. The act lays down provisions 
for accelerated approval, contingent on provision of early safety and in-
dicative evidence of therapeutic benefit of an investigational therapy  
studied in well-designed Phase 1/2 trials, after review by the Office of 
Cellular and Tissue based Products within Pharmaceutical and Medical 
Devices Agency (PMDA) [21]. The seven-year period following condi-
tional approval entails mandatory capture and provision of in-clin ic 
data on efficacy and safety through defined mechanisms. By the end of 
this period, the sponsor either applies for final marketing approv al  
(the equivalent of a Biologic License Application [BLA] in the US) or  
withdraws the product. 
In addition, the Act on the Safety of Regenerative Medicine 2014 
(ASRM) defines the pathway to oversee the cell therapies administered 
in medical practice using processed cells and in the context of academic 
clinical research [22]. The law has enabled a pathway of oversight that 
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involves a tier-based, risk-dependent analysis and enables accreditation of 
cell processing centres for safer and resource efficient manufacturing. 
The institution that provides the cell therapy has to report annually on 
safety evaluation and scientific acceptability of these products to the 
Committee for Regenerative Medicine and Ministry of Health, Labour 
and Welfare. 
2.4. Canada 
The Biologics and Genetic Therapies Directorate, Health Canada, pro- 
vides regulatory oversight for the clinical development of regenerative 
medicine products (Fig. 4) as stipulated mainly by the Food and Drug 
Act 1985 [23], Safety of Human Cells, Tissues and Organs for Transplanta-
tion Regulations 2007(CTO Regulations) [24] and the Guidance document 
- Safety of Human Cells, Tissues and Organs for Transplantation Regulations 
2013 [25]. The CTO Regulations currently regulate minimally manipu-
lated cell and tissue products that are intended for allogeneic and ho-
mologous use only. 
Health Canada reviews the conduct of clinical trials investigating  
the use of these products in human subjects. It also issued a ‘Guidance  
document for Preparation of Clinical Trial Applications for use of Cell 
Therapy Products in Humans’ in 2015 [26], that emphasised the need 
for appropriate characterisation and adherence to GMP requirements 
early in development and highlighted the need for proactive discussion  
to address ambiguity in this regard. Institutional human research ethics 
boards review clinical research in accordance with the ‘Tri-Counci l  
Policy Statement (TCPS): Ethical Conduct for Research Involving Humans’,
 
as well as other local and international guidelines. In 2014, the TCPS was 
amended to incorporate the ‘Guidelines for Human Pluripotent Stem 
Cell Research’ formulated by the Canadian Institute of Health Research 
(CIHR), which requires approval by a Stem Cell Oversight Committee  
for research activity funded by one of the national research funding  
agencies [27]. 
2.5. Australia 
In Australia, cellular therapy products are regulated under the  
‘Australian Regulatory Guidelines for Biologicals’ released by the  
Therapeutic Goods Administration (TGA) in 2014 [28] (Fig. 5). ‘The 
National Statement on Ethical Conduct in Human Research 2007’ up- 
dated in 2015 provides guidance for clinical research undertaken in 
Australia [29]. The Prohibition of Human Cloning for Reproduction and 
the Regulation of Human Embryo Research Amendment Act 2006 [30], place  
further stipulations specific to research with embryonic stem cells.  
Whilst materials used in initial clinical research may be exempted from 
requirements for GMP, the TGA requires that investigational products 
used for phase 2 and 3 clinical trials meet GMP requirements [31]. 
Clinica l Trial Notification or Exemption pathways (CTN/CTX) enable 
access to investigational products in the context of clinical trials [32]. 
Whilst CTN entails only a notification to the TGA, CTX mandates a com-
plete review by the TGA before a trial can commence. The sponsors of 
the trials (either academic or industry) determine, in consultation with 
institutional human ethics review committees (HERCs) and 
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Fig. 5. Oversight considerations for cell based therapies in Australia. 
 
relevant authorities, the most appropriate pathway dependant on the 
understanding of risk involved with a given investigational therapy. 
The primary accountability for oversight of research activities still vests 
with the relevant institutional authority and HERCs. 
In the context of cell therapies, HERCs often may not have sufficient 
local expertise to review such research proposals. Bodies such as the Ad-
visory Committee on Biologicals (ACB) and the Gene and Related Ther-
apies Research Advisory Panel (GTRAP) are available to provide such 
expertise. 
The autologous use of stem cell therapies, in the context of provision 
of a single course of treatment with self-donated cells provided or 
manufactured under the supervision of a medical practitioner who has 
the overall ‘management of care’ responsibility for the patient, is not 
regulated by the TGA as specified in the Therapeutic Goods (Excluded 
Goods) Order [33]. The Medical Board of Australia and the Australian 
Health Practitioner Regulation Agency (AHPRA) in accordance with 
the Health Practitioner Regulation National Law, 2009, currently regulate 
provision of such therapeutic options under ‘innovative clinical prac-
tice’. In 2015, the TGA released a discussion paper with possible options 
for regulation of such cell therapies that range from continuation of the 
current pathway to a complete oversight by the TGA, as implemented in 
context of other biological drugs [34]. The discussion paper sought to 
obtain public opinion on the need to create a framework for regulating 
autologous stem cell therapies, some of which are provided in private 
non-academic and for profit stem cell clinics in Australia at substantial 
costs to the patient, with limited scientific basis and usually without 
preclinical safety or efficacy studies. 
The lack of a clearly defined pathway for use of either autologous 
or allogeneic stem cells use in humans within federal legislation  
framework in Australia presents a confusing situation for investigators. 
Unfortunately, this uncertainty has the impact of slowing progress in 
regenerative medicine research in Australia. It also provides an 
opportunity for non-scientific use of stem cells in clinical practice in 
Australia, which can be detrimental for patients and this young field's 
reputation.
 
3. Challenges for academic research – considerations for the 
future 
 
3.1. Harmonisation across different regulatory bodies: challenges in 
standardisation of terminology 
Whilst the individual regulatory bodies around the world are contin -
ually evolving their oversight frameworks, certain common themes are 
emerging across the different regulatory environments, which may be 
the starting point for future harmonisation. Such efforts for conver -
gence, if successful, would be key contributors to future acceleration  
in the translation of advanced cell/gene therapies to the clinic. 
The definitions of key attributes in cellular therapies such as ‘mini- 
mal manipulation’ and ‘homologous/non-homologous use’ have hither- 
to varied in scope across different jurisdictions. Whilst different 
agencies, notably FDA and EMA, are clarifying these terms [18,35], 
there is need for convergence of these definitions across regulatory ju-
risdictions. This could prove a significant enabler for the success of mul-
tinational research collaborations that are critically required at this stage 
of translation with most cell therapies. This is borne out by the fact that 
sharing of expertise and new knowledge being generated is cited by 
most stakeholders as the need of the hour [36,37]. However, practical 
success in this direction can only be made if operational uncertainties due 
to divergent regulatory environments can be decreased, thereby 
creating opportunities for researchers to collaborate across the globe. 
At present, a significant proportion of cell therapy products under 
investigation represent heterogeneous populations of cells rather than a 
high purity single population of cells. Given the unique attributes of 
these therapies that make them straddle the boundaries between bio- 
logical drugs and surgical/transplantation products, developers will cer-
tainly benefit from working together and learning from experts through 
practical examples and innovative approaches towards characterisation 
and standardisation. Establishment of such research networks can also 
increase the commercial attractiveness of these therapies, potentially 
increasing the much-needed investment from industry. The majority 
 
 





FDA guidance for industry: Considerations for the design of early -phase clinical trials of cellular and gene therapy products - key facts. 
Clinical trial design considerations
 
Early-phase trial objectives Safety, feasibility assessment, dose exploration, activity assessment 
Choosing a study population Choice of healthy volunteers not appropriate in most  studies 
Assessment of the overall benefit-risk profile in diseased population depending on severity of 
disease Impact on interpretability of study outcomes 
Demonstration of lack of other treatment options  
Assessment of additional safeguards for pediatric subjects within the overall development program 
Control group and blinding Concurrent control group and blinding are generally not as critical but are useful 
especially in diseases where the natural history is not clearly understood. 
Blinding may not be feasible in certain therapies and risk of placebo/sham interventions 
may be unacceptable. 
Dose and regimen Important to collect data on characteristics of the administered product and clinical 
outcomes to enable correlative analyses to help in dose definition. 
Repeated dosing might not be an acceptable risk in most studies until availability of preliminary 
data on the product's toxicity and duration of activity. 
Treatment 
plan 
Staggered administration within a cohort or between cohorts -the staggering interval should be 
long enough to monitor for adverse events prior to treating additional subjects at the same/increasing do se. 
Cohort size determined by safety considerations and manufacturing capacity  
Failure-to-treat may be an important trial endpoint as part of a feasibility evaluation; plans to analyse 
the proportion of failure to-treat subjects to look for factors that may predict failure to administer the 
product and to evaluate the consequences to the subject if there is a failure to  treat. 
Monitoring and follow-up Assessments targeting specific safety issues that could be anticipated with these products; pre-
defined study -stopping rules. 
Duration of follow-up period in which the product might reasonably be thought to 
present safety concerns should be justified. 
 
 
of product development research involving cell therapies is occurring in 
academic centres involving scientists and clinicians. These academic re- 
searchers often lack the technical, financial and human resources to 
navigate the necessary but complex regulatory process required for  
clinical translation of these therapies. 
In the last few years, studies from the US, Canada and UK have re- 
ported on the level of awareness and understanding of the existing reg- 
ulatory framework as applicable to regenerative medicine amongst 
clinician scientists and academic researchers [7,8]. These studies have 
indicated consistently that whilst there is an elementary awareness of 
possible regulatory requirements, most academic research teams find 
the current regulatory pathways difficult to understand and implement 
in their development projects. This clearly can pose significant chal - 
lenges to clinical translation and eventual commercialisation. 
Researchers, whilst accepting the importance of regulations to en- 
sure safety and quality of regenerative medicine products, have indicat- 
ed a need for modifying the product testing and quality requirements 
applicable to cell therapies. The complexity in the application of often  
difficult to understand regulatory requirements, the ambiguity regard- 
ing the level and extent of evidence needed regarding effectiveness 
and safety and the classification of investigational products is often  
overwhelming for academic research teams. These teams usually lack  
the regulatory and quality control and assurance expertise available in 
industry. The enthusiasm to advance these therapies that potentially  
hold significant benefit for patients has seen researchers move into clin- 
ical trials with less than complete understanding of the biology of the  
therapy with attendant implications for safety. However, an important 
factor with cell therapies is the fact that their duration of action is poten - 
tially life long and irreversible. In this context, it is imperative to create 
global networks for knowledge sharing that may enable research teams 
to complement each other towards a more comprehensive understand- 
ing of different cell types in terms of their molecular and functional  
characterisation. This would provide critical opportunities to avoid rep- 
etition of negative experimentation. Creation of research consortiums 
focused on particular stem cell types similar to the disease specific re- 
search networks that currently exist could potentially enable inter- 
and cross-disciplinary exchange to address components of the develop- 
ment process that are common within and across the varied disease in- 
dications in which clinical application is investigated. This is likely to 
increase the efficiency and success of researchers in this field tremen- 
dously. However, for this to be a practical reality, government, legal
and regulatory structures have to evolve pragmatically to create these  
platforms for academic or industry-led research whilst ensuring protec-
tion of intellectual property and the ability to publish innovative find-
ings in high impact journals. 
Importantly, we propose that basic scientists and clinical research  
teams should be actively supported to seek access to their local regula-
tory agencies early in the development of potentially new regenerative 
medicine therapies. The documents cited in this review provide starting  
points for future dialogue. Most regulatory agencies are very willing to 
speak with academic research groups. Whilst it has been possible to 
administer investigational product that was manufactured without 
demonstration of GMP compliance in Phase 1 studies, it is critical for re- 
searchers to understand that they will be unable to move beyond Phase  
1 without transition to GMP compliance, a step that can prove expen-
sive in terms of time and money. 
With respect to the preparation of stem cells for human use, it is also 
important for research teams to understand the importance of xenoge-
neic agent exposure. Whilst there are ways to include certified sources 
of foetal calf serum in manufacturing processes, there are other impor-
tant issues. For example, murine sourced monoclonal antibodies used in 
cell selection may be a significant problem. 
Regulatory agencies can facilitate the transition to clinical trials for  
academic and clinical researchers by establishing single point contacts 
for advice and providing this information on their websites. The regula-
tory agencies have been participating in information sessions on basic 
regulatory and safety requirements at clinical and research meetings. 
However, given the complexities of regenerative medicine products, a  
system that enables early, product-specific dialogue that could start at 
the beginning of product development, could go a long way in building  
regulatory competence amongst developers, especially those from the  
academia. 
 
3.2. Access to expertise in manufacturing 
Stakeholders in this field agree on the need for established tech - 
nical standards, in terms of quality, safety and efficacy, through dem- 
onstrated adherence to GLP, GMP and GCP whilst conducti ng  
research through pre-clinical and clinical phases [38]. Having said 
that, the challenges in establishing appropriate quality standard s 
are underscored by the fact that most agencies have committed to 
developing guidance specific to advanced medical therapies. The 
 
 





unique and incompletely characterised structural and functional at -
tributes of these therapies are challenging for regulators and devel  
opers alike, especially when they are more familiar with ful ly  
characterised chemical and biological drugs, rather than living  
cells. This is clearly an area of regulatory science, that needs to ex- 
pand exponentially and interactively to keep pace with scientific 
progress in product discovery [39]. Research to identify key func- 
tional characteristics and possible biomarkers of efficacy, potency  
and safety risks such as tumorigenicity and unwanted biological ef -
fects requires long-term support, probably best done through insti -
tutions with basic science and commercialization expertise .  
Regulatory agencies can potentially facilitate widespread access to 
the findings of such research by exploring pragmatic ways to share  
those aspects, which have generic significance to these therapies 
whilst protecting intellectual property. This may contribute to trans- 
lational success and ensure safety of the patients participating in  
clinical trials [40]. Ensuring GMP compliant manufacturing of cel l  
therapies for the clinical phase of development is perhaps the biggest 
challenge for academic research teams seeking to translate their re- 
search clinically. The complexity of the cellular products often re -
sults in product characterisation and associated assays and 
standards being developed at the same time as the product itsel f.  
On the other hand, the regulatory reviewers are themselves at a  
stage of learning about the application of existing GMP require - 
ments, the body of evidence that is needed in the context of a given  
product and what is practically feasible in light of the current stag e  
of technology. This understandab ly protracts the decision making  
process and adds to the time and money required. The move from a 
small-scale laboratory to clinical grade production of investigational  
product is daunting, especially for investigators from academic insti - 
tutions, predominantly due to lack of funding and access to expertise  
in regulatory science and manufacturing. 
The National Heart Lung and Blood Institute (NHLBI), National Insti-
tutes of Health (NIH) has led the way to address this issue by establish-
ing the Production Assistance for Cellular Therapies (PACT) program in 
2003 which provides (i) clinical product manufacturing support for  
phase 1 and 2 trials and (ii) translational development support, to en- 
able the translation of laboratory-based techniques into GMP compliant 
production methods and Standard Operating Procedures (SOPs) for in-
vestigator initiated projects [41]. The fact that PACT has been able to 
support numerous projects with encouraging success and the present 
remit of its manufacturing support being limited to treatment of 
heart, lung, and blood diseases, begs for similar programs to be devel-
oped for diseases involving other organs (e.g. the brain) with significant 
disease burden such as stroke and neurodegenerative disorders. The 
CellCAN network, another promising example, was started in 2009 in 
Canada and incorporated as a not-for-profit corporation in 2014. The 
CellCAN presents a potentially replicable model of a national  
enterprise comprising different stakeholders such as academic 
researchers with demonstrated interest in the field, industry, clinicians,  
funding bodies and regulatory bodies [42]. The network aligns the re- 
quirements for manufacturing facilities with expertise in processing  
cell products for clinical trials to ensure capacity, scalability and quality  
management processes to ensure efficient trial execution. 
In 2016, EMA launched PRIME scheme [43] to enable early 
proactive regulatory dialogue between the applicant and the EU reg-
ulatory network regarding the development plan of therapies of 
‘major public health interest’ and which represent significant inno-
vation, through ongoing advice from relevant stakeholders. Whilst 
sponsors can apply to be considered for PRIME based on preliminary 
clinical evidence (proof of concept), EMA has expressed openness to 
provide exceptional earlier access to academia and small to medium 
enterprises if there is compelling nonclinical data (proof of principle) in 
a relevant model and first in human studies indicate adequate period of 
exposure for preliminary pharmacological and tolerability data.
3.3. Mechanisms for accelerated access: implications for cell therapies 
The regulatory bodies across the world have developed different 
mechanisms for providing accelerated access to therapies, particularly  
in disease indications with current unmet need. 
The FDA has put into place a number of potential pathways to de- 
crease the time to market availability of therapies that serve clear unmet 
needs such as Fast Track Approval [44], Breakthrough Therapy 
Designation [45], Priority Review and Accelerated Approval [46]. The 
Fast Track process is aimed to expedite the review and in-clinic avail- 
ability of investigational biological drugs and cell products for medical 
conditions with present unmet needs. Accelerated Approval allows for 
expedited review and approval based on data related to scientifically 
valid surrogate endpoints instead of established clinical endpoints. 
Breakthrough Therapy designation is the newest mechanism that is 
used if existing preliminary data on a therapy indicates substantial im-
provement in outcomes in a disease indication with an unsatisfactory 
therapeutic status quo. A number of cell-based therapies are currently 
being reviewed under the Fast Track Approval process.  
An interesting development is the passage of ‘right to try’ (RTT) laws 
in certain states in the US. The RTT can potentially be pursued for indi-
vidual ‘gravely ill’ patients for access to cell therapy products ahead of 
FDA-approval. The practical utility of these laws, however, has already 
been questioned as they are contrary to current federal legislations 
and may draw resources away from efforts to develop effective treat- 
ments and may further complicate the FDA pathway for compassionate  
use of medications [47]. This also raises concerns in that some stem cell 
clinics are already willing to provide inadequately tested stem cell 
therapies utilizing the current gap in the capability of the FDA to ensure 
adequate regulation. 
The EMA issued a ‘Guideline On Compassionate Use of Medicinal  
Products’ in 2006 which allows for access to potentially beneficial  
therapy to a group of patients ahead of regulatory approval but left its 
implementation to individual EU member states [48]. The European 
Commission introduced the ‘hospital exemption clause’ by the Regula- 
tion (EC) No.1394/2007 [49] for ATMPs that is applicable to those  
ATMPs that are prepared on a non-routine basis, i.e. individually pre- 
scribed, according to specific quality standards, for an individual patient. 
These therapies are provided in a hospital under the exclusive profes-
sional responsibility of a medical practitioner within the EU. This pro- 
vides a mechanism to provide individual patient-centred care in 
relevant clinical situations, whilst ensuring product quality and patient 
safety (through the requirement of a system for patient and product 
traceability). 
 
3.4. Dilemma named ‘innovative medical practice’ 
Growth of stem cell therapies, in particular autologous therapies, has 
brought forth an important issue that has defied consistent definition  
for many years [50]. The boundaries between research and innovative  
medical practice are being re-examined in the wake of an explosion in 
‘stem cell clinics’ offering various cellular therapies in routine practice .  
Most of this activity involves the use of autologous fat-derived stem 
cells with little or no supporting basic scientific preclinical data. Provi-
sion of cell therapies under the guise of ‘innovative medical practice ’  
may encourage widespread adoption of therapies that may be ineffec-
tive at best and harmful at worst. Academic researchers are understand-
ably very concerned with these practices, which can serve as a 
significant disincentive and message to the lay public that fundamental  
research is not required. Thus, these practices can challenge future sci- 
entific translational success in this field. Even now, the provision of 
cell therapies in such clinics is largely self-regulated in most parts of 
the world. Medical practitioners' regulatory authorities in different 
countries, variably regulate this practice and lack adequate legislative, 
financial or skilled human resources to provide effective oversight for  
practice involving this fast advancing field [51]. 
 
 




The stem cell industry has burgeoned not only in the developing re-
gions such as Mexico, China, India and south-east Asia but also in devel-
oped countries such as the US, Germany and Australia [36,52–55]. A 
recent report by Turner et al. indicates approximately 351 distinct ven-
tures providing commercial cell therapy interventions at 570 centres 
across the US for a range of diseases [56]. This is a significant reflection 
on the limited success of the initiatives of the FDA, in recent years, to-
wards increased involvement and the clear struggle for effective over-
sight of a fast expanding field. Berger et al. present an interesting 
perspective that the stem cell industry is a significant presence across 
the globe and not restricted to countries with poorly defined regulatory 
pathways [56]. In addition, an important consideration may also be that 
developed countries such as the US and Australia have higher numbers 
of clinics per capita, highlighting the ease with which access to such 
therapies is possible in these countries [57]. There is a formidable risk 
for patient safety, due to rampant lack of clarity on source and quality 
of cell therapies being administered at these sites. The aggressive and 
often misleading marketing of these therapies results in patients under-
going interventions with questionable safety and effectiveness [56]. 
Whilst the negative impact on patient safety is evident and increas-
ingly being highlighted, the implications for research success have per- 
haps not garnered as much attention [56,57]. On the one hand, patients 
undergoing such interventions become unavailable or ineligible for  
bona-fide clinical research, which increases recruitment challenges 
and cost of research. On the other hand, the discredit resulting from ad- 
verse safety incidents in recipients of these services, severely under- 
mines the confidence in the future potential for this research field. 
This has both immediate and far reaching impact on attractiveness of 
this research area for potential funding and investment in clinical trans-
lation from government and industry alike as well as the interest 
amongst academics to pursue research in this clearly emotive and 
polarised field. Clearly, this presents a cause for concern for all stake- 
holders in regenerative medicine and poses significant threat to future  
translational success in regenerative medicine. 
A pragmatic attempt to address this issue, which, if successful, may 
provide a way forward, would be the establishment of a dedicated path- 
way for the oversight of research as well as routine medical practice. 
Japan has been highly progressive in this respect enacting the Act on the 
Safety of Regenerative Medicine that came into effect in 2014 and aims 
to provide oversight of provision of cell therapies in medical practice [21]. 
This pathway enables medical institutions to outsource cell culturing 
and processing to industry/centres with the required expertise and 
accreditation under a much more streamlined process and mandates 
collection of necessary safety and efficacy data. 
 
4. Conclusions 
Regulation and innovation in clinical translation are closely linked and 
determine the success of commercialization of scientific discoveries.  
Changes in regulatory frameworks, often driven by scientific advances,  
can potentially enable or hinder innovation. Advancing regulatory policy 
and creating modalities for widespread access to this expertise, especially 
for academic research communities, will ensure robust interdisciplinary 
collaboration and foster shared learning critical to successful translation. 
As observed in different countries throughout the world, an environment 
of facilitative legislation is crucial. The hypothesis is that regenerative  
medicine may result in a paradigm shift in clinical medicine, not seen 
since the introduction of antibiotics. These therapies, if successfully trans- 
lated into clinical practice, may provide meaningful options to society ,  
currently reeling under the burden of diseases that take a substantial  
toll on lives of so many across the globe. 
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Regulatory science has evolved in the last few years to keep pace with the research using CTs. The 
regulatory bodies across the world have sought to harmonise terminologies used in CT research 
and development. In addition, guidance is evolving regarding quality and manufacturing standards 
expected in such research. Future clinical studies need to adequately justify the rationale for choice 
made with regards to study design, CT production and delivery methods, and overall study 





CHAPTER 5: ETHICAL CONSIDERATIONS 
5.1 Background 
As clinical studies with CTs are planned, researchers are faced with the dual challenge of 
maximizing trial recruitment while supporting individuals’ informed decision-making. This is 
further complicated by the limited data on long-term safety and efficacy with CTs available in early 
phases of research. Patient participation in the conduct of research as an active stakeholder beyond 
being a passive recipient has been encouraged world over, to sharpen the focus of research design 
and implementation to increase relevance to the patient community and to develop channels for 
communication between researchers and the patient community. 
5.2 Research Objectives 
A qualitative interview-based study was carried out with stroke survivors to understand key ethical 
considerations that impact on the execution of early phase studies with CTs. 
A qualitative thematic analysis was carried out to identify the perspectives of ischaemic stroke 
survivors on: 
• the relevance and importance of an early phase clinical study such as TOOTH (The Open 
study Of dental pulp stem cells (DPSC) Treatment in Humans) using adult human dental 
pulp stem cells in chronic ischaemic stroke  
• consent issues with participation in such research  
• the relevance of the planned outcome measures to individuals who have had personal 





5.3 Methods  
The protocol for a proposed phase I/II study investigating autologous use of dental pulp stem cells 
in patients with ischaemic stroke (TOOTH Study) was published in the International Journal of 
Stroke in 2016. The PERSPECTIVES Study was designed to collect insights from stroke survivors 
via face-to-face, semi-structured interviews on specific aspects of the design of the TOOTH Study. 
The methodology and relevant ethics approval for the PERSPECTIVES study are described in 





















TOOTH (The Open study Of dental pulp 
stem cell Therapy in Humans): Study 
protocol for evaluating safety and 
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Rationale : Stroke represents a significant global disease burden. As of 2015, there is no chemical or biological therapy proven to 
actively enhance neurological recovery during the chronic phase post-stroke. Globally, cell-based therapy in stroke is at the stage of 
clinical translation and may improve neurological function through various mechanisms such as neural replacement, neuroprotection , 
angiogenesis, immuno-modulation, and neuroplasticity. Preclinical evidence in a rodent model of middle cerebral artery ischemic stroke 
as reported in four independent studies indicates improvement in neurobehavioral function with adult human dental pulp stem cell 
therapy. Human adult dental pulp stem cells present an exciting potential therapeutic option for improving post-stroke disability. 
Aims : TOOTH (The Open study Of dental pulp stem cell Therapy in Humans) will investigate the use of autologous stem cell therapy 
for stroke survivors with chronic disability, with the following objectives: (a) determine the maximum tolerable dose of autologous 
dental pulp stem cell therapy; (b) define that dental pulp stem cell therapy at the maximum tolerable dose is safe and feasible in chronic 
stroke; and (c) estimate the parameters of efficacy required to design a future Phase 2/3 clinical trial. 
Methods and design: TOOTH is a Phase 1, open-label, single-blinded clinical trial with a pragmatic design that com- prises three 
stages: Stage 1 will involve the selection of 27 participants with middle cerebral artery ischemic stroke and the commencement of 
autologous dental pulp stem cell isolation, growth, and testing in sequential cohorts (n  3). Stage 2 will involve the transplantation of 
dental pulp stem cell in each cohort of participants with an ascending dose and  subsequent observation for a 6-month period for any 
dental pulp stem cell-related adverse events. Stage 3 will investigate the neurosurgical intervention of the maximum tolerable dose of 
autologous dental pulp stem cell followed by 9 weeks of intensive task-specific rehabilitation. Advanced magnetic resonance and 
positron emission tomography neuro-imaging, and clinical assessment will be employed to probe any change afforded by stem cell 
therapy in combination with rehabilitation. 
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Sample size estimates : Nine participants will step-wise progress in Stage 2 to a dose of up to 10 million dental pulp stem cell, 
employing a cumulative 3 3 statistical design with low starting stem cell dose and subsequent dose escalation, assuming that an 
acceptable probability of dose-limiting complications is between 1 in 6 (17%) and 1 in 3 (33%) of patients. In Stage 3, another 18 
participants will receive an intracranial injection with the maximum tolerable dose of dental pulp stem cell. 
Outcomes : The primary outcomes to be measured are safety and feasibility of intracranial administration of autologous human adult 
DPSC in patients with chronic stroke and determination of the maximum tolerable dose in human subjects. Secondary outcomes 
include estimation of the measures of effectiveness required to design a future Phase 2/3 clinical trial. 
Keywords 
Ischemic stroke, adult human dental pulp stem cells, post stroke disability, neurobehavioral outcomes 
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Introduction and rationale 
Stroke represents a significant global disease burden wit h 
33 million stroke survivors estimated worldwide in 2010, 
amounting to 4% of the total disability- adjusted life-
years (DALYs).1 
Up to 85% of all strokes are ischemic in origin with the 
middle cerebral artery (MCA) being the most common 
site of occlusion.2 All evidence-based treatments for 
ischemic stroke currently available target the acute 
phase: aspirin, management in an cute stroke unit,  
thrombolysis, and decompressive surgery.3 In the 
chronic phase, rehabilitation still remains the 
predominant therapeutic intervention.4,5 
As of 2015, there is no chemical or biological thera -
peutic agent that has been proven in large clinical trials  
to actively enhance neurological recovery during the 
chronic phase after stroke. While there is some prelim -  
inary evidence for the use of selective serotonin reup-  
take inhibitors (SSRI) to promote functional recovery 
independent of depression, this still needs to be sub- 
stantiated in large, well-designed clinical trials.6 
 
Cell-based therapy 
Cell-based therapy is at the stage of clinical translation 
globally, from preclinical studies to early phase human 
trials being conducted in many countries to investiga t e 
safety and feasibility in a number of neurologica l 
diseases.7–9 There is strong experimental evidence that 
stem/progenitor/precursor cell therapy may improve 
neurological function (Figure 1) through five 
mechanisms of action: neural replacement, neuro-  
protection, angiogenes is, immuno-modulation, and 
neuroplasticity.10–13 
In stroke, the predominant mechanism/s of action 
may be influenced by the timing of treatment. In the 
acute phase, neuroprotection, immune-modulation, 
angiogen esis, and neural replacement may play more 
important roles in restoring function. In comparison in 
the chronic stroke phase, improvement in neuro -  
logical function is likely to be driven by neural repla ce-
ment, angiogenesis, and neuroplast icit y.9 Stem cells are 
now recogniz ed to secrete a range of paracrine growt h 
factors, which may modulate neurogenes is, angioge n -
esis, and immunomodulation.9,12–14 
There are primarily three human tissue sources for 
stem cell treatments: embryonic, reprogrammed somatic  
cells, or adult organs. Pluripotent stem cells, namely 
embryonic or induced pluripotent stem cells, with their 
wide differentiation potential may also pre- sent a risk of  
tumor formation.9 On the other hand, multipotent stem 
cells, such as neural stem cells, mesenchymal stem cells ,  
and dental pulp stem cells (DPSC) have a limit ed 
differentiation potential, which makes them potentia lly 
safer for clinical use with no authenticated risk of tumor 
formation to date.9,15–18 
There has been extensive preclinical research with 
respect to stem cell therapy in animal models of ische -
mic stroke. A systematic review of published animal 
rodent studies using stem cell-based therapy reported an 
overall improvement in neurobeha viora l outcome of 
40.6% (37.1–44.0; P < 0.001).16 The demonstration of 
functional improvement independent of time since 
stroke indicates that the stem cells may exert neuropro -
tective effect as well as modulate neuroregenerat i o n,  
neuroplasticity, and/or angiogenes is.16 
To date, there are numerous published reports of early 
phase clinical trials using different types of stem cell 
therapy for stroke.19–38 The majority used autologous  
precursor cells from the bone marrow with remainder 
using allogeneic neural and umbilical- derived stem 
cells. 
Administration of stem cells during the acute stroke 
setting has inherent risk of morbidity and mortality as 
the patient may be medically unstable, making a case 
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for further research into feasibility of treatment institu-  
tion in the chronic phase.9 
Different routes of administration of stem cells have 
been investigated, with intravascular delivery being the 
predominant route, followed by intracranial and intra-  
thecal routes. Experiments in animal models suggest that 
in the acute stroke setting, the blood–brain barrier (BBB) 
is damaged and open to cellular transmigration and 
cytokine-medicated chemo-attraction of stem cells  
toward the site of infarction.39 Thus, in the setting of an 
acute stroke clinical trial, intravascular delivery of stem 
cells is likely to be efficacious. 
However, in the chronic stroke setting, the 
pathophysiological environment changes with relative 
restoration of BBB integrity and dampening of cytokine-
mediated chemo-attraction of cells toward the 
infarction.40 The intracranial delivery may potentially be 
an efficacious route of administration in the design of a 




Human DPSC were discovered in 2000 from young 
adults with impacted molar teeth. It was found that the 
dental pulp tissue within the tooth harbored a unique 
adult stem cell population.41 Recently, it was shown that 
DPSC originate from glial stem cells,42 which has  
confirmed the unique ecto-mesenchymal 
ontogeny of DPSC and their propensity to different ia t e 
down the neural lineage.43,44 It is postulated that neuro-  
logical diseases may best be treated by neural stem cells.12  
A clinically accessible source of neural-like stem cells  
such as dental pulp from the adult tooth is likely to be 
very attractive option.9 
There is strong experimental evidence from in vit ro 
and in vivo studies, that DPSC generat e bone fide neu -  
rons, which display neuronal morphology, express neur-
onal markers, and generat e action potentials .9,10,43 ,4 5  
The first direct evidence that DPSC induced neuropla s -
ticity within a receptive host nervous system was  
reported using a chick embryo assay (Ikaros assay) in 
which DPSC were found to secrete a cytokine, SDF-1 /  
CXCL12, which chemo-att ra ct ed trigemina l axons  
toward the implanted DPSC.46 It has been reported in 
the rodent stroke model that neural plasticity may 
underlie the improved neurobeha vioral funct ion 
afforded by DPSC treatment.10 
The first formal preclinical evidence for use of adult  
human DPSC (6 105) in rodent brain, given 24h fol-  
lowing ischemic stroke, showed improved neurobeha -
vioral recovery over a 4-week period in comparison wit h 
vehicle-cont rol treated animals.9 Numerous pre- clinica l 
studies in over 100 rodents have used intracra nia l 
transplantation of DPSC without tumorigenic 
consequences.10,47,48 To date, there are four preclinica l 
studies that have demonstrated that DPSC thera py 
improves neurobeha viora l function in a rodent model 
Figure 1. A schematic representation of the putative mechanisms of action in stem cell therapy used to treat ischemic stroke. 
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of MCA ischemic stroke.10,47–49 Inoue et al. reported that 
administration of human DPSC-derived condi- tioned 
medium resulted in improvement in motor func- tion 
and infarct volume.49 
Recently, we found that DPSC from healthy teeth of 
aged donors retained their proliferative, multipotent, and 
neurogenic potential, which has significant poten- tial 
clinical implications as the majority of prospect ive 
patients likely to benefit for this therapy are likely to 
belong to this age group (manuscript in preparation). 
Currently, there are two clinical trials in which 
autologous DPSC have been used for tissue engineer -  
ing. The first was in seven patients for oro-maxillo- facial 
bone repair, which was found safe and success- ful.50 The 
second is an ongoing Phase 1 clinical trial aimed to repair 
immature permanent teeth, which have been 
accidentally injured in childhood.51 Human adult DPSC,  
therefore, present an exciting potential therapeut ic  
option for management of post stroke disability. 
We, therefore, propose the ‘‘first-in-human’’ autolo-  
gous DPSC therapy clinical trial, TOOTH—The Open 
study Of DPSC Therapy in Humans, investigating the 
use of autologous stem cell therapy for stroke survivors  
with chronic disability, with the following objectives: 
1. Determine the maximum tolerable dose (MTD) of 
autologous DPSC therapy; 
2. Define that DPSC therapy at the MTD is safe and 
feasible in chronic stroke; and 
3. Estimate the parameters of efficacy required to design 
a future Phase 2/3 clinical trial. 
 
The present manuscript provides an a priori descrip -  
tion of the research protocol. 
Methods 
Design 
TOOTH is a Phase 1, open-label, single-blinded clinica l 
trial with a pragmatic design that comprises three stages, 
with each previous stage informing the next: 
 
• Stage 1 will involve the selection of 27 participant s  
with MCA ischemic strokes and the commencement  
of autologous DPSC isolation, growth, and testing 
(Figure 2). 
• Stage 2 will involve the transplantation of DPSC in 
sequential cohorts of participants with a n 
ascending dose and subsequent observation for a 6-
month period for any DPSC-related adverse event  
to deter- mine the MTD (Figure 3). 
• Stage 3 will investigate the neurosurgica l 
intervention of the MTD of stem cell therapy in 
combination with rehabilitation. Nine weeks of  






Figure 2. A schematic representation of TOOTH design. 
Figure 3. Identification of the Maximum Tolerable Dose (MTD) 
of DPSC. 
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stem cell therapy. Advanced magnetic resona nce 
(MR) and positron emission tomography (PET) neuro-
imaging, rigorous clinical assessment and group  
experimental design analyses will be employed to 
probe any change afforded by stem cell therapy in 
combination with rehabilitation. 
 
Patient population 
A Participant Selection Committee will coordina t e 
selection of 27 stroke survivors following an MCA  
ischemic stroke (18 non-domina nt hemisphere and 9 
dominant hemisphere stroke), who have reached a 
stable level of chronic motor, sensory, and/or 
language disability (Table 1). Participants will be 
selected from Adelaide, Australia for ease of regula r 
follow-up for the duration of study. Aphasia-friendly 
modifications52 to participant information and consent  
forms, and training of consent personnel in 
communication will be made to enable participant s  
with aphasia to fully participate in the informed 
consent processes.53 
This study will be carried out according to the 
Declaration of Helsinki, the NHMRC Nationa l 
Statement on Ethical Conduct in Research Involv i n g 
Humans and the Notes for Guidance on Good 
Clinical Practice as adopted by the Australian 
Therapeutic Goods Administration and the ICH/ GCP 
(International Conference on Harmonisation of Technica l 
Requirements for Registration of Pharmaceuticals for 
Human Use) guidelines. Human ethics committee review 




The study aims to examine safety and feasibility of first  
in human use of autologous adult DPSC in stroke sur-
vivors with moderate to severe disability. It is an open 
label, non-randomized study. The selection of patient s  




Preparation of autologous DPSC from each person’s healthy tooth. 
There are five steps in the generation of a per- son’s  
autologous DPSC, which include isolation from the 
dental pulp of a healthy tooth, initial growth, or 
expansion in defined DPSC medium, quality control of 
each participant’s own DPSC, cryopreservation until 
time of treatment and final expansion of DPSC for stem 
cell therapy. The generation of sufficient DPSC for stem 
cell therapy only requires one healthy 
 
Table 1. Inclusion and exclusion criteria 
 
Inclusion criteria 
1. Inclusion of both genders 
2. Age of the participant should be 18 years or over 
3. MCA ischemic stroke 
4. Moderate severity chronic disability—the participant would have a stable level (modified Rankin Score (mRS) of 2 to 
4) of chronic motor, sensory, and/or language disability for at least 6 months prior to selection. Dominant 
hemisphere MCA stroke survivors with aphasia will need to attain an aphasia quotient score of 33 –70 on the Western 
Aphasia Battery (WAB-AQ) to participate54 
5. Good cognitive function—the participant must achieve a Mini Mental State Examination (MMSE) score of 24 or more. 
Participants with aphasia must score above 23 on the Raven’s Colored Progressive Matrices (RPM) 55 
6. All participants must pass Mini International Neuropsychiatric Interview (MINI); in those with aphasia a score of <17 
on the Stroke Aphasia Depression Questionaire-21 (SADQ-21)56 
7. Healthy teeth to grow sufficient autologous DPSC 
Exclusion criteria 
1. The participant will be ineligible if they are at substantial risk under general anesthesia, have epilepsy, have had 
cancer diagnosed within the last 5 years, or have a coagulation disorder 
2. The participant will be ineligible if they have claustrophobia or other significant psychological issues, which may 
restrict their ability to undergo the required neuro-imaging investigations, rehabilitation, and clinical assessments 
3. Previous stem cell therapy 
International Journal of Stroke, 11(5) 




tooth.41 Two academic dentists on our team will coord -
inate dental procedures (pulpectomy or the whole tooth 
extraction), dependent upon the participant’s wish, at the 
Adelaide Dental Hospital. The isolated dental pulp will 
be transported to a good manufacturing practices (GMP)  
accredited laboratory in Adelaide for further processing.  
Rigorous standards of quality control will be used to 
exclude all hazardous infections throughout all five 
steps. Recently, it has been found that fetal calf serum 
used in defined DPSC media can be replaced wit h 
human platelet lysate, which does not alter DPSC 
biology, growth, and proliferation and is a preferred 
alternative to fetal calf serum, which cannot be used in 
clinical trials.57 Each person’s DPSC will be processed in 
accordance with rigorous standard operating procedures  
(SOPs) to test critical biological proper- ties of DPSC prior 
to stem cell therapy. These include DPSC 
immunophenotype using flow cytomet ry 
(CD75þ/90þ/105þ/146þ/p75þ), DPSC protein expres-s ion 
profile (SDF-1, GDNF, VEGF, and MMP2), and their 
neurogenic potential using our short-term Ikaros  
assay.41,43,57,58 
 
Neurosurgical procedure for DPSC transplantation. Patients will 
have preoperative magnetic resonance imaging (MRI)  
studies to select peri-infarct target and trajectory sites for 
implantation of DPSC. On the day of surgery, a Leksell 
stereotactic frame will be applied to the participant’s  
head using local anesthetic and intravenous sedation. A 
stereotactic computed tomography (CT) head scan will 
be performed and the images fused to the planning MRI  
study images using the BrainLabTM software system.  
Access to the brain for stem cell therapy will be via a burr 
hole and corticotomy with a Pittsburgh Cell Implantation 
Cannula inserted into the peri-infarct region to 
administer DPSC in Isolyte S® using a Hamilton syringe 
and delivered by the neurosurgeon at multiple pre-
selected target sites.59,60 The participant will be 
awakened during DPSC injec- tion to provide assessment  
of functional capacity, a technique routinely used in deep  
brain stimulation, as the brain parenchyma is anesthet ic  
and this is the best technique to monitor surgery. Post-
operatively, the patient will be observed in recovery and 
the neurosurgical high-dependency ward. 
 
Rehabilitation. Each participant will be asked to identify 
specific motor, sensory, and/or language disabilities ,  
which will become the focus for intensive task-specific 
rehabilitation schedules. Content, dosage, and evalu -
ation will be determined by rehabilitation researchers  
and will be evidence-based.61–64 
Initial baseline measurements before and after stem 
cell therapy will track baseline stability in critica l 
behavioral domains of sensation, limb function, 
walking, language, and communication, overall stroke 
severity and functional independence. Modules of 
rehabilitation based on the identified goals will then be 
delivered in 3-week epochs and blinded measures of 
function will be probed to track individual response to 
therapy and rate of acquisition of specific skills. A 
maximum of three epoch will be delivered (9 weeks total) 
and measures will be followed up over the subsequent 6 
months. 
 
Measurements. Each participant will be required to 
undergo periodic neurological and imaging follow up as 
outlined in Table 2. 
 
Clinical assessment. Measures of function will be con-
tinually probed to track individual response to therapy 
and rate of acquisition of specific skills. Outcome meas-
ures will be measured immediately prior to stem cell 
therapy, immediately following stem cell therapy and 
subsequently at 6, 9, and 12 months after stem cell 
therapy, to measure changes in clinical outcomes over  
time. 
 
Imaging with MRI/PET. Each participant will have a total of  
five MRI scans over the duration of the trial: at the time 
of participant enrolment, within 1 month prior to and 
following stem cell therapy, and at 6 and 12 mont hs  
following stem cell therapy. There are four sub-aims to 
our imaging schedule: (a) characterization of the infarct  
lesion, (b) planning peri-infarct neurosurgical inject ion 
sites, (c) monitoring for tumor or other pathologies (e.g.  
hemorrhage), and (d) quantifying any change in 
connectivity following stem cell therapy further to 
rehabilitation. To answer sub-aims (a), (b), and (c)  
standard 2D FLAIR sequences and high-resolution T1  
weighted anatomical 3D MPRage images (1 x 1 x 1 mm3)  
will be acquired. In relation to sub-aim (d), we will 
quantify the integrity and structural and functiona l 
connectivity of brain networks that support the targeted 
sensorimotor or language function using high angula r 
resolution diffusion imaging (measurement of whit e 
matter tracts) and resting state functional MRI (fMRI ;  
measure of connectivity).65 Diffusion-weighted imaging 
protocols for fiber tract integrity and for white matter 
tract estimation will be acquired to map bio- logica lly 
reliable brain networks.65,66 Intrinsic (resting-sta t e)  
connectivity data will be acquired over 7 min of  
continuous fMRI to provide information about  
functional connections, i.e. whether or how surviving 
tissue is working. 
Patients will undergo PET scan of the brain using 18F-
fluorodeoxyglucose (FDG), a radiopharmaceut ica l 
generated at a research-dedicat ed cyclotron located at 
SAHMRI. Studies have reported that PET can revea l 











DPSC Pre-therapy Stem 
cell Enrolment harvesting (month 1) therapy 
Post-operative stage 
Discharge 1 month 6 months 12 months 
Informed consent • 
Inclusion/exclusion criteria • 




Vitals • • • • • • • • 
Neurological examination • • • • • • • • 
mRS • • • • • • • • 
NIH stroke scale • • • • • • • • 
WAB-AQa • • • • • • • • 
Functional independence measure • • • • • • • • 
Stroke impact scale • • • • • • • • 
6-min walk test • • • • • • • • 
Upper limb motor activity log • • • • • • • • 
Euro QoL • • • • • • • • 
MMSE/APMa • • • • • 
M.I.N.I./SADQ-21a • • • • 
Safety • • • • • • • 
Imaging • 
MRI • • • • • 
PET • • • • 
aTests to be performed in patients with aphasia. 
N
a
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tissue environment before and after treatment.67 Meltz er 
et al. reported that metabolic changes observed at 6 and 
12 months may provide preliminary evidence for poten-
tial mechanisms associated with observed therapeut ic  
outcomes with intra-cerebral stem cell transplant -  
ation.68 Each participant will have a total of four PET 
scans, the first two scans within 1 month prior to and 1 
month following stem cell therapy, and then at 6 and 12 
months following treatment. PET performed before 
(baseline) and after (1 month) treatment may provide 
useful information on any regional damage or any 
inflammation associated with intra-cerebra l implant -  
ation and subsequent retention and biodistribution in the 
brain, which will be important for assessing safety of the 
transplantation procedure used in the study. 
 
Monitoring and blinding. A Stroke Fellow will be aware of the 
therapeutic status of each participant and provide 
neurological follow-up to accurately and safely docu-
ment any adverse events to be reported to the Data 
Monitoring Committee. Potential DPSC-related adverse 
event that the committee will investigate include the 
incidence of any tumors, seizures, and chronic pain 
syndrome associated with aberrant neuroregenerat io n.  
Rehabilitation and assessment will be performed in a 
single-blinded manner, such that the therapist involved 
in rehabilitation and assessment will be blinded to the 
therapeutic status of the patient. 
 
Outcomes 
Primary outcomes. Determine the MTD of autologous DPSC 
therapy. Define whether DPSC therapy at the MTD is 
safe and feasible in chronic stroke. 
 
Secondary outcomes. Estimate the parameters of efficacy 
required to design a future Phase 2/3 clinical trial. 
 
Data monitoring committee 
An independent and internationa lly renowned Data 
Monitoring Committee will oversee safety monitoring 
for adverse events and compliance to protocol. 
 
Sample size estimates 
Stage 2, to answer Aim 1, is based on a cumulative 3 3 
statistical design with a low starting stem cell dose and 
subsequent dose escalation, on the assumption that an 
acceptable probability of dose limiting complications is 
between 1 in 6 (17%) and 1 in 3 (33%) of patients. We 
anticipate that nine participants will be required to pro- 
gress to a MTD of 10 million DPSC. 
In Stage 3, to answer Aims 2 and 3, we have conser-
vatively proposed a further 18 participants, which is in 
keeping with the numbers (range 5–18) used in previous 
Phase 1 clinical trials of stem cell therapy administered by 
intracranial injection for ischemic stroke.18,24,33 
Based on preclinical meta-analysis data with an effect  
size of 40%16 at least 50 participants would be needed to 
investigate efficacy of stem cell therapy with 80% power 
at a significance level of 0.05. We propose that a first- 
inhuman Phase 1 clinical trial on large numbers of par-
ticipants is unethical until we determine treatment safety 
and feasibility. If the proposed study is successful, this  
can be considered in a future Phase 2/3 study. 
 
Statistical analyses 
A combination of group and single subject design ana-
lyses will be employed to probe any change afforded by 
stem cell therapy further to that of rehabilitation. Safety 
and feasibility outcomes will be estimated and report ed 
with corresponding 95% confidence intervals to answer 
objectives 2 and 3. Clinical and biomarker data will be 
analyzed and reported with the correspond- ing 95% 
confidence intervals to inform the choice of  the most  
appropriate outcome and power analysis for the 
subsequent Phase 2/3 clinical trial. 
 
Limitations of the study. The proposed study aims to 
investigate the safety and MTD of autologous adult 
DPSC in patients with post stroke disability. The limited 
number of participants recruited in the interest of patient  
safety may not provide sufficient power to evalua t e 
efficacy. However, the clinical and imaging outcomes  
evaluated through the course of this study will yield  
valuable information to define endpoints for future 
studies. 
 
Study organization and funding 
The research team at the Stroke Research Programme,  
University of Adelaide, will organize the study. Funding 
shall be provided in the first instance by the Roya l 
Adelaide Hospital Research Foundation and two 
philanthropic organizations, the Peter Couche 
Foundation and Stroke SA Inc. with subsequent funding 
for the remainder of the protocol requested through the  
National Health and Medical Research Council. 
 
Summary 
Therapies current ly available for stroke are all initia t ed 
in the acute phase of ischemic stroke. Up to 80% of  
patients with stroke return home after their acute hos -  
pitalization.16 The lifetime costs of first-ever cases of  
stroke alone exceed $3.15 billion in Australia.69,70 
There is an enormous and urgent unmet medical need 
to discover new therapies that will overcome chronic 
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disability following stroke. Stem cell therapy presents an 
attractive treatment option for stroke with resea rch 
ongoing to achieve clinical translation to early phase 
human trials across many countries. There is promis ing 
evidence from a preclinical and clinical perspective that 
autologous adult DPSC treatment is safe and feasible in 
the majority of stroke survivors who are over the age of 
65 years, in Australia, and retain their teeth. 
TOOTH aims to investigate the safety and feasibilit y 
of autologous human adult stem cell therapy and esti-  
mate the parameters of efficacy in participants wit h 
chronic stroke disability. The findings from TOOTH 
would allow progression to Phase 2/3 clinical trials to 
investigate efficacy of this stem cell therapy in combin-  
ation with rehabilitation. 
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The PERSPECTIVES study manuscript in submission reported that patients considered outcomes 
such as recovery in social participation and decreased dependence on carers as most meaningful to 
them. Whilst improved motor function was important, they communicated that the impact on 
cognition, memory, mood, pain and fatigue were important determinants of their perception of 
benefit from a given therapy. The perception of risk versus benefit was likely influenced by the 
time elapsed since stroke, with patients being more willing to accept a higher level of risk early in 
the post-stroke disease course. Study participants indicated that an opportunity to participate in 
research should be available to all stroke survivors, irrespective of their cognitive capacity and 
researchers should ensure that appropriate mechanisms of consent are available for participants 
with varied cognitive capacity. 
The findings of this study were synthesized into a manuscript for submission to Health 















PERSPECTIVES: Stroke survivors’ views on the design of an early phase cell therapy 
trial for patients with chronic ischemic stroke 
Abstract 
Background  
Stem cell research holds the potential for a paradigm shift in the management of diseases 
such as stroke. Patient and public involvement in research (PPIR) can bring a focus to 
issues of clinical relevance and accelerate translation to real world clinical practice. 
Objective 
A qualitative thematic analysis of the perspectives of stroke survivors regarding the 
conduct and design aspects of a proposed Phase I clinical cell therapy study in stroke.  
Design 
Twelve stroke survivors were purposively recruited in July 2016-August 2017 and 
participated in semi-structured, face-to-face interviews for input into the design of a 
proposed Phase I clinical study of autologous dental pulp stem cells. Concurrent thematic 
analysis was conducted until data saturation was achieved. 
Discussion and Conclusions 
Participants conveyed that the most relevant outcomes to them were regaining 
participation, decreased dependence on caregivers and improvement in cognition, 
memory, mood, pain and fatigue. The perception of risk vs. benefit was likely influenced 
by the time elapsed since stroke, with participants being more willing to accept a higher 




should be given an opportunity to participate in research, irrespective of their cognitive 
capacity. A relatively small sample population of 12 stroke survivors was studied as 
thematic saturation was achieved.  
PERSPECTIVES study applied principles of PPIR to early phase cell research. 
Incorporation of outcomes relevant to patients’ need within the study design are critical to 
generate data that will enable personalised application of regenerative medicine in stroke.  
Key words: stroke, patient participation, stem cell research, qualitative research, 







The Global Burden of Disease Study (2015) reported that stroke was the second 
highest cause of years of life lost globally.1 While the age-standardized mortality from 
ischemic stroke in the past decade has declined, approximately 33 million ischemic 
stroke survivors worldwide continue to experience lifelong disability and nearly 80% of 
patients with ischemic stroke return home with residual impairment.1  
Regenerative medicine represents a paradigm shift in approach to disease 
management with the possibility of potential cure or long-lasting remission for many 
disease conditions with high-unmet need. Early clinical studies with stem cell 
therapies support a novel approach for neuro-regeneration and repair following stroke 
with a potentially longer window of opportunity.2 Cell therapy comprises a composite 
of different cell types being investigated in different phases of stroke, with use of 
different dose and delivery regimens.   
Clinical translation in stroke has been riddled with a disappointing failure of numerous 
promising preclinical therapeutic candidates, over the last few decades. Currently 
available therapies are limited in application to the acute phase of stroke.3 Stroke 
represents a diverse set of disease trajectories defined by distinct temporal patterns 
of neurovascular injury unique to a given patient.4 The heterogeneity in patient and 
disease characteristics has contributed to challenges in choosing the appropriate trial 
design as well as population and efficacy parameters. This, in turn, makes it difficult 




Recognition of patients as key partners/stakeholders in research has been increasing 
over the past decade. It represents a promising approach to generate evidence that 
is relevant and trustworthy for patients and their families as well as clinicians.5 This is 
likely to contribute to a greater sense of empowered participation in patients who are 
the eventual users of the outcomes of such research.6 
Research evidence reporting facilitators and barriers to clinical trial participation and 
patient experiences with clinical research is increasing, particularly in areas such as 
cancer and stroke.7 Studies have investigated the relative importance of issues 
regarding research, in people with stroke.8,9 These reported that there was a 
discrepancy between priorities and relevance attributed to different outcomes by 
different stakeholders in research, such as patients, caregivers and researchers.8,9  
Early patient engagement is likely to be associated with increased recruitment and 
retention of study participants; development of research methods that are 
contextualized to patients’ experiences with the disease and utilization of relevant 
research questions and outcome measures. There is growing evidence for the value 
of ‘patient and public involvement in research’ (PPIR) in facilitating more patient -
focused research by offering insights into prioritization, design and implementation and 
making trials more effective and credible.10 PPIR is increasingly being mandated for 
publicly-funded trials in many developed countries.11  
Active participation of potential participants is likely to provide a sense of 
empowerment to people with chronic stroke. Their engagement as ‘lay experts’ to 




likely to improve the eventual study design. The increase in transparency and 
credibility of research associated with such partnership is specifically critical in 
innovative areas of research such as stem cell therapies. This was a key issue raised 
by stroke survivors who participated in the Stroke Survivors’ Forum held at the South 
Australian Health and Medical Research Institute (SAHMRI), in Adelaide in 2014.  
In response to this advice, the PERSPECTIVES study sought to formatively collect 
insight into the beliefs and perspectives of people with chronic stroke through their 
involvement in the design of the TOOTH study (The Open study Of dental pulp stem 
cell (DPSC) Therapy in Humans). The TOOTH study aimed to investigate the 
effectiveness of autologous administration of adult dental pulp stem cells in people 
with chronic ischemic stroke.12  
The study aimed to explore the views of people with chronic stroke on: 
• the relevance and importance of an early phase clinical study such 
as TOOTH, with adult human dental pulp stem cells in chronic 
ischemic stroke  
• the relevance and acceptability of the planned outcome measures 
and study design of the TOOTH study and  
• issues with consent to participate in the TOOTH study. 
2. Methods 
2.1. Study Design 
The study involved a naturalistic design, adapting from a participatory action-research 




cell therapy (TOOTH). The study methodology fits within a constructionist 
epistemology paradigm, utilizing an inductive thematic analysis. 
2.2. Study Population, Sampling and Participant Recruitment 
Ethics approval for conducting this study was granted by the Human Research Ethics 
Committees of the University of Adelaide (Ref: H-2016-089) and the University of 
South Australia (Ref: 0000035776).  
The study recruited people with chronic ischemic stroke who were residents of 
Adelaide and likely to fulfil the proposed selection criteria for participation in the 
TOOTH trial as listed below: 
Inclusion Criteria  
• Inclusion of both genders. 
• Age of the participant 18 years or over. 
• History of chronic ischemic stroke with a stable level of disability. 
• Sufficient cognitive and language ability to participate in an interview. 
Exclusion Criteria 
• Impaired cognition or significant psychological issues. 
• Inability to communicate in the absence of a caregiver. 
Inability to travel to the interview location.  
2.3.  Study Enrolment 
Eligible participants were recruited using purposive sampling from the research database 
of people with stroke, maintained by the Stroke and Rehabilitation Research Group (SRR) 




included in this database had previously consented to be contacted for future research 
and were invited to participate (SH). Participants were enrolled on an ongoing basis during 
the period: July 2016 to August 2017, until the concurrent thematic analysis suggested 
that data saturation was achieved.  
Following an expression of interest in participation, all potential study participants received 
a participant information pack containing the participant information sheet for the 
PERSPECTIVES study and the summary information sheet on the TOOTH trial. AN 
followed up with the participants by telephone to address any queries regarding the study 
information provided and obtain verbal consent to participate. Following written informed 
consent, the individuals participated in a semi-structured interview at SAHMRI. The 
interview was conducted in line with key areas of inquiry defined in the interview guide 
(Table 1), regarding the research design of the TOOTH trial. The sub-questions were 
adapted to lines of response provided by the participant. All interviews were audio-






Table 1: Interview Guide: Key areas of inquiry 
 
2.4. Data Analysis 
Analysis of audio transcripts was carried out immediately after every interview and 
data were coded by AN using NVivo software Version 11 (QSR International, 
Melbourne Australia). AN read and re-read the transcripts and constructed an index of 
multiple emerging codes. This index was discussed and cross-checked with SK, SH 
and AHB. Coding was an iterative process that proceeded concurrently with ongoing 
interviews. As new codes were added, previous transcripts were re-coded to further 
refine the coding framework analysis of the data.15 The inductive thematic analysis 
continued until no new code emerged from subsequent interviews, i.e. data saturation 
was achieved. Subsequent analysis crystallized the key themes that represented the 
aspects emerging from refining of codes from the data. 
  
                  Interview: Topic guide 
What has been the impact of stroke on your daily life? 
What are your views on using stem cell therapies for managing stroke? 
What are your thoughts on the usefulness of a study like TOOTH? 
What are the effects that are important to measure in a study like 
TOOTH? 
Are there any specific risks that you feel should be measured in the 
TOOTH? 
Would it be appropriate for participants with impaired thinking or 





3.1. Participant Disposition 
SH contacted 31 patients with stroke following review of their functional status. 
Following their indication of interest in participation, they were provided with study 
information by AN. Nineteen patients declined to participate, mostly due to time or 
mobility constraints. Twelve patients participated in face-to-face interviews, following 
provision of written consent. Patients were asked to complete a patient profile to 
understand the overall impact of stroke on their lives along with their age and stroke 
latency. The population was diverse concerning these parameters, but representative 
of the potential target population for stroke trials (Table 2). 
Data saturation was achieved after twelve interviews with no new themes emerging 





Table 2: Study Participants’ Characteristics 
×Visual Analogue Scale of 1-10: 1 being no/minimal impact to 10 being significant 
impact 
3.2. Themes 
The themes described below represent themes identified, even though some elements 
may overlap (Fig. 1). 
  
Age Range= 42-81 years 
Time since Stroke Range= 0.5-14 years 
Impact of stroke on activities of 
daily living and ability to 
function independently 
VAS* Scale16                    No. of Participants 
1-5 3 
6-10 9 
Interest in participation in 
TOOTH 
Response                      No. of Participants 
     Yes 7 
      No 2 




Fig. 1: Key Themes 
 
3.2.1.  Real-life relevance of study outcomes-are all equally meaningful? 
The participants conveyed that the most meaningful change for them would be a 
change in their ability to participate in life interactions and their ability to get back to 
doing activities of interest, i.e. ‘being more normal’ with lessened dependence on 
significant others (caregivers) in their lives.  
Participant 001: “I can’t play my music, I can’t sew, I can’t knit, I can’t sing 
anymore.  It’s changed it a lot. I guess I would like the use of the things I’ve 
said that I can’t do.” 
Participant 002: “Oh just being human. Just being able to get up in the morning 




Participant 008: “It affects your personal life and you’re sitting there like an 
inanimate lump and so it has an adverse effect on your intimacy too.” 
They conveyed that tests that can measure and track changes over time, in the 
impairments specific to a given patient, would be more meaningful to pursue as 
markers of therapy benefit.  
Participant 005: “Whilst I understand why there are certain tests that you do at 
the beginning of therapy, and at the end of the therapy range, I guess that 
understanding a person’s day to day life and how they do things, and being 
conscious of it, what improvements it could mean to the individual.” 
Participant 008: “So putting pegs on a board and things like that.  If they can 
measure that, and they should be, they’ve got the measuring devices now, 
say you got 40% one day, six months later you got 45%, that’d be brilliant.”  
Patients reported impairment of cognition and memory, especially in terms of the 
difficulty encountered in information processing and new learning situations. This was 
critical for patients as it jeopardized their ability to effectively participate in social and 
work-related interactions.  
This in turn decreased their sense of self-worth and contributed to depression reported 
by the participants. They reported that depression adversely impacted quality of life 
after their stroke.  
Participant 002: “And basically that stage, because you can't, can't do your 




frustration, call it what you want, but the more things don’t go right for you, the 
worse you become.  Yeah and it happens every day.” 
Measuring the impact of cell therapy on mood changes would be useful to monitor in 
any prospective study evaluating their effectiveness.  
Participant 002: “Yep.  If they can help that out that would be a major step, 
seriously.  Yep.  Because I reckon, I reckon your figure would be up over 90% 
of people who get very depressed.  And depression leads to sort of not wanting 
to do normal things.  And of course, while you’re not doing them, your body’s 
shutting down even further, so.” 
The interviewees also expressed their interest in measuring change in pain and 
fatigue, which they associated with a significantly adverse quality of life experienced 
post-stroke. 
Participant 005: “I’ve met so many people who’ve had strokes … but I think 
the only real common theme is the fatigue and, possibly, the pain.” 
While improvement in speech was acknowledged as a relevant outcome to be measured, 
the issue of interest was the impact of this impairment on ease of communication and 
confidence in social interactions.  
3.2.2. Risk- benefit-perception  
Interviewees were quite pragmatic in their expectation of recovery of function, accepting 




Participants believed that perhaps it was not realistic to expect complete recovery of 
function and they would consider any positive change in functional ability to be meaningful.  
Participant 006: “Obviously, I would love to have the use of everything perfect again, but 
I know that’s probably something that’s not going to happen.  But just, for me, just not to 
have the pain so much.” 
Interestingly, the perception of possible benefit was impacted by the time since stroke 
irrespective of the extent of present disability. Participants expressed that their willingness 
to participate in studies such as TOOTH would have been higher ‘earlier in their disease’ 
course and defined that period to be within the first year following the stroke event.  
The interviewees accepted that potential safety issues could be expected, given the early 
stage of the research. The perception of risk was consistent across the participant group. 
Participants expressed concern regarding risk of further functional impairment.  
Participant 010: “I would worry that I could end up, worse off.  That something unforeseen 
could happen and, maybe another part of my brain could die off.” 
Participants also expressed concerns with the transplantation procedure, related to the 
extent of hospital stay required and risk of complications (e.g. infections) associated with 
the procedure. Interestingly, these concerns were related to risk associated with the 
surgical procedure per se and not with the issue of stem cell implantation under MRI 
guidance. 
Death or cancer derived from cell transplantation was not cited as the most critical 




important events to investigate and report by the research community. However , 
participants expressed their desire to know about any available information with regards 
to cancer risk. 
3.2.3. Attitude towards trial participation  
The interviewees expressed varied interest in participation ranging from no interest, to 
unsure, to a very keen interest to participate– often this related to their perceived level of 
current disability.  
Participant 002: “Basically I got my body as good as it's going to get.  If I had stem cells 
put in me, and something went wrong, and it brought me back even 5%, then I've done all 
those years for nothing.  But if I got offered stem cells right at the start, I would’ve thought, 
yeah go for it.”   
Participants conveyed having very limited knowledge about stem cell research, 
particularly in the field of stroke, even though quite a few of them were aware of research 
with stem cells for other diseases such as Parkinson disease and multiple sclerosis.  
Participant 005: “I’ve heard about stem cell research, with the likes of Parkinson’s, and 
other heart problems, etc.  I haven’t heard of anything regarding stroke.” 
Interviewees expressed an opinion that the proposed TOOTH study was relevant for 
people with disability following stroke. The predominant driver of this belief seemed to be 
an altruistic thought process regarding this research contributing to a potentially beneficial 






3.2.4. Attitude towards participant selection 
Participants communicated that study participation should be available to any patient with 
existing disability and that it was inappropriate to exclude patients with cognitive 
incapacity. Proxy consent in such situations was deemed acceptable but only in situations 
where consent was provided by a close member of the family, who would likely be aware 
of the patient’s wishes and likely preferences. However, such consent should not be 
provided by a professional caregiver.  
Participant 002: “I’d like to see everybody involved in the study, it's probably an ethical 
thing. But in the case of (carer), if you’ve got full trust in the carer, yes, but, I mean that’s 
putting a lot on the individual carer. I mean if it is a family person, something like that, it's 
probably better. Like, someone of course had to care for me for a while and all that sort 
of stuff.” 
Participants expressed the view that it was important to ensure that relevant rehabilitation 
and secondary prevention strategies such as control of hypertension, lipid levels and 
weight are optimized for any patient selected in the study, as these are likely to influence 
the eventual study outcome. 
4. Discussion 
4.1. Key findings and implications for research 
The unique challenges posed by personalized application of stem cell therapies arise as 
a question of whether the research designs can be optimized to facilitate meaningful 




This study reports on the views and perspectives of ischemic stroke survivors on the study 
design of a proposed Phase 1 open label cell therapy trial. The study explores the key 
outcomes (effectiveness and safety) of interest to them. The insights generated are likely 
to have an important impact on the design of such proposed studies and to be a useful 
reference to guide trial design for similar stem cell studies in the future. Importantly, it 
highlights that active participation of patients in research design can result in trials that 
generate data, which are more meaningful for the patient community. This provides 
additional specific evidence to support the value of PPIR in optimizing research quality. 
The critical focus of early phase research has always been to gather evidence for safety 
while establishing proof of concept. In the context of stem cell therapies, it is universally 
accepted that early phase studies in healthy volunteers is ethically unacceptable.17 The 
early clinical trials in stroke published to date, have confirmed feasibility of use in varied 
phases of stroke.2,17,18 This presents an interesting opportunity to engage these 
individuals and tap into their lived experience of stroke, which can inform research design 
to produce clinically relevant data that enables efficient decision making in clinical 
practice.19 Patient involvement in early phase research is likely to help researchers 
understand what potential safety concerns are important/relevant to them.20,21 The study 
reports that patients are more concerned about the risk of losing their current level of 
functioning, rather than the potential risk listed in study materials, based on preclinical and 
postulated biological mechanisms, such as tumorigenicity, or conventional risks such as 
mortality. This highlights the need for researchers to ensure that research data specifically 




Early clinical studies seek to collect exploratory evidence of benefit. The heterogeneity in 
presentation and recovery trajectory of stroke has always presented a challenge in terms 
of defining study designs that can generate scientifically rigorous yet clinically meaningful 
data.21 Our study indicates that the patient community has a significant depth of insightful 
about this conundrum. Stroke survivors suggested that the selection criteria of patients 
should include optimization of secondary prevention strategy and patient-specific 
rehabilitation strategies. Emerging research postulates that the recovery trajectory in most 
patients can be predicted based on existing integrity of neural pathways and current level 
of brain atrophy are likely to be involved.22 It might be interesting to consider whether the 
suggestion by our community for optimization post-stroke is an intuitive exercise in 
enrichment for ‘responders’ on the proportional recovery prediction rule, thereby selecting 
individuals that are likely to have most benefit with additional investigational interventions. 
Finally, patients suggested that measurement of change in clinical outcomes needs to be 
personalized to patient specific impairment. Using this approach can potentially lead to 
identification of homogenous patient clusters, which may enable a more efficient 
assessment of effect size and appropriate target population.   
A continuing debate in the research and clinician community is whether the outcome 
measures currently utilized are valid and relevant to the patients’ life experience following 
stroke.23,24 The National Institutes of Health Stroke Scale (NIHSS) is an established 
measure of stroke severity and literature supports its use in the prognosis of post-stroke 
recovery.25 The Modified Rankin Score (mRS) is the most commonly selected primary 
endpoint in drug and rehabilitation studies.26 While it assesses a range of outcomes, 




mood or return to social and occupational functioning.23 The use of these endpoints on 
their own to define success or failure of studies, particularly those involving personalized 
therapy options such as stem cell therapies, may not adequately measure the range of 
outcomes found to be critical from a patient perspective. The World Health Organisation 
(WHO) proposed the International Classification of Functioning (ICF) 27 and recommend 
outcomes evaluation within dimensions of body function impairments, activity limitations 
and participation restrictions. In the context of stroke, a very small percentage of 
pharmacological or rehabilitation studies have to date examined impact on participation 
restriction, as is also the case for cognition and mood outcomes.23 Evidence for 
widespread prevalence of issues in these domains reported by patients has been steadily 
increasing in recent years.24 Research involving patient-reported outcomes has described 
persistent and significant impact on patients’ lives even for those that fully recover their 
pre-stroke functional level. The present study reiterates the importance of these outcomes 
and their measurement to the patients. The International Consortium for Health Outcomes 
Measurement (ICHOM) conducted an iterative Delphi process that included diverse 
stakeholders such as clinicians, patients, stroke registers and stroke societies .28 The 
study suggested a ‘Stroke Standard Set’– a minimum dataset of outcomes and risk 
adjustment variables to collect for all patients hospitalized with stroke. The categories 
recommended within the ICHOM standard set for assessment were survival and disease 
control, acute complications, and patient-reported outcomes (PROM). PROM included 
assessment at 90 days for pain, mood, feeding, self-care, mobility, communication, 
cognitive functioning, social participation, ability to return to usual activities, and health -
related quality of life, along with data on mobility, feeding, self-care, and communication, 




different phases of stroke targeted in early clinical studies, would build the quantum of 
data available on the magnitude of effect that is plausible with cell therapies. The 
increased understanding of anticipated effect can better inform decisions on minimal 
clinically important difference (MCID) that are acceptable and meaningful to clinical 
practice. It stands to reason that such informed decision making would contribute to 
increased efficiency in later phases of development and more informed and relevant study 
size determination and design. 
Participants indicated an acceptance of their current level of functioning and that the return 
of functioning over time, was due to consistent effort on their part to engage with the 
rehabilitation options available. This drove the heightened concern for the potential risk of 
loss of this functional improvement that they worked very hard to achieve. They indicated 
that they would have been more accepting of this potential risk if an opportunity to 
participate in a clinical study such as TOOTH had arisen ‘earlier’ in their disease course, 
defined as within a year of their stroke occurrence. This insight has important implications 
for study recruitment for stem cell studies in chronic stroke. A recently reported study also 
highlighted these as important determinants of interest in participation.13 Allowing for 
stabilization of patient’s general medical condition and spontaneous post-stroke recovery 
to take place are reasonable postulates.29 Our study suggests that targeting a narrower 
window for recruitment (up to 1 year after the stroke event) might facilitate recruitment and 
provide a more favorable risk-benefit proposition to potential participants. Most 
researchers in stem cell research in stroke accept that stem cell therapies in practice are 




point following stroke where rehabilitation has achieved maximum possible benefit, may 
enable clearer distinction of incremental change with stem cell therapies. 
A long-standing debate in stroke trials is the issue of consent particularly for patients with 
cognitive deficit.31 Proxy consent by next of kin is now well accepted in the context of 
acute trials.8 Participants indicated that proxy consent might be considered in stem cell 
studies, even in the chronic phase of stroke. However, they highlighted that this was likely 
to place a significant psychological burden on the caregivers. Cunningham et al. reported 
similar findings as a potential ‘care conflict’ between patients and caregivers in such 
research situations.13  
Our study reports low levels of awareness about ongoing research with stem cell therapies 
in stroke and limited understanding of postulates regarding their mechanism of action. A 
recent study by Aked et al. also reported similar findings regarding the low level of 
awareness regarding stem cell research.32 Patient advocacy groups constitute a 
promising though still underutilized means of increasing this awareness. The participants 
in our study, who reported prior knowledge of stem cells, attributed this to information they 
received from such groups. Patient involvement in research from an early phase can also 
help build awareness and knowledge in the stroke patient community. This is likely to 
enable patients to become more informed and empowered participants in research.  
In a broader societal and medical practice context, the increased awareness of current 
state of regenerative neurology in stroke and evidence-based estimation of risk and 
benefit to be expected can become a deterrent to unscrupulous use of unproven stem cell 




4.2. Strengths and Limitations 
The study utilized face-to-face interviews with stroke survivors, as the method of 
qualitative enquiry. This enabled a relaxed and supportive environment in which they 
shared their individual preferences, contextualized to their unique lived experience with 
stroke. The study findings highlighted key outcomes considered important from patient 
perspectives, and that need to be measured within study design. 
This approach also minimized the dilution of information likely with other modalities such 
as combined focused groups with other stakeholders such as caregivers. Our study is a 
part of a wider exercise that will also explore views from different stakeholders, particularly 
caregivers, in separate studies. The rationale behind this strategy is based on the growing 
body of evidence for disconnect in the perception/acceptance of risk and benefit, between 
patients and caregivers. 13,14,19,21,33 
The requirement to travel and engage in an in-depth interview meant that the study did 
not include patients with very severe disability, cognitive deficits and severe aphasia. The 
participants were therefore, not fully representative of the overall stroke survivor 
community. However, the perspectives shared by them in the context of preferences for 
study design components were largely agnostic to the degree of severity of post-stroke 
disability and may well be more relevant to the broader group. The severity of present 
disability has been shown previously to impact on motivation to participate in other studies 
8,32 and this was corroborated in our study. However, it did not appear to influence the 
relative importance assigned to different outcome and design elements. In addition, the 
eventual number of participants may appear rather small. Previous studies with similar 




was to provide rich thematic description of our qualitative enquiry. The research team 
conducted constant comparison of emerging themes to ensure that data saturation was 
confirmed to ensure validity of study findings. 
5. Conclusions 
The PERSPECTIVES study applied principles of patient and public involvement in 
research in early clinical stem cell research in stroke. Engagement of stroke survivors as 
‘lay experts’ to provide input into study designs can provide critical insights that can enable 
more targeted research. In an evolving field such as cell therapy in stroke, this partnership 
can potentially help researchers to efficiently address the challenges posed by the 
inherently ‘personalized’ field of regenerative medicine. 
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Our findings highlight insights from stroke survivors regarding their perspectives on cutting-edge 
medicines such as cell therapies. Incorporation of patient-centric outcomes in clinical trial 
protocols, targeting information on perceived risk associated with CTs and delivery mechanisms 
and conveying balanced information on the present state of knowledge regarding efficacy are key 




CHAPTER 6: HEALTH ECONOMICS CONSIDERATIONS 
6.1 Background 
Early phase research in the use of CTs in stroke, Alzheimer’s disease, Parkinson’s disease and 
progressive multiple sclerosis has indicated a potential for meaningful benefit (419). As research 
with CTs progresses from bench to the bedside, both reimbursement and broad patient access are 
likely to represent key challenges (420, 421). The assessment of health outcomes and clinical 
effectiveness in the context of a personalised nature of the clinical application of CTs, presents a 
challenge to their value proposition (422). 
Economic evaluation encompasses comparative analysis of alternative courses of action, in terms 
of both their costs and consequences (423). This analysis can take many methodologica l 
approaches including full analysis (both the costs and consequences of alternatives are examined), 
as well as partial approaches, which examine only some of these components (423). Full economic 
evaluations are preferred in the healthcare setting, as they provide a greater understanding of the 
potential costs and benefits of healthcare interventions to assist decision-makers considering 
alternative paths of action (423). Three approaches form most of the full economic evaluations 
undertaken in healthcare settings: cost-benefit analysis, cost-effectiveness analysis and cost-utility 
analysis (423). Cost-benefit analysis measures both costs and benefits in monetary terms, to 
determine the net benefit of the intervention of interest (423). However, several limitations to the 
application of cost-benefit analysis within healthcare exist, including difficulty in valuing the 
outcomes of healthcare (such as improvements in physical health, mental health and wellbeing) in 




incremental costs associated with alternative health interventions, with the incremental benefits of 
those interventions measured as changes in clinical and/or patient focused outcomes (424). CEAs 
usually report their findings as an incremental cost-effectiveness ratio (ICER) which provides an 
indication of the incremental cost per unit change in clinical effect (423). This allows decision-
makers to compare alternative courses of action that result in similar benefits. However, it becomes 
difficult to compare benefits across different disease groups and treatments in which benefits are 
logically measured using different outcomes (423). To assist, a specialized form of cost-
effectiveness analysis, cost-utility analysis (CUA) has been developed (423). A CUA compares the 
incremental costs associated with alternative interventions with a standardized measure of benefits 
such as a quality adjusted life year (QALY) (423).  
The QALY incorporates a measure of quantity of additional survival, assessed in life years 
associated with an alternative intervention, with a calculation of the quality of those years or 
‘utility’ (424). This provides a standardized measure of benefits that maintains its meaning across 
different health interventions and across different patient age groups. The quality of the years is 
measured using standardized generic preference-based instruments, designed to measure quality of 
life, which include a standard health state descriptive system, and off-the-shelf scoring weights 
usually based on the preferences for the health states of members of the general population (424). 
Healthcare budgets are already facing a ballooning of long-term costs of illness. This represents a 
risk to research and development (R&D) investment in high technology products such as CT with 
unclear benefit at present, as the value of such an investment is continually challenged in the wake 
of more pressing current needs (425). Generation of economic evidence early in the development 
of new therapies is becoming increasingly important to ensure development costs are in line with 




early heath technology assessment in parallel with phase I/II clinical research (426). Generating 
economic evidence at an early stage can accelerate clinical translation by enabling strategic R&D 
decisions (427). These include preclinical market assessment, portfolio decisions, clinical trial 
design, market access and pricing strategies (427) . Therefore, there is an imperative to explore 
health technology assessment (HTA) methods that are more specific to early stages of product 
development and used by industry and academia alike to inform decision making that will 
accelerate productive translational research (412). In recent years, the evidence base has built in 
support of the efficacy and safety of use of CTs (419) in neurological diseases, but there has been 
no formal assessment of economic outcomes of CTs in terms of cost-effectiveness and the value to 
patients or healthcare systems to date. 
6.2 Research Objective 
A systematic review was conducted to evaluate potential cost-effectiveness measures that are 
critical to CT research in stroke.  
6.3 Methods  
This systematic review aimed to assess the breadth of current economic evaluation undertaken on 
the use of CTs in stroke. The scope of this review was broadened to include neurological disorders, 
following a preliminary search of literature that yielded minimal data.  
An appraisal of the quality of evidence generated by these studies was undertaken to determine the 
current state of knowledge in this fast-growing area of research, which is likely to become a critical 
determinant of success in the translation of regenerative medicine as a viable and broadly available 
clinical strategy. The protocol for the review was defined a priori and published in PROSPERO: 
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To identify, describe, appraise and summarize economic evaluation studies of stem cell therapies in 
neurological disorders, particularly in stroke. 
To provide an overview  of the quality of the economic evidence available on this topic. 
Searches 
Systematic searches w ill be undertaken in MEDLINE, CINAHL, Embase, PsycINFO, Scopus, Cochrane Central 
Register of Controlled Trials (CENTRAL), Web of Science, EconLit, Database of Abstracts of Review s of Effects 
(DARE), Cochrane Database of Systematic Review s (CDSR), NHS Economic Evaluation Database (NHS EED), the 
Health Technology Assessment (HTA) database and the Cost-Effectiveness Analysis (CEA) Registry for the period: 
2007-2017. 
Additional material w ill be obtained by scanning the reference lists of included studies and from grey literature 
sources. 
Types of study to be included 
Eligible studies w ill include cost-utility analyses, cost-effectiveness analyses, or cost-benefit analyses. In addition, 
partial economic evaluations w ill also be included (e.g. those reporting costs associated w ith the intervention 
alongside clinical trials). Both analyses conducted alongside clinical trials, as w ell as those modeled studies based 
on empirical data, w ill be included. Studies of effectiveness/outcomes w hich do not report costs, and studies purely 
reporting the burden of disease w ithout including the intervention w ill be excluded. 
Condition or domain being studied 
Neurological diseases, particularly in stroke. 
Participants/population 
Inclusion Criteria: Studies performing economic evaluation of use of stem cell therapy in adult patients w ith any 
neurological diseases. 
Exclusion Criteria: Studies of effectiveness/outcomes w hich do not report costs, and studies purely reporting the 
burden of disease w ithout including the intervention w ill be excluded. 
Intervention(s), exposure(s) 
Any stem cell therapy intervention applied in the management of a neurological disease in adults. 
Comparator(s)/control 
Any comparison – active, alternate, sham/placebo, usual care or no intervention, if  feasible. 
Context 
The review  w ill evaluate studies involving adult patients reported betw een 2007- 2017 in English databases. 
Primary outcome(s) 
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The primary outcomes of interest w ill include cost analyses that report the costs of the stem-cell therapy and economic 
evaluations that report both costs and outcomes. 
Timing and effect measures 
There w ill be no restrictions on study outcomes because the purpose of the review  is to document w hat outcomes  
have been or could be estimated in the context of economic evaluation of the use of stem cell therapies in 
neurological diseases, particularly in stroke. 
Secondary outcome(s) 
To provide an overview  of the quality of the economic evidence available on this topic. 
Timing and effect measures 
There w ill be no restrictions on study outcomes because the purpose of the review  is to document w hat outcomes  
have been or could be estimated in the context of economic evaluation of the use of stem cell therapies in 
neurological diseases, particularly in stroke. 
Data extraction (selection and coding) 
Tw o review ers w ill independently screen titles and abstracts against the inclusion criteria. Subsequently, the full texts of 
all studies deemed to be potentially relevant w ill also be assessed independently by tw o review ers. Any disagreements 
w ill be resolved through discussion or by recourse to a third review er. A data extraction form w ill be used to extract 
relevant information from the studies in a consistent format. Both data extraction and quality assessment w ill be 
undertaken independently by both review ers. Any disagreements w ill be resolved through discussion or by recourse to 
a third review er. Extracted data w ill include: study details (author, year of publication country and setting); study 
population; disease indication; intervention and comparator (if  relevant), main analytical approaches for the economic 
analysis; view  point, sources of effectiveness and resource use estimates, prices and currency for reporting economic 
outcomes, any sensitivity analyses undertaken; main economic outcomes reported. 
Risk of bias (quality) assessment 
The quality of reporting w ithin the cost-effectiveness studies w ill be assessed using the revised CHEERS checklist 
developed by Drummond et al (2013). The checklist can be accessed at: http://w ww.equator - netw ork.org/w p-
content/uploads/2013/04/Revised-CHEERS-Checklist-Oct13.pdf. All studies w ill be included in the review  regardless of 
the quality of the individual study, although commentary w ill be made on the quality and risk of bias of individual 
studies and the available evidence as a w hole, and recommendations for future research w ill be provided. 
Strategy for data synthesis 
A narrative synthesis, based on the preceding data extraction and critical appraisal, w ill provide a descriptive overview  
of all studies included. The evidence w ill be mapped according to patient population and methods for economic 
analysis used. This exercise w ill assist decision-making for future economic evaluations; for example, the analysis 
approach, view  point, population groups, and any gaps in the evidence w here further research w ould be beneficial. 
Analysis of subgroups or subsets 
If  feasible, a subgroup analysis of all studies conducted in a stroke population w ill be undertaken. 
Contact details for further information 
ANJALI NAGPAL 
anjali.nagpal@adelaide.edu.au 
Organisational affiliation of the review 
University of Adelaide; University of South Australia; South Australian Health & Medical Research Institute (SAHMRI)  
Review team members and their organisational affiliations 
PROSPERO 
International prospective register of systematic reviews 
Page: 3 / 4 
 
 
Dr ANJALI NAGPAL. University of Adelaide 
Dr RACHEL MILTE. University of South Australia 
Dr SUSAN W KIM. South Australian Health & Medical Research Institute (SAHMRI) Dr 
SUSAN HILLIER. University of South Australia 
Professor JULIE RATCLIFFE. University of South Australia 
Dr MONICA ANNE HAMILTON-BRUCE. University of Adelaide 
Professor SIMON ANDREAS KOBLAR. University of Adelaide 
Anticipated or actual start date 
01 August 2017 
Anticipated completion date 
01 November 2017 
Funding sources/sponsors 
University of Adelaide 
Conflicts of interest 





Stage of review 
Review _Ongoing 
Subject index terms status 
Subject indexing assigned by CRD 
Subject index terms 
Cost-Benefit Analysis; Genetic Therapy; Humans; Nervous System Diseases; Stem Cell Transplantation 
Date of registration in PROSPERO 
25 July 2017 
Date of publication of this version 
25 July 2017 
Details of any existing review of the same topic by the same authors 
Stage of review at time of this submission 
The review  has not started 
PROSPERO 
















This information has been provided by the named contact for this review . CRD has accepted this information 
in good faith and registered the review  in PROSPERO. CRD bears no responsibility or liability for the content 
of this registration record, any associated f iles or external w ebsites. 
Stage Started Completed 
Preliminary searches No No 
Piloting of the study selection process No No 
Formal screening of search results against eligibility criteria No No 
Data extraction No No 
Risk of bias (quality) assessment No No 





The published review reported that there is sparse evidence for economic evaluation at early stages 
of research in CT. Only three economic evaluation studies have been published to date, of which 
only one was in stroke. All studies undertook a cost-utility analysis of CT versus the current 
standard of care using decision analytical modelling. The studies reported that CTs could provide 
meaningful cost savings in terms of direct costs of disease management accrued to the government 
(healthcare bodies and social services). The findings of this systematic review were published in 
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A B S T R A C T  
 
Objectives : To examine economi c evaluation studies of stem cell  
therapies (SCTs) in neurological disorders and to provide an 
overview of the quality of the economic evidence available on thi s  
topic. Methods: The review examined studies that performed an 
economic evaluation of the use of stem cells in adult patients with 
neurologi cal diseases and that were published in English duri ng 
the period 2007 to 2017. Data analyzed and reported includ ed  
study populati on, disease indication, main analytical approa ch es  
for the economic analysis and perspecti ve, key assumpti ons mad e 
or tested in sensitivity analyses, cost outcomes , estimates of  
incremental cost effectiveness , and approaches to quantifyi n g 
decision uncertai nty. Results: A total of three studies reporting on 
the findings of the economi c evaluation of the use of SCT in stroke, 
Parkinson disease, and secondary progressi ve multiple scleros i s ,  
respectivel y , were identified. All three studies conducted a cost -
utility analysis using decision-analytic models and reported an 
incremental cost per quality-adjus ted life-years gained 
(incremental cost-ef fecti v eness ratio) versus standard car e. 
These studies reported meani ngful cost savings in str oke, 
Parkins on disease, and seconda ry progres si ve multipl e scler os i s  
in the base-cas e scenarios. Conclu sion s: Despite significa n t  
progress in clinical research in the use of SCT in neurol ogi ca l  
diseases , economi c evaluati on of these therapi es is still at a 
nascent stage. Given the early stage of research inputs (clini ca l  
and cost outcomes data) into the models per  se, further resea r c h 
is urgentl y need ed to enable meani ngful assessment of the cos t  
effecti venes s of these advanced therapi es and to ens ur e 
sustaina bl e access for populat ion groups most likely to bene fit  
in clinical practice. 
Keywor ds : economi c evaluation, neurological disease, stem cells , 
stroke. 
Copyright © 2018, ISPOR–T he Professional Society for Hea l th 




In recent decades, improved nutrition and health care have led to  
decreasing mortality across the entire spectrum of diseases. Thi s  
has been associated with an increasing gap between life 
expectancy and healthy life expectancy. This gap has recently been 
reported to be more than 10 years, indicating increasing years of  
life with suboptimal health and disability [1]. Neurologi cal dis-  
eases such as stroke [2], Parkinson disease (PD), Alzhei mer  
disease, and progressive multiple sclerosis [3] have been 
increasingl y contributi ng to this emerging pattern. Deterior a t i o n 
in quality of life associated with these conditions has either risen or  
stayed stable despite inroads made in terms of mortality. The 
situation is further worsened by the fact that, for most of these 
conditions, research into novel therapeutic options over the last  
few decades has met with multiple and costly failures [4]. 
In this context, regenera tive medi c i ne 
(cell/gene/bioengi neeri ng products) offers an exciting option for  
delivering a meaningful solution to the current unmet need from a 
patient and public health perspecti ve [5]. Stem cell thera pi es  
(SCTs) potentiall y replace or regenerate diseased human cells , 
tissues, or organs to restore or establish normal function. Early-
phase research in the use of SCT in stroke [6], Alzheimer disea s e 
[7], PD [8], and progressi ve multiple sclerosis [9] has indicated a 
potential for meaningful benefit . Despite the increased number of  
regulatory approvals for SCT in different countr i e s , 
reimbursement and broad patient access remain challenges [5,10] . 
The personaliz ed nature of their clinical application and  
assessment of health 
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outcomes and measur es of clinical effecti veness pose a challenge 
to an assess ment of their value proposi ti on [11]. 
The present global explosion in health care budgets ha s  
resulted in fiscal tighteni ng of spending on research and clinica l  
translation of innovative therapies [12]. In recent years, the 
evidence base has expanded to support the efficacy and safety of  
SCT in neurologi cal diseases [6–9]. Generating economic evid ence 
at an early stage can accelerate clinical translation by enabl i ng 
strategic research and development decisions, preclinical market  
assessment , portfolio decisions, clinical trial design, and market  
access and pricing strategy arrangements [12–15]. Neverthel es s , 
there has been no formative assessment of literature repor t i ng 
economic outcomes in terms of cost effectivenes s and  value to  
patients or health care systems of SCT to date. 
This systematic review presents an overview of the quant i ty  
and quality of economi c evaluations of the use of SCT in neur o -  
logical diseases. This is likely to become a critical determina nt of 





Protocol and Registration 
The protocol for the review was prepared and registered on 
PROSPE RO (Internati onal Prospecti ve Register of Systema t i c  
Reviews; Ref-CRD420170 72937 ) [16]. 
 
Eligibility Criteria 
All studies that performed an economi c evaluation of the use of  
stem cells in adult patients with neurological diseases and tha t  
were published in English during the period 2007 to 2017, whi ch 
reflects the period of maximum publications in the field of stem 
cell research, were eligible for inclusion. Although there were no  
restrictions on the types of study design eligible, studies of  
effectiveness that did not report costs and studies purely repor t -
ing the burden of disease or the cost of illness without includ i ng 
the interventi on were excluded. 
 
Search and Study Selection 
Systematic searches were undertaken in MEDLINE , PubM e d , 
CINAHL , Embase, PsycINFO, Cochrane Central Register of Con -  
trolled Trials, Database of Abstracts of Reviews of Effects , 
Cochrane Database of Systematic Reviews, National Hea l th 
Service Economic Evaluation Database, the Health Technol og y 
Assessment database, and the Cost-Effecti venes s Analys i s  
Registry. The reference lists of included studies were scanned for  
any additional studies. The database search used primary sear ch 
terms on cell therapy, health economics, and neurological diseas es  
(see Appendix 1 in Supple- mental Materials found at 
https://doi .org/10.1016 /j.jval.2 018.07.878) . 
 
Data Extraction 
The screening and data extraction for this review was cond uct ed  
using the Covidence platform [17]. 
Two of the reviewers independ entl y conducted screening agains t  
the inclusion/ex cl usi on criteria and subsequent full -text review of  
all potentially relevant studies. Data extraction included stud y 
details (author, year of publication, country, and setting), stud y 
population, disease indication, main analytical approaches for the 
economic analysis and perspective, key assumpti ons made in the 
base case or tested in sensitivity analyses, costs, estimates of  
incremental cost-effectiveness , and approaches to quantifyi n g 
decision uncertai nty (e.g., deterministi c and/or probabili s t i c  
sensitivity analysis). Any disagreements 
were resolved through consens us or by recourse to a third review er .  
 
Quality Assessment 
The quality was assessed using the revised checklist propos ed in the 
International Society for Pharmacoeconomi cs and Outcom es  
Research Consolidated Health Economic Evaluation Repor t i ng 
Standards (CHEERS ) Task Force Report [18]. One of the review er s  
provided additional specific input on the quality assessment of  
analytical methods (item no. 17). Any disagreements were resol ved  
through discussion or by recourse to a third reviewer. Each item 
was rated as “fully satisfied,” “partia lly satisfied,” or “not satisfied ”  
or “not applicable.”  
 
Data Synthesis 
A narrative synthesi s, based on the preceding data extraction and  
quality appraisal, was undertaken. A meta-analysis was not feasib l e 
because of the low number of studies overall and the fact tha t  
eligible studies involved different diseases, SCT types, and input  
variables in the models. The costs were converted to a common 
currency (US dollars) and inflated to the price level of 2016 usi ng 




In total, 12,840 titles were identified in the preliminary search. 
Removal of duplicates resulted in 7116 potentiall y relevant articles . 
Of these, 6888 articles were excluded after screening of title and  
abstract, and 228 articles underwent a review of the full text. Of  
these articles, 225 were excluded for reasons provided in Figure 1. 
The remaining three studies were included in the review. Key 
descriptions of included studies are presented in Table 1. The 
quality assessment of these studies is presented in Table 2. 
 
Study Characteristics: Disease Indication, Intervention,  
Design, Time Horizon, Discount Rate, and Perspective 
The studies differed in terms of type of SCT used and neuro- logica l  
diseases studied: stroke [20], PD [21], and secondary progres s i v e 
multiple sclerosis (SPMS) [22]. The PD study com- pared the use of  
embryoni c neural stem cells with standard care. The study on SPM S  
looked at the use of hematopoi eti c stem cell transplantati on (HS CT )  
versus mitoxantrone therapy. The stroke study model did not d efine 
the SCT type and compared assumed effect to existing standa r d  
care, on the basis of expert opinion. 
The stroke and SPMS studies evaluated cost outcomes over a 
lifetime [20,22], whereas the PD study reported them over a 25-yea r  
horizon [21]. 
The SPMS study compared a patient cohort with SPMS w ho 
received HSCT to a matched comparator group receiving mitox -
antrone as part of standard care [22]. The target population in the 
PD study included patients with motor impairment (Hoehn and  
Yahr [HY] stages III–IV) who received SCT [21]. The HY stagi ng 
captures increasing severity (stage I [minimal impairment] to stage 
V [confinement to bed]) of progressive motor impairment in PD [23]. 
The data on the comparator population (standard care) wer e 
sourced from a clinical practice cohort [24]. The stroke study defined  
its target populati on as patient cohorts of age 55, 65, and 75 year s  
with a modified Rankin Scale (mRS) score of 1 to 4 at discharge [20]. 
The mRS is commonl y used to measure disability (0 indicates no  
disability and 6 is death) in patients with stroke [25]. The data for  
comparator populati on, that is, standard of care, were derived from 
a previous randomized multicenter study [26]. 
The stroke model allowed for subgroup analysis according to age 
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Fig. 1 – PRISMA flowchart [41]. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analy ses. 
 
 
assumed effectiveness of SCT, mode of stem cell administrat i o n, 
risk of recurrent stroke, or death caused by intervention [20]. The 
PD study evaluated subgroups according to age (o64 and Z64 
years) [21]. By comparison, the SPMS study did not report on any 
specified subgroups [22]. All three studies used discounting for  
future costs and benefits: the PD and stroke studies used a 3%  
discount rate for all calculations, as recommend ed in Swed en, 
whereas the SPMS study used 3.5%, in line with existing recom -
mendations in the United Kingdom. The PD and SPMS studi es  
examined the costs from a government perspective. The stroke 
study adopted a societal perspecti ve. 
 
Quality 
All studies differed in the type of SCT used. The evidence fr om 
clinical studies to date does not indicate a significant difference i n 
clinical effect of different cell types [27]. None of the studies ha s  
examined SCT type as a potential variable in the economic analys i s  
model. The time horizon for model application was reported in all  
studies, but justification for the choice was missing. The select i on 
of target and comparator populations is well described for all the 
studies. Only the SPMS study, however , reported matching the 
SCT cohort and comparator group on the basis of basel i ne 
diagnosis of SPMS and Expanded Disability Status Scale (EDS S )  
values [22]. The PD and stroke studies did not report whether the 
SCT and comparator had been matched. None of the stud i es  
explained in detail why the chosen perspecti ve provides the mos t  
appropriate economic viewpoint of analysis. Two of three stud i es  
did not report on potential conflicts of interest. 
 
Estimating Resources and Costs: Model-Based 
Evaluations and Currency 
The PD study (Table 1) was limited to direct medical (hospital care, 
pharmaceuticals, and investigations) and direct nonmedical
(transportati ons and home help) costs [21]. The cost data for  
management of PD, SCT transplanta tion, and associated compl i -
cations were sourced from previous clinical  studies. Calculati on s  
were made in euros (€) according to the price level of 2002. 
The SPMS study included interventi on costs (treatment costs  
for mitoxantrone and autologous HSCT and any related adver s e 
events) and other costs (Table 1) associated with the manage- m e nt  
of multiple sclerosis [23]. Hospital resource use and phar -
maceutical costs were calculated in pounds using the Nationa l  
Health Service and the British National Formulary reference costs  
for the year 2006 to 2007. 
The stroke study included direct health care costs for initial and  
recurrent events (Table 1), sourced from a previous study. Long-
term costs included social services and indirect costs owing to  
disability and producti vity losses, sourced from a study on the cos t  
of stroke in Sweden. Calculations were expressed in US dollars for  
the year 2009. 
 
Quality 
The PD study used resource costs from a previous study but  
provided limited details about where unit costs were derived fr om 
[28]. No opportunity costs were included. The stroke study dr ew  
from assumptions based on expert opinion and previ ous l y  
published literature but did not clearly describe where some uni t  
costs were drawn from. Opportunity costs were not included. The 
SPMS study described the sources for cost estimations in detai l .  
Neverthel ess , indirect costs such as lost producti vity and out -o f -  
pocket expens es were excluded from the analysis. 
 
Outcomes: Choice of Health Outcomes, Assumptions, and 
Valuation of Preference-Based Measures of Effectiveness 
All the studies used quality-adjusted life-years (QALYs) as a  
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Table 1 – Summary of included studies. 
Study 
characteristic 
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(value in US 







Markov state transition model 
Embryonic neural stem cells 
Standard pharmacological therapy 
Idiopathic patients with PD (HY stage 





Government (direct and nonmedical 
costs) 
 
Patients aged o64 years with early 




Initial progressive improvement 
during first 2 y, followed by a 
stationary period up to 5 y after 
transplantation, and return to 




HY stage III: €156,467 (US $22,206) 




HY stage III: €158,943 (US $22,557) 




HY stage III: 0.873 
HY stage IV: 1.133 
 
HY stage III: cost-saving 
HY stage IV: cost-saving 
 
€38,000 (US $5,393) 





Univariate analysis: time horizon (10–
20–30 y); discount rate (0%– 
5%); treatment efficacy (±50%); 
occurrence of complications 
(±100%); analytical perspective 
(direct medical costs only vs. 
including other direct costs); 




Markov state transition model 
HSCT 
Mitoxantrone 
Patients with SPMS in two MS 
registries: the Lyon Clinique de 
Neurologie MS Registry and the 




Government perspective (UK NHS 
and Personal Social Services) 
Patients with a baseline EDSS score 
Z3 and r8; modeled with three 
scenarios with different 
interpretations of the disease 
progression 
Transitions between EDSS states 







Scenario 1*: £131,666 (US $23,615) 
Scenario 2†: £124,262 (US $211,041) 
Scenario 3‡: £111,008 (US $188,531) 
 
 
Scenario 1*: £107,126 (US $181,938) 
Scenario 2†: £107,126 (US $181,938) 
Scenario 3‡: £107,126 (US $181,938) 
 
 
Scenario 1 *: -1.02 
Scenario 2†: 0.23 
Scenario 3‡: 1.40 
Scenario 1*: dominated 
Scenario 2†: £74,210 (US $126,035) 
Scenario 3‡: £2,783 (US $4,726) 






Univariate analysis: transplant- 
related mortality rate (0/1.3%); 
relative PFS hazard ratio between 
HSCT and mitoxantrone; tariff cost 
of HSCT (±25%), costs of managing 
MS (±25%); discount rate (0/3.5%) 





Decision tree model 
Intracerebral stem cell implantation 
Standard poststroke care 
Cohort aged 55 y at stroke onset, 
with mRS 2 at hospital discharge, 
and an assumed increase in the 
probability to improve 1 mRS 





Patients aged 55 y at stroke onset, 




Relative effectiveness of 
intracerebral SCT transplantation 





US $ (2009) 






















Univariate analysis: relative efficacy 
of SCT; mode of transplantation; 
age at stroke onset; annual risk of 
recurrent stroke; SCT procedure 
risk of death; intervention on mRS 
3/4; extended leave period 
 
 
























clinical practice [21] and an SCT study cohort [28] at thei r  
institution. Health state utilities were generated for every HY stage 
of PD, using the generic EuroQol five-dimensi onal questionna i r e 
(EQ-5D), measured by the time trade-off method [29]. QALYs wer e 
obtained by multiplying the number of mortality-adjus ted life-
years spent in each HY stage with its health utility weight. 
The stroke model used assumpti ons regarding effecti v e n e s s  
of stem cells on the basis of expert opinion. The change in 
functi on and quality of life after a stroke was classified into  
distinct health states in accordance with the different mRS  
scores. A previousl y publis hed algorithm that translates the 
mRS into EQ-5D utility was used to genera t e QALYs for ea ch 
mRS score [30]. 
The SPMS model sourced individual patient-level disea s e 
progression data from a real-world clinical practice regist r y  
(mitoxantrone) [31] and an HSCT patient registry and 
estimated relative effectivenes s based on Kaplan-M ei er  
progression-fr ee survival curves [32]. Discrete health states , 




















unique health-rela ted quality of life. The time spent in each EDSS  
state weighted by its respective health-related quality-of-li fe level  
(from previous literature) provided an estimate of the number of  
QALYs gained in each treatment group. 
 
Quality 
All the studies reported QALYs as the health outcome. None of the 
studies, however, justified its choice in the study context. Wi th 
respect to reporting study parameters, all the studies mis s ed  
reporting variability around mean estimates of effectivenes s. 
 
Model-Based Economic Evaluations: Choice of Model and 
Analytical Method 
All three studies conducted a cost-utility analysis of SCT vers us  
standard care. In addition, the stroke study reported a cost- benefi t  
analysis in terms of societal value express ed as the value of hea l th 
benefits (QALYs x willingness to pay per QALY gain) less the 
incremental cost of SCT over standard care [20–22]. The 
Table 1 – continued 
Study 
characteristic 


























The results were sensitive for 
patients in HY stage III to changes 
in time horizon, discount rate, 
treatment effect, and health utility 
method, but were stable for 
patients in HY stage IV 
 
 
No explanation provided 
 
 
Long-term cost savings in most 
instances in early onset PD 







Enables cost-effecti venes s analysis 
based on real-world progression 
using a clinical surrogate end 
point (HY stages) 
Small number of patient- level data; 
clinical effectiveness data based 
on open-label transplantation 
trials 
Shorter treatment effect persistence 
resulted in HSCT not being cost- 
effective in optimistic scenario; 
decreased intervention cost and 
mortality risk associated with 
HSCT improved cost effectiveness 
 
 
No explanation provided 
 
 
A potential to achieve a level of cost 
effectiveness that is acceptable to 
policymakers and health care 
purchasers, but is largely 
determined by the interpretation 
of available clinical effectiveness 
data and the duration over which 
such effects may be observed 
 
Focus on the potential cost 
effectiveness of autologous HSCT 
in the management of SPMS only 
 
The absence of direct RCT evidence 
to input into the model 
SCT remained cost-effective but 
societal value decreased— 
decreased QALY gain and 
increased incremental costs with 
decrease in relative efficacy, 
higher age at stroke onset; 
intervention in patients with 
higher disability (mRS 4) 
Variable ranges based on expert 
opinion 
 
A potential for long-term cost 
savings by reducing the disability 
after stroke; societal value up to 
US $166,500 (US $184,567), 
particularly in younger patients 
with stroke with moderate 
disability, with possible cost 
effectiveness estimated down to 
relative efficacy of 14%  
Enables CBA for patients with stroke 
under a wide range of 
assumptions 
 
Effectiveness of SCT in humans was 
based on expert opinion; did not 
include differential costs on early 
vs. late administration poststroke; 
limited standard care data 
reflecting survival, treatment 
patterns, and transition 
probabilities for mRS 
CBA, cost-benefit analysis; CUA, cost-utility analysis; EDSS, Expanded Disability Status Scale; HSCT, hematopoietic stem cell transplantation; 
HY, Hoehn and Yahr stages of PD; ICER, incremental cost-effectiveness ratio; mRS, modified Rankin Scale; MS, multiple sclerosis; NHS, Nationa l  
Health Service; PD, Parkinson disease; PFS, progression-free survival; QALY, quality-adjusted life-year; RCT, randomized controlled trial; SCT, 
stem cell therapy; SPMS, secondary progressive multiple sclerosis. 
* Scenario 1: Strict 6-mo sustained progression from baseline EDSS. 
† Scenario 2: Next-visit sustained progression from baseline EDSS. 
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Table 2 – Quality assessment of the included studies: CHEER S checklist.  




et al. [21] 
Tappenden 
et al. [22] 
Svensson 
et al. [20] 
Title 1 PS FS FS 
Abstract 2 PS FS PS 
Background and objectives 3 FS FS FS 
Target population 4 FS FS FS 
Setting and location 5 FS FS FS 
Study perspective 6 FS FS FS 
Comparators 7 PS FS PS 
Time horizon 8 FS FS FS 
Discount rate 9 FS FS FS 
Choice of health outcomes 10 PS PS PS 
Measurement of effectiveness: single study–based estimates 11a NA NA NA 
Measurement of effectiveness: synthesis-based estimates 11b FS FS FS 
Measurement and valuation of preference-based outcomes 12 FS PS NS 
Estimating resources and costs: single study–based economic 13a NA NA NA 
Evaluation     
Estimating resources and costs: model-based economic evaluation 13b PS FS PS 
Currency, price, date, and conversion 14 FS FS FS 
Choice of model 15 FS FS FS 
Assumptions 16 FS FS FS 
Analytical methods 17 FS FS FS 
Study parameters 18 PS PS PS 
Incremental costs and outcomes 19 FS FS FS 
Characterizing uncertainty 20b FS FS PS 
Characterizing heterogeneity 21 FS FS PS 
Study findings, limitations, generalizability, and current knowledge 22 PS FS FS 
Source of funding 23 FS FS FS 
Conflicts of interest 24 NS FS NS 




stroke study used the decision tree model [20], but the PD and  
SPMS studies [21,22] used the Markov state transition model. 
 
Quality 
All the studies justified that their analytical method and choice of  
model, along with the input parameters used in the model, wer e 
appropriate, given the early stage of research with SCT. The 
models were explained using a schematic in the stroke and SPM S  
studies. 
 
Incremental Costs and Outcomes 
The PD study reported overall cost savings ($351.40 [HY stage III]; 
$3224.62 [HY stage IV]) and gains in QALYs (0.873 [HY stage III]; 
1.133 [HY stage IV]) with the use of SCT in the base-case scenar i o : 
patients with early onset PD (HY stages III–IV) with an assumed  
initial improvement during the first 2 years, after a stationa r y 
period of up to 5 years after grafting, and return to preopera t i v e 
rate of disease progression thereafter [21]. These were evalua t ed  
against the cost-per-QAL Y thresholds acceptabl e to UK ($5393)  
and Swedish ($9934) payers. This predicted that a price premi um 
($5109–$9083) was available for recovering investment on 
development . 
The stroke study reported a QALY gain of 1.34. Although t he 
SCT intervention increased costs by $70,960, these were offset by  
decrease in producti vity losses to result in an overall saving of 
$21,122. SCT dominated standard care in terms of incremental
 
cost-per-QAL Y gain in base-case populati on: patients were aged 55 
years at stroke onset, had an mRS score of 2 at hospital discha r ge, 
and were given intracerebrall y transplanted SCT with an assumed  
relative effectiveness of 50% and experienci ng no side effects [20] . 
The study reported that the societal value of SCT in stroke was 
$184,567, assuming a Swedish willingness to pay for a QALY of 
$122,379. This represented a potential headroom of $21,122 per  
treatment for developer s to realize a return on investment [20]. 
The SPMS study presented the central estimates of cost  
effectiveness for autologous HSCT versus mitoxantrone across  
three base-case scenarios incorporati ng different methods of 
measuring disease progression (EDSS) [22]. The study reported an 
incremental cost per QALY gained (incremental cost-effecti ve n es s  
ratio) of $4726/QAL Y in the scenario in which disease progres s i o n 
was measured as EDSS progression sustained for 6 months from 
any EDSS [22]. Neverthel es s, HSCT may be dominated (costli er  
and less effective) by mitoxantrone in the scenario in whi ch 
confirmation of disease progression required sustained increa s e 
over 6 months since baseline. In the scenario requiring next-vi s i t  
sustained progression from baseline, the incremental cost of  
$125,678/QAL Y gained was not cost-effecti ve as per the UK  
threshold of $33,967 to $50,950/QAL Y [22]. 
 
Quality 
All the studies reported on incremental costs and outco m e s  
adequa tel y in terms of costs per QALYs or incrementa l cos t -  






VALUE IN H EALTH (2018) 7 
 
Characterizing Uncertainty 
All three studies undertook univariate sensitivity analyses to tes t  
for the impact of changes in parameters included in the model on 
the study results. In addition, the SPMS study undertook a  
scenario analysis involving different durations of persistence o f  
clinical benefit. 
The PD study undertook a univariate sensitivity analysis to tes t  
whether changes in model specifications had an impact on the 
robustness of the results, focusing on the time horizon, discount  
rate, treatment efficacy, occurrence of complications, and cha nges  
in the analytical perspecti ve (only direct medical costs vs. other  
direct costs as well). The outcome was varied from the EQ-5 D 
health state–based utilities to the time trade-off visual anal ogue 
scale method. The results were found to be sensitive to changes in 
time horizon, discount rate, treatment effect, and health utility  
method for patients in HY stage III, but were stable for patients in 
HY stage IV. 
The stroke study undertook univariate sensitivity analys i s  
when model assumptions and specifications regarding effect size, 
age of onset, aspects of the therapy provided, risk of stroke, and  
procedur e-r el ated mortality risk were varied to see their impact on 
the robustness of the results. SCT remained cost- effective, but  
there was a decrease in QALY gain with increased increme nta l  
costs associated with decrease in relative efficacy, higher age at 
stroke onset, and intervention in patients with higher disability  
(mRS score of 4), leading to lower societal value. SCT, however , 
remained cost-effecti ve down to a relative efficacy size of 14%. 
The SPMS study undertook a scenario analysis incl ud i ng 
optimistic, pessimistic , and middle-ground scenarios according to  
the assumpti on of the duration of sustained benefit and the method  
of measuring EDSS progression. The interpretati on of clinica l  
effectiveness (on the basis of different scenarios for meas ur i ng 
EDSS) had a significant impact on cost effectiveness . Univar i a te 
sensitivity analysis was also undertaken with varying mod el  
inputs such as the mortality rate associated with the intervent i o n, 
treatment effect duration, cost of the intervention, cost o f  
managing multiple sclerosis, and the discount rate. 
 
Quality 
Although all the studies performed univariate sensitivity analy-
ses, the choice and range of variables examined were not expl a i ned  
in detail. Only the SPMS study explained why some variables wer e 
included. Although univariate sensitivity analysis is a vali d  
approach, more sophisticated approaches can provide a n 
indication of the impact of the overall uncertainty in the mod el  
when uncertai nty around the model parameters exists (such as i n 
the included studies). Approaches such as multiway analys i s , 
threshold analysis, scenario analysis, and probabilistic sensit i vi ty  
analysis can account for differences in multiple parameters at the 
same time and provide a more comprehensive picture of the tota l  





This is the first systematic review of published studies conduct i n g 
economic evaluation of the use of SCT in neurologi cal disea s es . 
The studies included in our review differed in terms of disea s e 
indications, SCT types, clinical measures, evaluation perspect i v e s , 
and cost outcomes included, which makes it difficult to compa r e 
results across the studies. All the included studies conducted a  
cost-utility analysis using early-stage health economic model i ng. 
The models estimated the value proposition
 
of SCT in disease populations over a long-term time horizon. All  
the studies reported potential cost savings over long-term and  
ongoing benefit in terms of decreased rate of disease progres s i o n 
and disability. 
The individual studies examined different types of stem cell s . 
The evidence from clinical research with SCT to date does not  
indicate that differences in cell types have a significa nt impact on 
effecti venes s of therapy or safety. Having said that, the impact of 
using different cell types on potential clinical benefit (in terms of 
relative efficacy and safety) and thereby on cost effecti ve nes s has  
not been specificall y examined. This may reflect the early stage at 
which clinical research was at the time of publica ti on of thes e 
studies [27]. As more studies are being conducted with distinct l y  
characteriz ed cell types, it may be possible in futur e to deter mi n e 
whether cell type should be a variable to examine in the cos t -
effecti venes s analysis. There are uncer tai nti es regarding the 
effect size of SCT, given the early stage of research and the 
inherent heter ogenei ty of disease characteris ti cs , which ma ke 
assessment of cost effecti ven es s complicated . Never thel es s, as 
newer data emerge regardi ng longer term clinical benefi t with 
SCT, these models can be reworked with more substa nti v e data  
to assess economic value and identify patient groups that are 
likely to maximall y benefi t . 
Diseases such as stroke and PD contribute substantially to the 
health care budget [34,35]. Assessing effectiveness from this  
limited perspecti ve may, however , underesti ma te the value of  
personalized interventions such as SCT. It fails to consider the 
potential gains in terms of decreased disability for the patients and  
increased participation in work and society. This is important to  
consider while assessing negotiated pricing strategies. 
The quality of study methods and reporting is importa nt  
because economi c evaluations in this field are likely to grow. We 
assessed the quality of the reviewed studies using the CHE E RS  
checklist [18]. None of the included studies fully satisfied all the 
criteria listed in the CHEERS checklist, with only 50% of the items  
being rated as “ fully satisfied.”  Even though these studies wer e 
published before the formulation of the CHEERS checklist, the 
review highlights the need for incorporati ng these requirements i n 




The included studies differed in terms of disease populati ons and  
SCT types. In addition, heterogeneity in terms of analytica l  
methods, cost, and effectiveness measures used meant that only a 
narrative synthesis of findings is presented , because a formal meta -
analysis was not appropriate. 
Two of the three studies examined cost effectivenes s from a 
government perspective only. Although this is key for deter mi n -
ing future access strategy, economi c evidence from a broad societa l  
perspective may provide directions to optimize value by targeted  
research in specific patient groups and health care deliver y 
pathways. 
All the studies have sourced their effectivenes s data from either  
single-arm studies, registry, or expert opinion. Although this ma y 
be acceptabl e for rare disease indications, effectiveness data in the 
more common neurological diseases such as stroke or PD may be 
more informative if adequately powered for the clinical outcome 
end points. A methodologi cally sound meta- analysis of smaller  
studies in future with appropriate sensitivity analysis may provi d e 
a reasonable early estimate of cost effectivenes s. This, however , 
requires these studies to collect data on resource use in terms of  
effectiveness of the therapies in their study design. The model s  
proposed in the studies included in the review may then be able to  
incorporate data from such analysis appropriatel y. The use of  
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research, and these models are amenable to more extensive data  
inputs as they become available. Neverthel es s, it is current l y  
difficult to provide a detailed assessment of bias and gener a l -
izability of the findings of this review. 
 
Potential Value of Health Economics Data at Early Drug  
Development 
As research in regenerati ve medicine for neurologi cal disea s es  
approaches an exciting juncture, it becomes imperative to expl or e 
the associated cost outcomes [36]. This is critical to inform a  
targeted development strategy that maximises chances of a n 
eventual product that resonates with the value expectati ons for  
patients in need as well as for payers [37,38]. The focus on 
development efficiency is heightened by the constant shortening of  
the window of opportuni ty to realize returns on investme n ts ; 
research and development teams are faced with complex trade-offs  
in terms of developi ng an efficient product development strategy 
[39]. Early health economics data can provide useful input into  
defining these strategies. 
 
Recommendations for Future Practice for Economic 
Evaluation in Regenerative Medicine 
SCTs have been investigated in an increasing number of phase I 
and II trials across the globe for different neurologi cal indicat i ons  
[6–9]. Incorporati ng cost outcomes into the research protocol at thi s  
stage will enable formative evidence to be generated and maxi mi z e 
the unique opportuni ty that stem cell research pro- vides, in tha t  
these therapies are often researched in patient populati ons fr om 
the earliest stage rather than in healthy volunteer s. The long -ter m 
persistence of the effects of SCT is a key consideration in choos i ng 
appropriate clinical and cost out-comes to calculate cos t  
effectiveness [39,40]. A patient or societal perspecti ve may be 
preferred because the high initial costs of SCT could be justified by 
ongoing cost savings because of sustained clinical improve m e n t , 
improved independ ence, and participation in activities of dail y  
life. This represents a more comprehensive measure of va l ue. 
Participants in early-phas e clinical studies with SCT ar e 
increasingl y being followed over a longer time duration vi a  
extension studies or registries [40]. Collection of resource use data  
in these settings represents a useful means to examine cos t  
effectiveness over longer durations. This will enable credi bl e 
analysis of economi c evidence and the complex trade-offs betw een 
investments during development and potential returns and hel p 
manage access to these innovative therapies in a sustainable way. 
 
Conclusions 
Economic evaluation of SCT in neurological diseases is still at a 
nascent stage. Neverthel ess , the recent progress in terms of clinica l  
research underlines the urgent need to advance this field i n 
tandem. Research to build economic evidence for cost ef fec -
tiveness of these innovative therapies can potentially accel er a te 
their clinical translation and provide channels for provi d i ng 
sustainable access to these therapies to patients in clinics. 
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Economic evidence for cost-effectiveness of these innovative therapies is critical to accelerate their 
clinical translation and provide channels for providing sustainable access to these therapies for 
patients. Early CT research is carried out in stroke patients rather than in healthy volunteers as is 
more common in early phases of research with other therapies and this provides a unique 
opportunity to evaluate ways to collect economic evidence for CTs. Future studies need to consider 





CHAPTER 7: DISCUSSION 
7.1 Discussion 
This thesis describes a compendium of projects that assessed the different considerations in design 
and implementation of early phase clinical studies investigating the use of CTs in stroke. The 
research applied a mixed method approach to identify and describe the study design, regulatory 
policy, ethical concerns and health economic considerations that are likely to be critical to the 
quality of early phase CT study execution in patients with ischaemic stroke. This research may 
potentially lead to the development of a framework including suggested standards for early phase 
CT research in ischaemic stroke. 
Significant advances have been made in our understanding of brain injury and recovery following 
stroke at molecular, cellular and systems levels, due to the availability of sophisticated applications 
that use various ‘omics’ techniques and advanced structural and functional brain imaging. This 
research has yielded numerous promising preclinical therapeutic candidates in the past years. 
However, except for thrombolytics, none of the biological or pharmacological candidates have 
succeeded in clinical trials so far (298). Whilst there could be multiple reasons for this to happen, 
the complexity of the disease and the repair mechanisms operational in stroke are certainly 
important contributors (146). The preclinical research in CTs across different cell types indicates 
a two-way responsive mechanism of action that modulates the brain microenvironment towards  
optimization of neuroinflammatory cues and facilitates neurogenic and angiogenic processes (156). 
Early phase studies of CTs in human stroke subjects indicate functional benefit and credible safety 
to date (428). As clinical testing moves into a more definitive assessment of efficacy with numerous 




aspects of trial conduct in stroke, which have been likely contributors to translational setbacks in 
the past. Furthermore, it is important to examine these considerations in the specific context of 
CTs, as these innovative therapies bring with them unique challenges in terms of trial execution, 
regulatory oversight mechanisms, ethical debates and demonstrating cost effectiveness.  
The first clinical study with CTs in stroke, published in the year 2000, was sponsored by Layton 
BioScience Inc. and investigated pre-differentiated neuronal cells from the NT2/D1 human 
precursor cell line (429). Since then, academic research groups, predominantly, have carried the 
research effort forward. In 2014, 70% of CT trials across different disease indications were led by 
academic groups and 30% were led by industry (430). This may perhaps be because the clinical 
development of these products is likely to be characterised by a high degree of uncertainty and risk 
compared with conventional drug development (425).  
7.1.1 Is Research Design Letting CT Research Down? 
Evidence based medicine has long established that randomised clinical trials are the ‘gold standard’ 
for generation of data for supporting the clinical use of investigational modalities (431). By 
reducing bias and enhancing the rigor of investigation, RCTs have contributed significantly to 
improving the quality of health research outcomes by clarifying the benefits and drawbacks of 
countless interventions (431). RCTs determine average treatment effects in a target population and 
rely on the deliberate selection of a homogenous population to study and compare, to reduce the 
effect of bias, confounding and effect modification (431). This is achieved by establishing 
appropriate inclusion and exclusion criteria, standardizing interventions and selecting the most 
relevant outcomes. However, the suitability of RCTs has often been challenged in areas of clinical 
research where the disease characteristics are inherently heterogeneous and therefore therapeutic 




requirement of RCTs) (432). Some examples have been fields such as surgical and psychotherapy 
interventions (432). In the context of stroke, rehabilitation is one such area of research, which has 
struggled with applying aspects of RCT design (139). Despite requiring a long duration to recruit 
and complete, most RCTs remain relevant to a very selective patient population (432). This 
understandably limits the real-world clinical applicability of their eventual findings (432). 
CTs research in stroke represents a similar conundrum. The effect of a stroke injury is a sum of 
individualized patterns of injury that are influenced by numerous patient and management factors. 
In this context, the application of CTs that inherently rely on the cross-talk with an injured brain 
environment to facilitate recovery, poses challenges with artificially fitting diverse patients into a 
group and analysing global functional outcomes (433). Chapter 3 summarised our review which 
reported that the bulk of clinical studies (20/26 studies) with CTs have so far used alternative 
methodologies to RCT (mostly single-arm open label studies or case series with historic and 
contemporary controls). Meta-analysis to derive the magnitude of effect on outcomes indicates a 
potential benefit in these studies although the effect size in the subgroups of studies with 
comparator arm was marginal (428). The high level of heterogeneity across these studies weakened 
the overall strength of evidence (428). Future effectiveness studies may be more efficient if 
designed to identify a benefit in a specific subpopulation within the broader stroke population. This 
would require a priori selection of a specific nature of impairment within the stroke population and 
choice of outcome measures that specifically measure relevant domains of impairment, activity 
and participation. Methodologies to modify the conventional RCT design have been proposed in 
the literature to enable this (434) and regulators have recently expressed their openness to engage 




One of these methodologies is the use of randomised trial designs that adaptively change enrolment 
criteria during a trial, called adaptive enrichment designs (436). Adaptive designs can potentially 
provide clinically relevant information about which subpopulations are likely to benefit from the 
investigational therapy. The intended subpopulations, enrolment modification rules and statistical 
analyses need to be pre-specified in the study protocol. These subpopulations could be defined, 
based on baseline characteristics such as functional or prognostic phenotype or the use of structural, 
functional or imaging biomarkers. The advantage of using this approach is that the trial population 
could be enriched by a greater proportion of subjects with a potential for benefit from the treatment 
(434). Furthermore, it allows for the early stopping of exposure in subpopulations that do not 
demonstrate any benefit. In the context of early phase CT research, this approach can enable 
researchers to have increased power to detect and measure true effect size in the subpopulations 
that show benefit and improve efficiencies in designing subsequent confirmatory trials. From a 
safety standpoint, the ability to limit exposure in suboptimal populations wherein potential long-
term adverse events need to be prevented is an important advantage, especially relevant to CTs 
(437). This methodology can also prove useful for adaptively choosing the patient subgroups, 
focused on data on baseline characteristics of interest and stratified randomization of study 
participants according to those subgroups of interest. The recent DIFFUSE 3 study used this 
methodology to evaluate endovascular treatment in ischaemic stroke patients with imaging-
perfusion mismatch (438).  
The other methodology to consider is the use of cluster randomization. Cluster randomization has 
been used in rehabilitation trials to evaluate the treatment impact of interventions in different 
patient groups clustered by site or patient characteristics (439). The key premise is that clusters 
share common characteristics and that observations on individuals in the same cluster tend to be 




into sample size calculations. Design effect depends on the average cluster size and the degree of 
correlation within clusters (intracluster correlation coefficient or ICC). ICC for outcome measures 
such as BI, mRS and NIHSS have been calculated previously and can be used in planning future 
studies that use these models (368). Rehabilitation is recommended as a necessary concomitant 
therapy that should be included in all CT clinical studies (328). There is evidence that CT and 
rehabilitation may have a mutually facilitative biological effect (440). Clinical guidelines 
recommend the delivery of rehabilitative interventions individualized to specific patient needs 
(137). In the context of designing future effectiveness studies with CT, it may be useful to consider 
CT in combination with rehabilitation as an integrated therapeutic package. While this may have 
labelling implications, it makes intuitive clinical sense. Randomizing patients into clusters with 
similar rehabilitative needs, based on similar functional deficits, may enable delivery of 
rehabilitation that is targeted, yet can be standardized enough to fulfil the requirements of an RCT. 
This will potentially help in understanding the clinical relevance of any changes seen in chosen 
outcome measures after CTs administration.  
In addition to the overall study population disposition, the choice of outcome measures assessed 
can have a critical impact on research output. The systematic review indicated that the majority of 
CT studies enrolled patients with middle cerebral circulation infarction. Most patients were 
therefore likely to have had predominantly sensory-motor deficits. It is interesting to note that only 
six of the 26 studies used outcome measures that specifically measured change in motor 
impairment. In most studies, the change in disability following CTs administration was evaluated 
using either a global measure of impairment such as NIHSS, or a measure of activity dependency 
such as mRS or BI. While these studies followed conventional advice from stroke trials to use 
established (hard) global disability endpoints, future effectiveness studies may be more efficient if 




selected study population. This endpoint could be supported by secondary endpoints such as 
changes in domains of activity and participation. Regulatory agencies have communicated their 
willingness to accept such choices in effectiveness studies as these would hopefully provide clearer 
data guidance for eventual clinical use (441). 
7.1.2 The Regulatory Maze on the Way to Market?  
The pace of clinical translation with CTs in different disease indications (Fig.2) has increased in 
the last decade (430). Regulatory agencies across the globe are cognizant of a paradigm change in 
medicine that CTs potentially represent in terms of being able to generate replacements for cells 
that are lost to injury or disease. The agencies are increasingly aware of the unique challenges to 
researchers and healthcare providers and of the potential for harm if adequate oversight 
mechanisms are not in place to ensure patient safety. Chapter 4 examined key developments in 
the regulatory field over the last decade that have come forth in response to this acceleration and 
provide guidance to researchers in the field of regenerative medicine. These guidelines have created 
certain requirements that developers in academia and industry must fulfil to have a successful path 
to market. Our review analysed guidelines from regulatory jurisdictions that have been at the 
forefront of research and development in CTs and included the USA, Europe, Canada, Japan and 
Australia. We analysed these different guidelines to identify key commonalities and differences, to 
define the critical considerations that developers need to address in future effectiveness studies 





Figure 3. Regulatory Approval of Cell Therapy Trials Across the World since 1997  
Reproduced with permission from Bersenev et al.(430) 
CTs are technically challenging to develop, when compared to conventional pharmaceutical 
products. Their clinical use is likely to be more akin to cell and organ transplant products making 
their development fit better with academic institutes than conventional manufacturers. Multiple 
early phase exploratory clinical trials have resulted in a rising number of high impact publications. 
However, about 98% of clinical cell therapy trials have not yet resulted in licensed products, as 
most of these successful exploratory studies have not been followed by well-designed (controlled) 
efficacy trials (442).  
Academic centres with their scientific expertise in diseases with high unmet need and relatively 




research in innovative areas like CTs (443). However, they are inherently limited in taking this 
research all the way to market due to key issues regarding systems, funding and capacity (443). 
Academic groups, driven by scientific principles, are often limited in their capability to analyse an 
investigational product in terms of its ‘target product profile’ (TPP) and to implement required 
standardization and quality control processes essential to medicinal product development (444). 
TPP is a term commonly used by commercial drug developers and regulators but may be relevant 
in the context of CTs, even at early phases of research, due to their unique characteristics (322, 
445). Establishing TPP in the early phases of development is essential for targeted research with 
complex interventions such as CTs. In addition, academic groups often lack regulatory expertise 
and most academic institutions have sparse resources available to enable access to such expertise 
for a research group (444). In this scenario, CTs tested in early phase studies cannot be taken further 
as they do not meet the product quality assurance requirements for GMP and Investigational 
Medicinal Product Dossier compliance.  
The key themes to emerge from our review that are relevant to address in the course of research 
planning are: 
1 Clear articulation of the TPP for the CTs in development is critical. This will potentially 
ensure that the development plan results in generation of data that justifies the suitabilit y 
of the structural and functional profile of CTs for the intended clinical use. Furthermore, 
the research groups should articulate the intended clinical use in terms of regulatory 
terminology for use. This is an essential component of clinical trial planning and 
regulatory approval process, as the pathways for assessment and oversight differ 
substantially, depending upon the exact conditions of clinical use. 
2 The clinical use should be linked to the level of processing and manipulation that the cells 




risks these manipulations may represent to CTs recipients. The development plans are 
required to justify how the selected clinical trial designs optimally assess and capture 
these often-unpredictable safety risks and ensure ongoing risk-benefit assessment.  
3 Access to GMP compliant cell therapy processing services and expertise in product 
development has emerged as perhaps the most important rate-limiting step in successful 
translation in academic settings. Its significance is underscored by the fact that 
collaborative networks established for facilitating this have been established in countries 
that have been leading the CT research field, such as the UK (Cell Therapy Catapult)  
(446), Canada (Canadian Centre for Commercialization of Regenerative Medicine) (447) 
and the USA (Production Assistance for Cellular Therapies (PACT) program) (448).  
7.1.3 What are Patients with Stroke Expecting from CT Research? 
The current stage of research with CTs in stroke faces ethical issues that are also seen in early stage 
research in other clinical areas (400). However, the novelty of science with CTs in general and 
aspects of the evolving knowledge in this field (449), combined with challenges specific to stroke, 
raise some important considerations that are vital to address for efficient trial planning and 
implementation. Chapter 5 examined key ethical issues that can impact on the practical aspects of 
patient participation in CT clinical research. The ‘PERSPECTIVES’ study conducted thematic 
analysis of perspectives shared by a purposive sample of stroke survivors in Adelaide, regarding 
their expectations from research with CTs in stroke in general and provided inputs into the research 
design of a proposed early phase CT study developed by our research group (TOOTH study 
protocol and study materials). The study used qualitative research methods to collate patient 
experiences with stroke and issues and outcomes of importance to them in line with the principles 




PPIR is an emerging field that aims to evaluate whether research is relevant to issues in disease 
management or therapy delivery that are considered important by patients and the public (399). 
PPIR seeks to ensure that the results of research investment represent value from a patient’s (the 
ultimate beneficiary) perspective (450). PPIR can be implemented at various levels such as: 
engaging patient or carer communities to define areas in which to prioritize research funding; to 
develop more patient-relevant research questions, study designs, and outcomes; to develop research 
materials to improve readability and recruitment; and the dissemination of study results (397). 
There is a worldwide push to establish PPIR as an essential element of research, especially with 
publicly-funded research projects.  
The stroke survivors who participated in our study provided interesting insights about their 
perception of risk and benefit that are useful to understand in the context of the promise that CT 
research potentially offers. Previous studies have reported a general positive attitude towards 
participation in CT research but there was a wide divergence in efficacy expectations between 
study participants and research teams. Informed context in the context of CTs in stroke presents an 
argument to re-examine the process in terms of an ongoing dialogue rather than a one-off event at 
the start of the trial. This is due to the possibility of unpredictable but long-term effects of CTs that 
may be seen later in the course of the study or safety follow-up and consent may be required for 
management of these complications. Therapeutic misconception can arise for various reasons and 
appropriate information sharing is the key to addressing this. Participants in our study 
communicated a pragmatic realistic approach to anticipated benefits. This finding seems to differ 
from the findings from similar patient research done in the context of CT in haematological 
malignancies (405). It would be useful to explore the factors driving this difference. Perhaps the 
difference in anticipated survival may play a role in this. It was also interesting that patients were 




such as tumourigenicity and death. The importance of measuring changes in often neglected 
outcomes such as cognition, mood and overall ability to restore ‘normal’ pre-stroke participation 
levels is a key insight that should inform future trial designs. This patient perspective about 
recovery expectation has been reported in previous qualitative research with stroke survivors  
(394,451). Thus, patient involvement in research design with future CT studies is likely to provide 
key insights that can result in more relevant trial conduct, increase motivation to participate and 
improve recruitment in these complex clinical studies. 
7.1.4 Will CTs Eventually be Worth It? 
Regenerative medicine potentially represents a paradigm shift due to the potential for modification 
of the underlying causes of disease by repairing, replacing, or regenerating damaged cells in the 
body. If successful, CTs may potentially reduce the burden of disease and improve the health-
related quality of life of many patients with chronic diseases such as stroke. This may potentially 
translate into cost reductions to health services. The lack of cost outcomes data with CTs can make 
the demonstration of value proposition for these innovative, but high cost therapies, extremely 
challenging. CT researchers may be required to anticipate the access challenges that may represent 
the last component of the widely acknowledged ‘translation roadblock’. 
Incorporation of health economic considerations in early stages of research with CTs can serve two 
purposes:  
• inform researchers and developers about the regulatory and reimbursement strategy, using 
early-stage (or iterative) health economic modelling including headroom analysis 
• estimate unknown effect sizes and beliefs using methods like stakeholder preference 
elicitation and multi-criteria decision analysis to refine trial designs and maximize the 




Chapter 6 presented the findings of the first systematic review of health economic evaluation of 
CTs at the early phase of research. This area of research is still in infancy as is borne out by the 
fact that only three studies have been published on a cost-effectiveness analysis of the use of CTs. 
The modelling study in stroke using expert opinion on probable effect size of CTs, reported overall 
societal value driven by long tern cost savings due to decreased cost of disability and productivity 
losses (414). Early health technology assessment (HTA) studies are required to generate evidence 
for the value proposition of CTs. Inclusion of measures relevant to the impact on costs associated 
with healthcare resource use and avoidance of productivity losses, as secondary endpoints in early 
phase trials, will generate data for input into early HTA studies. This will enable simultaneous 
generation of supportive evidence for efficacy and economic sustainability for CTs. 
7.2 Contribution and Impact 
There is a scientific imperative for a successful clinical translation of CT into relevant treatment 
strategies for patients with stroke related disability. STEPS recommendations proposed high-level 
consensus based pragmatic concepts underpinning the development of CTs in stroke. However, 
academic groups engaged in CT research would benefit from an expanded and practical framework 
that can help in planning research and the development of investigational CT into viable medica l 
products. 
This thesis used a mixed methodology approach as relevant, to explore and analyse the critical 
quality determinants of early phase clinical studies investigating CT in stroke. Based on the 
findings of the subprojects of this thesis, a practical framework in a checklist form, incorporating 
study design, regulatory, ethical and health economic parameters is proposed. This checklist can 
potentially serve as a tool for research teams, particularly in academic settings, to efficiently plan 




expertise gaps and enable them to allocate resources accordingly, for capacity building. The 





Table 7: Clinical Translation of Cell Therapies in Stroke: Checklist for efficiency 






Is the intended patient population 
clearly identified (from preclinical 
and other exploratory studies)? 
 
  
Is the applicable patient 
population yet to be adaptively 
selected in the trial due to the 




Are baseline characteristics of 
participants mapped to ensure 
alignment to primary impairment 
of interest, before randomization?  
 
  
Is imaging required to support 






Trial design  Is the trial use group 
randomization by cohorts defined 




Is there value in adopting adaptive 
trial design versus fixed RCT? 
 
  
Does the trial design allow interim 
selections of design aspects (dose 
levels or sample size) or design 
parameters (effect threshold)? 
 
  
Is the interim analysis pre-






Table 7: Clinical Translation of Cell Therapies in Stroke: Checklist for efficiency 
in trial conduct  (continued) 
 
  Items Response   
Are rules for efficacy/futility pre-
specified in trial protocol? 
 
  
Is MCID for selected primary 
outcome measure established a 
priori and used to decide on 
efficacy/futility? 
 
    
 
Study endpoint Is primary outcome measure 
appropriate to the primary 
impairment of interest? 
 
  
Do secondary endpoints include 
domain specific outcome 




PROM incorporated as secondary 
endpoints? 
 
    
 
Timing of study 
after stroke 
Which is the preferred phase of 




What additional logistics 
challenges does this phase pose 
for CT delivery? 
 
  
Is CT processing feasible for time 
of delivery after stroke? 
 
  
Is time window for delivery 





Table 7: Clinical Translation of Cell Therapies in Stroke: Checklist for efficiency 
in trial conduct (continued) 
 
  
Items  Response 
 
Intervention Is CT (dose/route) selected based 
on extrapolation from preclinical 




Is rehabilitation intervention 




Is dose of rehabilitation defined a 
priori in protocol 
 
  
Is temporal sequencing of CT & 
rehabilitation used in study 
protocol? – justification from 
available evidence? 
 
    
 








Is intervention and dose of 
rehabilitation in control arm 
matched to experimental arm? 
 




Does statistical plan support 
adaptive design, if chosen, and 
pre-specify the interim analysis 
and study progress rules? 
 
  
Does statistical plan justify the 
analytical methods used for 





Table 7: Clinical Translation of Cell Therapies in Stroke: Checklist for efficiency 
in trial conduct (continued) 
 
  
Items  Response 
 
Safety reporting Is there a mechanism for long-
term safety follow-up through 
extension studies/registries? 
 
    







Is CT combined with tissue 
engineering products or devices 
 
  
Would CT delivery need invasive 
procedure and/or use of delivery 
devices? 
 
    
 




Will CT be processed on-site or 





Does the site/outsourced facility 




Does the site/outsourced facility 




Does the site/outsourced facility 
have CT specific release criteria? 
 
  
Do the release criteria include 
structural and functional 






Table 7: Clinical Translation of Cell Therapies in Stroke: Checklist for efficiency 
in trial conduct (continued) 
 
  Items  Response   




Does the site/outsourced facility 
have required quality control 
processes in place? 
 
  Does the site/outsourced facility 
have required cryopreservation 
protocols to store and transport 
CT? 
 







Does the team have access to 
expert support for regulatory 
submissions and negotiations? 
 




Has any PPIR been 
conducted/planned for the 
proposed CT study? 
 
  
If yes, what aspects of study 
design were evaluated in PPIR? 
 
  
Does the study protocol address 
the findings from the PPIR? 
 
  
Is there patient/public 




Were patient materials such as 
information sheet and other 







Table 7: Clinical Translation of Cell Therapies in Stroke: Checklist for efficiency 
in trial conduct  (continued) 
 
  
Items  Response 
  
Are endpoints measuring change 
in participation, independence of 
living, mood, pain and fatigue 
included in study protocol? 
 
  
Has a lead-in period to optimise 
secondary prevention in 
participants prior to participant 




Is formal cognitive assessment 
performed for all potential 
participants prior to consent? 
 
  
If cognitively impaired patients 
are included in study, is process 
for proxy consent defined in 




If implementing an adaptive 
research design, has the study 
team considered a dissemination 
strategy for changes in study 






Does the study committee include 
patient representation? 
 
    
Health 
economic 
Cost outcomes Is resource use data for study and 




Is data on direct costs of 
intervention/comparator defined 





Table 7: Clinical Translation of Cell Therapies in Stroke: Checklist for efficiency 








7.2.1 Evaluation of TOOTH Study Protocol  
The above checklist was used to analyse a Phase I/II study (TOOTH) proposed by our research 
team, the Stroke Research Programme at the University of Adelaide. It was used to identify key 
areas where the trial planning needed to be optimised and resources identified and secured. The 
completed checklist for this study is included as Appendix 1. 
7.3 Limitations 
The thesis examined different aspects critical to the development of innovative cell therapies and 
analysed the key factors that need to be addressed by development teams. Having said that, there 
are some limitations to the research conducted that are highlighted below. 
First, since the predominant share of early clinical research in CTs is coordinated in academic 
institutions, this research focused on factors important in these settings. While we acknowledge 
Items  Response 
  
Is data on direct costs of 
concomitant 
medications/interventions defined 
and collected in protocol? 
 
  
What indirect costs data can be 
collected during the study period, 
and during study follow-up? 
 
  
Is a PROM instrument that 
measures work productivity 
included in the study? 
Justification for 





that these determinants are equally critical in the industry setting, our current research was focused 
on academic groups, as the need for the proposed framework is likely to be higher in those settings.  
Second, access to patient level data proved to be a challenge whilst conducting the systematic 
review of clinical studies with CT in stroke. Access to such datasets is likely to be key in collating 
evidence from multiple smaller studies, which are likely to represent a major part of evidence in 
the early stages of translation. Access to this data would enable researchers to analyse whether 
heterogeneity in patient and disease characteristics have been adequately addressed. Database 
resources such as Virtual International Stroke Trials Archive (VISTA) database, established to 
serve as repository of anonymized data from completed clinical trials in stroke are already 
functional. Creating a similar resource for CT trials may be a way forward to collate data across 
numerous small studies.  
Third, in the context of ethical considerations, our study specifically examined patients’ 
perspectives and there is a need to follow this up with a similar study conducted in stroke carers. 
This is important as carers are important stakeholders in PPIR. Simultaneous enquiry with both 
stakeholder groups in a single study is likely to limit insights as there is evidence from prior studies 
that there can be wide differences in patient and carer perspectives. Qualitative methods are best 
suited for evaluation of the needs and perspectives of different stakeholders in research and PPIR. 
Having said that, these methods are not well accepted in conventional medical literature, as 
evidenced by the very low numbers of published studies using these methods for PPIR in the 
context of CT use in stroke.  
Fourth, health economic analysis was limited by the sparse availability of literature in this field. 
Our analysis and suggested framework will potentially highlight the need for the early generation 




the majority of approved CTs are still struggling with reimbursement challenges and are not 
available to patients in need. 
Lastly, our research underscores the urgent need for researchers to be trained in the requirements 
of medical product development. However, analysis of gaps in training curricula as a potential 
consideration in improving research efficiency, was not undertaken, given the time limitation. It 
would be important to understand the interdependencies across disciplines that underlie the present 
capacity gap in the research community.  
7.4 Future Directions 
The proposed checklist needs to be validated for use with key stakeholders such as clinicians, 
researchers, patient advocacy groups, patients, ethics committees, regulators and HTA experts. 
Future research could potentially involve this validation. This could be done using focus group 
discussions or using DELPHI methodology. The proposed checklist, if validated, can serve as a 
decision aid for academic research groups engaged in cell therapy research, to improve their 
research output and enable them to lead CT product development effectively for stroke. Some 
components of this checklist are relevant beyond stroke research to critical factors affecting wider 






CHAPTER 8: CONCLUSIONS 
Stroke represents one of the leading causes of disease burden in Australia and across the globe  
(10). The landmark success in the clinical translation of reperfusion strategies – thrombolysis and 
endovascular thrombectomy, represents significant mortality and morbidity benefit. However, 
these therapies are limited by a narrow window of opportunity. Despite declining mortality and 
morbidity due to general improvements in systems of stroke care, there is a present unmet need for 
impactful new therapeutic strategies in addition to rehabilitation.  
Cell therapies represent an exciting option with demonstration of neurovascular repair and 
abrogation of neuroinflammation in preclinical stroke models. Despite a robust amount of 
exploratory clinical trial data published over the last decade, only a minimal percentage of these 
cell therapies have progressed further towards medical product development. Given a long history 
of expensive translational failures in stroke research and the fact that CTs research has been driven 
by academic research groups primarily, there is an urgent need to identify and address key factors 
that can enable efficient execution of clinical development of cell therapy products for stroke.  
Firstly, innovative, adaptive study designs that identify specific homogenous subpopulations likely 
to benefit from a chosen cell therapy candidate and measure the impact of cell therapies in terms 
of domain-specific endpoints, along with conventional endpoints such as NIHSS and mRS, are 
critical. Secondly, the study team would need to address regulatory requirements for the 
development of cell therapies, which may vary depending on specific composition and conditions 
of use. Thirdly, patient and public involvement in early research with cell therapy can help make 
this research more relevant to real world practice. Lastly, researchers would do well to generate 




considered in a timely manner during early clinical study planning, this thesis proposes a practical 
framework that can help the research team to identify existing capacity gaps and build financial 
and human resources to address these gaps. This can enable academic institutes to improve their 
translational research programs with increased focus on cell therapy development, identifying 
existing skill gaps and allocating resources to address these gaps. This will potentially lead to 
enhanced efficiencies in early clinical research and accelerate clinical translation of these 
innovative therapies that hold a promise, if successful, of ushering in a paradigm change in stroke 





   APPENDICES 
APPENDIX 1 
Analysis of TOOTH Study against Clinical Translation of Cell Therapies in Stroke: 




Target population  Is the intended patient 
population clearly 
identified (from 




Is the applicable patient 
population yet to be 
adaptively selected in the 
trial due to the potential 








participants mapped to 
ensure alignment to 







Is imaging required to 
support clinical 






Trial design  Is the trial use group 
randomization by cohorts 
defined by impairment 







APPENDIX 1: Analysis of TOOTH Study against Clinical Translation of Cell 





Items  Response 
  
Is there value in adopting 
adaptive trial design 
versus fixed RCT? 
✓ 
  
Does the trial design 
allow interim selections of 
design aspects (dose 
levels or sample size) or 




Is the interim analysis 




Are rules for 
efficacy/futility pre-
specified in trial protocol? 
NA 
  
Is MCID for selected 
primary outcome measure 
established a priori and 
used to decide on 
efficacy/futility? 
× 
    
 
Study endpoint Is primary outcome 
measure appropriate to the 
primary impairment of 
interest? 
Needs to be 
defined 
  
Do secondary endpoints 
include domain specific 
outcome measures for 
activity & participation? 
✓ 
  






APPENDIX 1: Analysis of TOOTH Study against Clinical Translation of Cell 
Therapies in Stroke: Checklist for efficiency in trial conduct (continued) 
  
Items  Response 
 
Timing of study after 
stroke 
Which is the preferred 
phase of stroke for use of 




What additional logistics 
challenges does this phase 




community   
Is SCT processing 
feasible for time of 
delivery after stroke? 
✓ 
  
Is time window for 
delivery defined a priori? 
✓ 
    
 
Intervention Is SCT (dose/route) 
selected based on 
extrapolation from 
preclinical research or 





intervention targeted to 




Is dose of rehabilitation 






APPENDIX 1: Analysis of TOOTH Study against Clinical Translation of Cell 
Therapies in Stroke: Checklist for efficiency in trial conduct (continued) 
 
APPENDIX 1: Analysis of TOOTH Study against Clinical Translation of Cell 
Therapies in Stroke: Checklist for efficiency in trial conduct (continued) 
Items  Response 
  
Is temporal sequencing of 
SCT & rehabilitation used 




    
 
Comparator Is control arm receiving 
placebo delivery?  
NA 
  




Is intervention and dose 
of rehabilitation in control 
arm matched to 
experimental arm? 
NA 
    
 
Statistical analysis  Does statistical plan 
support adaptive design, if 
chosen, and pre-specify 
the interim analysis and 
study progress rules? 
Not defined 
  
Does statistical plan 
justify the analytical 
methods used for selected 
endpoint analysis? 
✓ 
    
 
Safety reporting Is there a mechanism for 
long term safety follow-







Items  Response 







homologous   
Is SCT combined with 
tissue engineering 
products or devices 
× 
  
Would SCT delivery need 
invasive procedure and/or 




injection     
 





Will SCT be processed on 




Need to be 
defined 
  
Does the site/outsourced 
facility have required 
manufacturing approvals? 
Need to be 
defined 
  
Does the site/outsourced 
facility have GMP 
compliant cell processing 
protocols? 
Need to be 
defined 
  
Does the site/outsourced 
facility have SCT specific 
release criteria? 





APPENDIX 1: Analysis of TOOTH Study against Clinical Translation of Cell 
Therapies in Stroke: Checklist for efficiency in trial conduct (continued) 
 
  Items  Response 
  
Do the release criteria 
include structural and 
functional characterisation 
using validated assays? 
Need to be 
defined 
  
Do the release criteria 
include infection 
screening? 
Need to be 
defined 
  
Does the site/outsourced 
facility have required 
quality control processes 
in place? 
Need to be 
defined 
    
 
Expertise in submission 
of clinical trial 
applications to regulators 
Does the team have 





    
Ethical Patient involvement in 
research (PPIR) 
Has any PPIR been 
conducted/planned for the 
proposed SCT study? 
✓ 
  
If yes, what aspects of 
study design were 




Does the study protocol 






APPENDIX 1: Analysis of TOOTH Study against Clinical Translation of Cell 
Therapies in Stroke: Checklist for efficiency in trial conduct (continued) 
 
  Items  Response 
  
Is there patient/public 




Were patient materials 
such as information sheet 
and other recruitment 





Are endpoints measuring 
change in participation, 
independence of living, 
mood, pain and fatigue 




Has a lead-in period to 
optimize secondary 
prevention in participants 
prior to participant 
randomization, considered 
in study protocol? 
× 
  
Is formal cognitive 
assessment performed for 
all potential participants 
prior to consent? 
✓ 
  
If cognitively impaired 
patients are included in 
study, is process for proxy 
consent defined in 







APPENDIX 1: Analysis of TOOTH Study against Clinical Translation of Cell 
Therapies in Stroke: Checklist for efficiency in trial conduct (continued) 
 
  Items  Response 
  
If implementing an adaptive 
research design, has the study 
team considered a 
dissemination strategy for 
changes in study conduct 






Does the study committee 
include patient representation? 
✓ 
    
Health 
economic 
Cost outcomes Is resource use data for study 
and comparator groups 
defined in protocol? 
× 
  
Are data on direct costs of 
intervention/comparator 




Are data on direct costs of 
concomitant 
medications/interventions 




What indirect costs data can 
be collected during the study 




Is a PROM instrument that 
measures work productivity 
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